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Abstract   
 
Cardiac function is defined by the process of excitation and contraction. During this 
process, the electrical excitation of the surface membrane is coupled to Ca2+-ion release 
at the sarcoplasmic reticulum, resulting in contraction. The small membrane-protein 
phospholamban (PLN) is an essential regulator of cardiac contraction by inhibiting the SR 
Ca2+-ATPase (SERCA), which modulates the reuptake of Ca2+-ions at the SR and 
ultimately results in cardiac relaxation. The inhibitory effect of PLN on SERCA is disrupted 
upon its phosphorylation by two different kinases. Beta-adrenergic stimulation activates 
protein kinase A (PKA), which phosphorylates PLN at S16, meanwhile increased 
intracellular Ca2+ levels stimulate Ca2+-calmodulin-dependent protein kinase II (CaMKII) 
phosphorylation of PLN at T17, causing a longer-lasting activation of SERCA.  
This study focused on the identification and characterization of novel protein-protein 
interactions involved in the regulation of cardiac excitation and Ca2+ metabolism.  
Pull-down approaches from rodent and human cardiac membranes, proximity labelling in 
live cardiac myocytes and immunoprecipitation experiments identified the phospho-
adaptor protein 14-3-3 as a novel PLN interaction partner. Pull-down experiments with 
monomeric or pentameric PLN demonstrated that 14-3-3 preferentially binds 
phosphorylated PLN pentamers. The potential 14-3-3 binding motif in PLN was further 
dissected with recombinant binding assays and surface plasmon resonance 
measurements revealing that phosphorylated S16 or T17 transform PLN into a 14-3-3 
target with different binding affinity sites. In line, molecular dynamic simulations uncovered 
different placement of PLN, phosphorylated at either S16 or T17, in the 14-3-3 binding 
groove resulting in different binding energies, favoring phosphorylated T17 PLN. 
Functionally, upon beta-adrenergic stimulation of cardiac myocytes PKA activity was 
stimulated and endogenous 14-3-3 was found to be enriched in these membrane fractions. 
Recombinant dephosphorylation assays showed that 14-3-3 bound to phosphorylated PLN 
protects PLN from rapid dephosphorylation. In line, increased SERCA activity was 
observed upon PKA stimulation in the presence of 14-3-3 in cardiomyocytes during patch 
clamp analysis. The observation that CaMKII-phosphorylated PLN at T17 results in a high 
affinity binding of 14-3-3 suggests that 14-3-3 may regulate the less dynamic pool of PLN 
and raises the question of whether 14-3-3 binding is involved in the regulation of PLN 
disease mutations (R14del, R9C), for which PKA phosphorylation is abolished. 
Recombinant binding assays confirmed that 14-3-3 could still interact with PLN R9C or 
R14del mutants, which are associated with dilated cardiomyopathy and heart failure.  
Additionally, 14-3-3 together with the coat complex COPI are well characterized regulators 
of the potassium ion channel family TASK, responsible for phosphorylation dependent 
Abstract 
 xiv 
trafficking and cell surface expression. TASK-1 is strongly expressed in the atrium, 
involved in setting the resting membrane potential and associated with atrial fibrillation. 
Little is known about regulation and trafficking of these channels in the heart. A mass 
spectrometry approach and recombinant binding assays performed from cardiac 
membranes identified the PDZ domain containing proteins Dlg1 and Dlg4 as direct TASK-1 
interactors. Further analysis of the PDZ binding site in TASK-1 confirmed the existence of 
a previously hypothesized PDZ-binding motif, which overlaps with the well characterized 
14-3-3 binding motif located at the distal C-terminus of TASK-1. This finding suggests a 
phosphorylation dependent regulation of TASK-1 via 14-3-3 and PDZ domain containing 
proteins at the plasma membrane, yielding insight into trafficking of TASK-1 beyond the 
secretory pathway.  
Taken together, in this study 14-3-3 was identified as a novel interaction partner of PLN. It 
was further demonstrated that 14-3-3 binding to PLN results in a stabilization of 
phosphorylated pentamers and prolonged SERCA activity, indicating a novel mechanism 
of PLN regulation dependent on cardiac kinase activity. In addition, the PDZ domain 
containing protein Dlg1 was identified as a direct interaction partner of TASK-1 in cardiac 
tissue. These findings expand our knowledge about the interactome and regulation of the 
cardiac protein PLN and the ion-channel TASK-1 underlining the importance of regulatory 
proteins such as 14-3-3 or Dlg1 in cellular processes like Ca2+ handling or protein 
trafficking.  
Chapter I: Introduction 
 1 
1 Chapter I: Introduction 
1.1 Calcium regulation by excitation-contraction coupling mechanism in the 
heart 
Cardiac function is regulated on a beat-to-beat basis by the sympathetic and 
parasympathetic nervous system. The parasympathetic system lowers cardiac output by 
decreasing the heart rate through the neurotransmitter acetylcholine (Najafi et al., 2016). 
The sympathetic activation releases the catecholamines adrenaline and noradrenaline 
responsible for increased cardiac output (Najafi et al., 2016).  
The beat-to-beat regulation allows adaption of the heart rate and blood flow based on the 
demands of the organism. To fulfill the function of the heart as a pump, cardiomyocytes 
have to rhythmically contract in a coordinated or syncytium manner (Thomas et al., 2018). 
All process which are happening between the electrical stimulation until the contraction of 
cardiomyocytes is summarized under excitation-contraction coupling (Pfeiffer et al., 2014). 
An electrical stimulus, in form of a cardiac action potential, travels through voltage gated 
ion channels from the atria to the ventricle inducing cardiac contraction. The voltage gated 
ion channels open due to the stimulus and positive ions flow into the cardiomyocyte leading 
to depolarization and muscle contraction (Bartos et al., 2015).  
To achieve a fast electromechanical coupling, cardiomyocytes have structural features. 
The sarcolemma forms the T-tubules system that allows fast electrical excitation through 
the cell (Walker & Spinale, 1999). Moreover, the amount of voltage-gated calcium channels 
(Cav) is high in the T-tubule (Shaw & Colecraft, 2013), which enables fast influx of Ca2+ 
ions into the cardiomyocyte after depolarization of the sarcolemma. During the plateau 
phase of the cardiac action potential, the Cav1.2 channels transport Ca2+ from the 
extracellular space in the cardiomyocyte (Rougier & Abriel, 2016) (Figure 1). The 
intracellular Ca2+ stores are located in each T-tubules as the sarcoplasmic reticulum (SR) 
(Figure 1). The rising intracellular Ca2+ concentration activates the ryanodine receptor 
(RyR) in the SR which releases large amounts of Ca2+ ions from the SR (Laver, 2007). The 
cytosolic Ca2+ concentration increases from 500 nM to 1 µM upon excitation (Fearnley et 
al., 2011). As a consequence the intracellular Ca2+ ions bind to troponin C which allows 
muscle contraction in the thin filament by actin and myosin interaction (Gomes et al., 2002).  
 
After contraction, relaxation of cardiomyocytes is regulated by reducing the intracellular 
Ca2+ concentration (Eisner et al., 2017). Lowering the intracellular Ca2+ concentration is 
mainly performed by a combined activity of SERCA2a, plasma membrane Ca2+-ATPases 
and Na+/Ca2+ exchanger (NCX) (Calderón et al., 2014). In humans, SERCA transports 
more than 70% of the cytosolic Ca2+ back to the SR. (MacLennan & Kranias., 2003). 
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Thereby, SERCA is mainly responsible to mediate cardiomyocyte relaxation after a 
contraction (MacLennan & Kranias 2003). SERCA is inserted into the SR membrane and 
regulated by a small protein called phospholamban (PLN) (MacLennan & Kranias 2003) 
(Figure 1). PLN is the reversible inhibitor of SERCA, phosphorylation disrupts the 
PLN/SERCA interaction and relives the inhibitory effect resulting in enhanced 
cardiomyocyte relaxation (Chu et al., 2000).  
Phosphorylation of PLN is regulated by the beta-adrenergic signaling pathway in parallel 
with the excitation-contraction pathway (Figure 1). Beta-agonists, such as catecholamines, 
bind a beta-adrenergic receptor which activates a Gs protein-coupled signal cascade 
resulting in an activated adenylate cyclase and increased intracellular cyclic AMP (cAMP) 
levels in cardiomyocytes. High cellular cAMP levels activate the cAMP-dependent protein 
kinase A (PKA) which phosphorylates several cardiac proteins including PLN (MacLennan 
& Kranias 2003) (Figure 1). PKA also phosphorylates phosphatases such as protein 
phosphates 1 (PP1) which is known to dephosphorylate PLN (Mattiazzi et al., 2005; 
Vafiadaki et al., 2013). Upon PKA phosphorylation PP1 is inhibited (Mattiazzi et al., 2005). 
PKA phosphorylation of PLN and PP1 at the time avoids fast dephosphorylation of PLN 
and allows SERCA to pump Ca2+ back into the SR. Lowered Ca2+ levels, due to the function 
of SERCA, reduces cellular cAMP levels which consequently release PP1 and 
dephosphorylates PLN leading to the inhibition of SERCA until a new cycle starts 
(MacLennan & Kranias 2003). The cardiac excitation-contraction coupling mechanism is 
an excellent example for how cardiac signaling pathways work together (MacLennan & 
Kranias 2003). 
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Figure 1. The cardiac-excitation-contraction coupling scheme. 
Cardiomyocyte contraction and heart function is achieved by an electrical stimulus which activates 
voltage regulated Ca2+ channels (DHPR) leading to an increased cellular Ca2+ concentration. The 
Ca2+ ions activate ryanodine receptor (RyR) which releases large amounts of Ca2+ from the 
intracellular Ca2+ storages of the SR. The Ca2+ ions bind the myofilament and induce cardiac 
contraction. Relaxation of the cardiomyocyte requires removal of the Ca2+ ions out of the cytosol. 
This is done by SERCA2a, plasma membrane Ca2+ ATPase (PMCA) and the Na+/Ca2+ transporter 
(NCX). Most of the Ca2+ is transported by SERCA which is inhibited by PLN, but the inhibition is 
relieved after phosphorylation of PLN. PLN is phosphorylated by cAMP or Ca2+ dependent kinases 
which are regulated over receptor mediated signal transduction. Figure adapted from (MacLennan 
& Kranias 2003). 
 
1.2 Phospholamban 
PLN is a small tail-anchored protein which is located in the SR. PLN is the reversible 
inhibitor of the cardiac isoform of SERCA and therefore important for intracellular Ca2+ 
handling and cardiac contraction (James et al., 1989). PLN is abundantly expressed in 
cardiac muscle and in reduced amounts also in smooth and slow skeletal muscle. In 
comparison to the cardiac expression, PLN is 10-50-fold less abundant in the skeletal 
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muscle (McTiernan et al., 1999). PLN is regulated by oligomerization and phosphorylation 
mediated by different kinases. 
 
1.2.1 Structure of PLN  
The PLN monomer consists of 52 amino acids (aa) which forms 4 dynamic domains: Ia (1-
16 aa), the loop (17-22 aa), Ib (23-30 aa) and II (31-52 aa) (Figure 2) (Traaseth et al., 
2007). The 4 dynamic regions form 3 structural and functional domains: the cytoplasmic 
helix Ia (1-16 aa) responsible for PLN phosphorylation and regulation, the loop (17-22 aa) 
which connects the cytoplasmic with the transmembrane helix, and the transmembrane 
helix including domain Ib and II (23-52 aa) (Figure 2) (Zamoon et al., 2003).  
 
Figure 2. Schematic representation of PLN.  
The 52 aa of PLN are organized in 4 dynamic domains. Domain Ia (1-16 aa) is the cytoplasmic helix 
which is connected via the loop (17-22 aa) with the transmembrane helix consisting of domain Ib 
(23-30 aa) and domain II (31-52aa). 
 
The cytoplasmic helix domain Ia is a rigid, amphipathic alpha-helix that contains 
hydrophobic amino acids which allow insertion into the SR membrane facing the cytoplasm 
(Figure 3) (Kimura et al., 1997; Simmerman et al., 1996). The positively charged arginine 
residues (R9, R13, R14) bind to the negatively charged lipid head groups in the membrane 
and stabilize the insertion of the Ia helix (Ablorh & Thomas, 2015). Domain Ia contains a 
serine 16 (S16) phosphorylation site which is phosphorylated by PKA, S16 
phosphorylation disrupts the PLN/SERCA interaction resulting in SERCA activation 
(Coyler, 1998). Phosphorylation of PLN shifts the equilibrium of domain Ia from the T-state 
to the R-state (Karim et al., 2006; Metcalfe et al., 2005). The structural order-to-disorder 
(T- to R-state) shift unwinds the cytoplasmic helix domain Ia and loosens the hydrophobic 
and electrostatic interactions with the SR membrane (Figure 3) (Karim et al., 2006). This 
was shown with nuclear magnetic resonance (NMR) residual dipolar coupling indicating a 
reduced number of contacts between the SR membrane and PLN cytoplasmic domain 
helix Ia in the disordered R-state (De Simone et al., 2013). Altogether, the cytosolic domain 
Ia can be present in two different conformational states: The rigid L-shaped T-state in 
which the cytosolic domain is helical and membrane bound, and the R-state in which the 
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cytosolic domain is partially unfolded and extended (Gustavsson et al., 2013). Folding and 
unfolding of the cytosolic domain of PLN and therefore the transition from the T-state to 
the R-state and vice versa happens relatively fast in the µs-ms range (Traaseth & Veglia, 
2010). 
The loop region in PLN (17-22 aa) connects the cytoplasmic loop with the transmembrane 
region and consists mostly of hydrophobic aa which allow the localization over the 
membrane surface (Ablorh & Thomas, 2015). The loop is the only region in PLN which is 
permanently exposed to the cytoplasm. The second phosphorylation site in PLN is located 
in the loop region and a Ca2+-calmodulin-dependent protein kinase II (CaMKII) target site. 
Phosphorylation of the threonine 17 (T17) residue also disrupts the PLN/SERCA 
interaction (Mundiña-Weilenmann et al., 1996). After phosphorylation of either S16 or T17 
in PLN, the loop extends and stabilizes the shift to the dynamic, unstructured R-state (Ha 
et al., 2012) (Figure 3). 
 
Figure 3. PLN exists in two different structural states.  
The rigid T-state where domain Ia is helical and attached to the membrane or the extended and 
dynamic R-state, where domain Ia partially unfolds and loses contact to the SR membrane. In the 
T-state, PLN inhibits SERCA, but not in the R-state. The shift from T- to R-state is initiated by 
phosphorylation. Figure adapted from (Ablorh et al., 2015). 
 
The transmembrane region of PLN consists of two domains Ib and II, which are both 
hydrophobic alpha-helices aligned on top of each other (Yu & Lorigan, 2014). The 
transmembrane region is important for PLN oligomerization and the interaction between 
PLN and SERCA (Ablorh & Thomas, 2015). The PLN transmembrane helix was found to 
be sufficient to fully inhibit SERCA (Kimura et al., 1997; Metcalfe et al., 2004). S16 
phosphorylation in the cytosolic domain Ia shifts the PLN equilibrium towards the R-state 
also causing a structural change in domain Ib from an alpha-helix to an uncoiled structure 
which loses the alignment with domain II (Traaseth et al., 2006). This changes in the 
dynamics of the transmembrane domain Ib result in a decreased inhibitory effect of PLN 
on SERCA (Gustavsson et al., 2011; Karim et al., 2006; Traaseth et al., 2006).  
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Mutagenesis studies showed that the residues L31, L42 and L52 are essential for the 
physical PLN/SERCA interaction (Afara et al., 2006). These residues are located at one 
site of the domain II helix, creating a PLN/SERCA interface (Afara et al., 2006). Molecular 
modeling shows that the PLN residues P35, I38, I48 and V49 form a hydrophobic pocket 
near the SERCA N-terminus and stabilize the PLN SERCA interaction (Afara et al., 2006). 
The opposite face of the domain II helix is required for PLN oligomerization and pentamer 
formation. The residues L37, I40, L44, I47 and L51 form a leucine/isoleucine zipper which 
is required for pentamer formation (Simmerman et al., 1996) and stabilized by disulfide 
bridges formed between C36, C41 and C46 residues (Karim et al., 1998). In the PLN 
pentamer, the leucine/isoleucine zipper symmetrically pack and stabilize the pentamer 
conformation (Cornea et al., 2000; Simmerman et al., 1996). The PLN pentamer is SDS 
resistant and persists in a 1% SDS-PAGE (Simmerman et al., 1996). Detergent or gentle 
heating dissolves the PLN pentamer into the five monomers (Peuch et al., 1979; Wegener 
et al., 1986). On average, most PLN monomers and pentamers exist in the inhibitory T-
state, the R-state population is around 16-20% in the absence of SERCA (Gustavsson et 
al., 2011).  
 
1.2.2 Phosphorylation of PLN 
PLN is the reversible inhibitor of SERCA2a in cardiomyocytes (Tada et al., 1975) and 
regulated by phosphorylation. PLN has three different phosphorylation sites present in the 
cytosolic Ia domain: S16 is a PKA target site, T17 is phosphorylated by CaMKII and serine 
10 (S10) is a target site of protein kinase C (PKC) (Coyler, 1998). However, S10 
phosphorylation by PKC was abolished in-vivo and no physiological effect could be 
identified (Edes & Kranias, 1990). Phosphorylation of S16 or T17 via beta-adrenergic 
stimulation resulted in positive inotropic and cardiac relaxant effects due to increased 
SERCA activity and Ca2+ uptake in the SR (Mattiazzi & Kranias, 2014). The two different 
phosphorylation sites in PLN, which are regulated via two different kinases, offer several 
possibilities of PLN regulation. 
During beta-adrenergic stimulation, both S16 and T17 are phosphorylated simultaneously 
(Bilezikjian et al., 1981; Davis et al., 1990). Phosphorylation at T17 required increased 
intracellular cAMP levels to activate CaMKII kinase in-vivo (Kuschel et al., 1999; 
Lindemann et al., 1983). A study with transgenic mice expressing PLN WT, PLN S16A and 
PLN T17A in a PLN knockout mice background showed that phosphorylation at S16 in 
PLN is necessary to phosphorylate T17 (Luo et al., 1998). As a follow up, it was 
demonstrated that S16 can be phosphorylated without T17 phosphorylation in vivo and 
that phosphorylation of S16 alone still leads to maximal cardiac output upon beta-
adrenergic stimulation (Chu et al., 2000). In addition, it was found that phosphorylation of 
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T17 requires higher levels of beta-adrenergic stimulation than S16. At low beta-adrenergic 
stimulation, just S16 is phosphorylated because the intracellular Ca2+ levels are not 
sufficient to activate CaMKII and phosphorylate T17 (Said et al., 2002). This implies that 
phosphorylation of S16 is also happening before T17 phosphorylation in-vivo. However, 
higher beta-adrenergic stimulation (>10 nM isoprenaline) results in a 1:1 ratio of S16 and 
T17 phosphorylation in PLN (Mundiña-Weilenmann et al., 1996). 
In vitro S16 and T17 in PLN can be phosphorylated independently from each other 
(Bilezikjian et al., 1981). Under high Ca2+ levels and suppression of phosphatase activity, 
it was shown that T17 can be phosphorylated by CaMKII without prior S16 phosphorylation 
or beta-adrenergic stimulation (Mundiña-Weilenmann et al., 1996). This demonstrated that 
T17 phosphorylation mediated by CaMKII plays an important role for SERCA regulation 
under increased cardiac stimulation frequencies or elevated intracellular Ca2+ levels 
induced due to stress or pathophysiology conditions like ischemia-reperfusion injury or 
acidosis (Zhao et al., 2004; Mattiazzi, et al., 2005). 
Dephosphorylation of PLN is as important as phosphorylation regarding PLN regulation. 
PP1 was identified to be responsible for dephosphorylation of PLN at both phosphorylation 
sites S16 and T17 (MacDougall et al., 1991). PP1 is a serine/threonine phosphatase which 
consists of two subunits, a catalytic subunit PP1C and a regulatory subunit PP1GM 
(Mattiazzi et al., 2005). The PP1GM subunit is responsible for the correct localization of the 
catalytic subunit PP1C to the SR membrane and the target protein. PKA also 
phosphorylates the PP1GM subunit at Ser67 upon beta-adrenergic signaling resulting in 
dissociation of the PP1C subunit (Mattiazzi et al., 2005). As a consequence, PP1C binds 
with high affinity to the regulatory proteins inhibitor 1 (I-1) and the small heat shock protein 
(HSP20) followed by inhibition (Vafiadaki et al., 2013) until dephosphorylation of PP1. 
Overall, PKA phosphorylation ensures PLN phosphorylation by simultaneous 
phosphorylation and inhibition of PP1 (Mattiazzi et al., 2005; Vafiadaki et al., 2013). 
However, in contrast to PKA, CaMKII kinase cannot phosphorylate PP1 after activation 
(Mattiazzi & Kranias, 2014).  
 
1.2.3 Function of PLN monomers and pentamers 
PLN exists in two different physiological conformations in the heart, the monomer and the 
pentamer which are in a dynamic equilibrium (Traaseth et al., 2008).  
The SERCA interaction site in the PLN transmembrane domain is located on the helical 
face which is not required for pentamer formation, therefore pentameric PLN can 
theoretically interact with SERCA (Kimura et al., 1997). Whether pentameric PLN inhibits 
SERCA was analysed with an alanine-scanning mutagenesis and further aa substitution 
studies revealing that pentameric PLN has a very reduced inhibitory effect on SERCA 
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(Cornea et al., 2000; Kimura et al., 1996, Kimura et al., 1997). On the basis of these results, 
the general assumption, that PLN monomers act as an inhibitor of SERCA and the 
pentamers serve as a storage, were developed (Becucci et al., 2009; Kimura et al., 1997; 
MacLennan & Kranias 2003).  
It was also found that upon beta-adrenergic stimulation and subsequent phosphorylation 
of PLN, the inhibitory effect on SERCA was relieved (MacLennan et al., 1998). 
Furthermore, it was suggested that after phosphorylation the PLN monomers are stored in 
the pentameric form until more PLN monomers are required (Kimura et al., 1997). 
Radioactive labeled PLN shifted the isoelectric point (pI) after PKA phosphorylation from 
basic (pI = 10) to neutral (pI = 6.7) in isoelectric focusing gels, indicating an increased size 
of the PLN protein after phosphorylation (Jones et al., 1985). Later the number of contacts 
of recombinant PLN in a phospholipid bilayer was measured with electron spin resonance 
experiments before and after PKA phosphorylation. The number of contacts of PLN with 
the lipid bilayer decreased after phosphorylation, supporting a theory that phosphorylation 
leads to PLN pentamer formation (Cornea et al., 1997).  
However, Wittmann et al found with phosphorylation stimulation experiments that the 
pentamer can be directly phosphorylated by PKA even with a higher affinity for the 
pentamer. Phosphorylation patterns of different monomer/pentamer ratios in mammalian 
cells showed that PLN pentamers delay monomer phosphorylation. From this, the authors 
postulate a model where PLN pentamers are first phosphorylated after beta-adrenergic 
phosphorylation which prolongs the PLN monomer SERCA interaction and therefore the 
inhibitory effect of PLN on SERCA (Wittmann et al., 2015).  
Despite the evidence that pentameric PLN has a very reduced effect on SERCA inhibition 
(Cornea et al., 2000; Kimura et al., 1996, Kimura et al., 1997), Wittmann et al pulled down 
both PLN monomers and pentamers in co-immunoprecipitation experiments with SERCA 
(Wittmann et al., 2015). Already in 1998, it was shown with transgenic mice models 
expressing different conformational states of PLN, that the PLN pentamers play an 
important role for cardiac contraction in vivo (Chu et al., 1998). In 2005 a first model for 
the interaction of PLN pentamers with SERCA was suggested (Oxenoid & Chou, 2005). 
With NMR analysis, it was shown that the aa which are involved in the SERCA interaction 
are exposed on the transmembrane segment opposite to the aa which are required for 
pentamer formation. A model was suggested where pentameric PLN binds a lateral binding 
groove in SERCA (Oxenoid & Chou, 2005). Recently, 2-D crystals show first evidence of 
an interaction between a PLN oligomer and the SERCA transmembrane segment M3 
(Glaves et al., 2019). The binding site of PLN pentamers in SERCA is far away from the 
binding groove of monomeric PLN. Moreover, it was shown that the SERCA binding groove 
of monomeric PLN containing helix M2, M4, M6 and M9 is flexible, while the binding site 
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of pentameric PLN helix M3 is more rigid. The M3 helix is a stable interaction site for 
pentameric PLN, allowing additional SERCA regulation (Glaves et al., 2011). The 
physiological function of this interaction remains unknown. 
 
1.2.4 The PLN and SERCA2a interaction  
The PLN and SERCA interaction site in both proteins were analysed with mutagenesis and 
cross-linking experiments. It revealed that transmembrane domain II of monomeric PLN 
interacts with helices M2, M4, M6 and M9 of the transmembrane domain of SERCA which 
form a hydrophobic groove (Figure 4). The interaction is additionally stabilized by 
interactions of K3 and I18 of PLN and a stretch of K397 to V402 in SERCA (Figure 4) 
(Kimura et al., 1997; Toyofuku et al., 1994). The Ca2+ binding site in SERCA is on the 
opposite face of helix M6 (Asahi et al., 2001). The cytoplasmic domain of PLN was 
completely unresolved in the latest X-ray structure of PLN and SERCA (Akin et al., 2013). 
Interaction of the transmembrane domain of PLN to the hydrophobic cleft in SERCA occurs 
only in the Ca2+-free E2 conformation preventing closing of the cleft during the transition of 
E2 to the high affinity E1 conformation (Vandecaetsbeek et al., 2011).  
 
Figure 4. PLN interaction sites in the crystal structure of SERCA1a.  
The transmembrane domain II of PLN binds to transmembrane domain M6 in SERCA in a groove 
between helices M2 and M9. The loop of PLN unfolds and stretches toward the N-terminus of 
SERCA and bind with the K3 residue the SERCA residues K397-V402. PLN is depicted as cyan 
sticks. Figure adapted from (MacLennan & Kranias 2003).  
 
Different interaction models currently exist regarding the PLN/SERCA2a interaction. A 
dissociation model was postulated assuming that after phosphorylation or under high 
cellular Ca2+ concentrations the PLN monomer dissociates from SERCA which disrupts 
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the inhibitory effect on SERCA (Figure 5). After dissociation of PLN from SERCA, the PLN 
monomers are stored as pentamers. The dissociation model was developed based on 
cross-linking and co-immunoprecipitation experiments between SERCA and PLN (Chen 
et al., 2003; James et al., 1989). 
 
Figure 5. PLN/SERCA interaction in the dissociation model.  
The PLN monomer bound to SERCA inhibits SERCA. After phosphorylation PLN dissociates from 
SERCA consequently SERCA is relieved from inhibition and transport Ca2+ ions. 
 
The dissociation model is challenged by the subunit-model, which suggests a structural 
rearrangement of PLN after phosphorylation without dissociation of the PLN/SERCA 
construct (Dong & Thomas, 2014). Gustavsson et al identified an additional conformation 
of PLN called the B-state, which means bound to SERCA but not inhibitory (Gustavsson 
et al., 2013). The subunit model proposes a structural rearrangement of PLN after 
phosphorylation of PLN and does not induce dissociation of the PLN/SERCA construct 
(Dong & Thomas, 2014). Phosphorylation shifts the inhibitory T-state of PLN to the more 
flexible and non-inhibitory R-state (Gustavsson et al., 2013). In the T-state confirmation, 
the cytosolic domain Ia of PLN is attached to the SR membrane, phosphorylation leads to 
partial unfolding of the cytosolic domain which binds to the cytosolic region of SERCA 
(Gustavsson et al., 2013). This rearrangement of PLN in the B-state disrupts the inhibitory 
effect on SERCA without dissociation (Figure 6) (Gustavsson et al., 2013). 
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Figure 6. PLN/SERCA interaction in the subunit model.  
The subunit model postulate that the inhibitory effect of PLN on SERCA depends on the 
confirmation of PLN and not on PLN SERCA binding. Upon phosphorylation, the cytosolic domain 
of PLN is partially unfolded and PLN is converted towards the R-state. In this conformation, the 
cytosolic domain of PLN binds the cytosolic region of SERCA and shifts the transmembrane domain 
of PLN and therefore loosens the SERCA/PLN interaction without dissociation. Figure adapted from 
(Gustavsson et al., 2013). 
 
1.2.5 Pathophysiological relevance of PLN in the human heart 
PLN is a direct inhibitor of SERCA and an important modulator of cardiac diastolic function. 
Consequently, decreased expression of SERCA and PLN at the RNA and protein levels 
were associated with cardiac dysfunction in animal models (McTiernan et al., 1999). A 
couple of PLN mutations in humans were identified and are usually single aa substitutions 
or deletions in the cytosolic domain of PLN as R9C, R9L and R14del (Young et al., 2015). 
The L39Stop mutation is the only human PLN mutation identified in the transmembrane 
domain of PLN (Haghighi et al., 2003). All mentioned mutations in the PLN gene are 
associated with dilated cardiomyopathy (DCM), right ventricular arrhythmogenic 
cardiomyopathy (ARVC) and heart failure (HF) (Young et al., 2015). DCM is associated 
with left ventricular contractile dysfunction due to an enlarged ventricle causing a 
progression to HF (van der Zwaag et al., 2012). ARVC is characterized by ventricular 
arrhythmias, predominantly from right ventricle leading to HF and sudden cardiac death 
(van der Zwaag et al., 2012). ARVC is the most-well known sub-form of arrhythmogenic 
cardiomyopathy (ACM) (van Opbergen et al., 2017). 
The R14del mutation was identified in many patients with DCM or ACM in the Netherlands 
and could be traced back to originating from the north of Friesland (van der Zwaag et al., 
2013). The R14del mutation disrupts the PKA binding site in PLN and therefore avoids S16 
phosphorylation (Haghighi et al., 2006; te Rijdt et al., 2016). Interestingly, Haghighi et al 
showed that PLN R14del is a super-inhibitor of SERCA when expressed together with 
healthy WT PLN in mammalian cells (Haghighi et al., 2006). Later, it was also shown that 
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just PLN R14del expression in mammalian cells leads to mislocalisation of R14del PLN to 
the plasma membrane (Haghighi et al., 2012). So far just R14del heterozygous patients 
were identified, showing super-inhibition of SERCA which alters Ca2+ transport and leads 
to ventricular remodeling over time as well as the development of HF (Hof et al., 2019). In 
line, it was also shown that the R14del mutation destabilizes PLN pentamers subsequently 
increasing the amount of PLN R14del monomers and enhancing the super-inhibitory effect 
of the R14del PLN mutation (van Opbergen et al., 2017).  
The L39Stop mutation was identified in heterozygous patients resulting in hypertrophy 
without reduced contractile performance and in homozygous patients resulting in lethal 
DCM (Haghighi et al., 2003; Landstrom et al., 2011). The functional consequence of the 
L39Stop mutation was analysed by co-expression experiments of PLN Leu39Stop and 
SERCA in mammalian cells resulting in no SERCA inhibition and a loss of function 
mutation in a homozygous background (Haghighi et al., 2003). To mimic a heterozygous 
model PLN, WT and PLN Leu39Stop were co-expressed with SERCA showing SERCA 
inhibition (Haghighi et al., 2003). Moreover, PLN carrying the L39Stop mutation was nearly 
absent in Western blotting and immunofluorescence (IF) experiments in mammalian cells 
indicating that the L39Stop mutation is either misrouted, highly unstable or fast degraded 
(Haghighi et al., 2003). The identification of humans carrying a homozygous L39Stopp 
mutation is the first natural loss-of-function PLN mutation in humans (PLN null) resulting 
in lethal DCM with early death (Haghighi et al., 2003). Strikingly, these findings are in 
strong contrast to findings of PLN ablation in mice resulting in increased cardiac function 
without development of HF (Hoit et al., 1995; Luo et al., 1994). 
These surprising results can be explained due to differences in cardiac physiology in 
human and mice (Haghighi et al., 2003). Mice show a faster contraction, different Ca2+ 
transport strategies into the SR (SERCA pumps 92% of Ca2+ to the SR in mice) and 
different isoforms of motor proteins in comparison with humans (Haghighi et al., 2003; 
MacLennan & Kranias 2003).  
The R9C mutation was also associated with early onset DCM (Schmitt et al., 2003). In the 
R9C mutation, a positively charged arginine residue is substituted by a reactive cysteine 
residue altering the hydrophobicity of the cytosolic PLN region resulting in a loss of function 
mutation (Schmitt et al., 2003). Until today, the R9C mutation was just identified in 
heterozygous patients. To mimic heterozygous conditions, equal R9C PLN and WT PLN 
were reconstituted in proteoliposomes together with SERCA and resulted in a dominant 
negative effect on SERCA (Ceholski et al., 2012). The same was true for the R9L mutation 
(Ceholski et al., 2012).  
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1.3 The phosphoadaptor protein 14-3-3  
The 14-3-3 proteins are a ubiquitous class of regulatory proteins and were the first family 
of proteins to be regarded as phospho-serine/-threonine binding modules, regulating and 
influencing various phospho-proteins (Gardino et al., 2006).  
First identified as a brain protein, the 14-3-3 protein family turned out to be ubiquitously 
expressed in all eukaryotic cells (Aitken et al., 1992). Seven different 14-3-3 isoforms were 
identified in mammals, two different isoforms were identified in yeast and 15 different 
isoforms in plants (labelled with Greek letters) (Sluchanko & Bustos, 2019).  
The 14-3-3 proteins are homologous proteins and highly conserved among species 
(Ichimura et al., 1988; Wang & Shakes, 1996). In eukaryotic cells, 14-3-3 proteins are 
mostly cytosolic proteins (Mhawech, 2005) with a broad range of protein targets, like 
receptors, kinases, phosphatases, transcription factors and several docking or regulatory 
proteins, as well as oncogene products (Cau et al., 2018; Fu et al., 2000). Related to this 
broad spectrum of interaction partners, 14-3-3 proteins are involved in many cellular 
functions, such as intracellular trafficking, cell proliferation, signal transduction, apoptosis 
and stress response, underlining the physiological importance (Cau et al., 2018; Fu et al., 
2000). 
 
1.3.1 14-3-3 proteins in eukaryotes: Structure and function  
The broad number of 14-3-3 ligands draw the idea that shared binding requirements 
mediate the 14-3-3 interaction (Fu et al., 2000). Early investigations of 14-3-3 interactions 
suggest that phosphorylated residues in the ligands are a requirement (Fu et al., 2000). 
The first suggested 14-3-3 consensus motif was RSX(pS/T)XP, where X represents any 
aa and pS/T a phosphorylated serine or threonine residue (Muslin et al., 1996; Rittinger et 
al., 1999). According to its proposal, this consensus motif is called mode I binding motif. 
Later, several additional sequences which are recognized by 14-3-3 proteins were 
identified, resulting in a mode II binding motif RX(F/Y)XpSXP and a mode III motif 
(pS/T)XCOOH (Johnson et al., 2010; Obsil et al., 2003). Mode I and II 14-3-3 binding 
ligands require an arginine at position -3 with respect to the phosphorylated residue and a 
proline residue at position +2 (Yaffe et al., 1997). Various examples showed that 14-3-3 
interaction is regulated via phosphorylation of the ligand, however 14-3-3 can interact with 
unphosphorylated residues (Johnson et al., 2010; Obsil et al., 2003). It has been reported 
that unphosphorylated 14-3-3 interaction partners have several negatively charged 
glutamine residues in their sequence to overcome the phosphorylation residue (Wang et 
al., 1999). 
Crystal structures from different human 14-3-3 isoforms have been resolved showing very 
similar structures (Gardino et al., 2006). Each monomer consists of nine antiparallel 
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organized alpha-helices forming an amphipathic binding grove (Stevers et al., 2018). A 
14-3-3 monomer has a U-shaped conserved inner concave surface and a variable outer 
surface. The inner concave surface is an amphipathic groove, which contains helices 3 
and 5 on one side creating a charged, polar surrounding. Meanwhile on the opposite side, 
helices 7 and 9 create a hydrophobic area (Figure 7) (Fu et al., 2000). The 14-3-3 binding 
groove is conserved among the 14-3-3 isoforms (Obsil & Obsilova, 2011; Rosenquist et 
al., 2000). Mutagenesis and co-crystallization experiments showed that the basic residues 
K49, R56 and R127 are important for the interaction with the phosphorylated 14-3-3 
interaction partner (Rittinger et al., 1999). Many 14-3-3 interaction partners can bind all 
14-3-3 isoforms expressed in that species, indicating the highly conserved amphipathic 
14-3-3 binding groove mediates the interaction (D. Liu et al., 1995). Furthermore, it was 
shown with co-crystallization that the contact between 14-3-3 and a phosphorylated serine 
is stabilized over salt bridges to the side chains K49, R56 and R127 and a hydroxyl group 
in Y128 (Figure 7). Extended ligand confirmations are stabilized in the 14-3-3 binding 
groove by the residues K120, N173 and N224 which make contacts to the backbone 
groups of the +1 and -1 residue and allow the correct positioning of the phosphorylation 
group (Rittinger et al., 1999). 
 
Figure 7. Crystal structure of 14-3-3 monomeric subunit.  
The amphipathic groove where 14-3-3 ligand binding occurs (human zeta isoform PDB ID code 
2C1). The basic residues K49, R56, R127 are required for contacting the binding partner. The 
residues K49, R56 and R127 and Y128 stabilize the phospho-residue through salt bridges and 
hydroxyl groups. The hydrophobic area of the binding groove is indicated in green (zero charges, 
“0”) and the polar side is shown in blue (positive charges, “+”). Figure adapted from (Sluchanko & 
Gusev, 2016). 
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Functional 14-3-3 proteins form a dimer with the N-terminus of another 14-3-3 protein 
(Figure 8) (Liu et al., 1995; Xiao et al., 1995). Dimerization of 14-3-3 proteins allow the 
formation of homo- and heterodimers (Benzinger et al., 2005; Jones et al., 1995). For the 
dimer formation, contacts between the alpha1 helix of one monomer and the alpha 3 as 
well as alpha helix 4 from the other monomer are necessary (Figure 8) (Jones et al., 1995). 
The dimer is stabilized by hydrophobic and electrostatic forces formed between the amino 
acid side chains and a highly conserved salt bridge between R18 of the alpha helix 1 and 
E89 of alpha helix 4 (Cau et al., 2018). Interestingly, a 14-3-3 dimer is able to bind two 
ligands at once (Cau et al., 2018). The ligand binding grooves in a 14-3-3 dimer is arranged 
in a way that they are facing in opposite directions. 
 
Figure 8. Crystal structure of 14-3-3 protein dimer.  
(A) Ribbon representation of dimeric 14-3-3 showing the position of 9 alpha helixes per monomer 
and the contact between helix 1 of one monomer with helix 3 and 4 of the other monomer (human 
zeta isoform PDB ID code 1QJB). (B) Surface representation representing the conserved residues 
among all seven human isoforms in red. Within the conserved residues the conserved binding site 
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Even though the spectrum of 14-3-3 ligands is huge and 14-3-3 proteins are involved in 
various intracellular functions, four different modes of action have been suggested for 
14-3-3 protein interactions: (1) inducing conformational changes in the target protein, (2) 
interference of protein-protein or DNA-protein interactions, (3) assembly of two proteins in 
close proximity and (4) stabilization of specific conformations (Figure 9) (Cau et al., 2018; 
Coblitz et al., 2006; Fu et al., 2000). 
 
 
Figure 9. Different functions of the 14-3-3 protein interaction.  
(A) Binding of 14-3-3 can change the conformation of the ligand and stabilize different 
conformational changes which influence the function of the ligand. (B) 14-3-3 can separate 
interacting ligands by clamping one ligand and stabilizing the separation. (C) The dimeric structure 
of the 14-3-3 protein allows to bind two ligands at the same time, bring them in close proximity and 
stabilize them as a complex. (D) 14-3-3 can stabilize proteins in a phosphorylated conformation and 
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1.3.2 Isoform specificity and regulation of 14-3-3 proteins 
The expression of seven different 14-3-3 isoforms in mammals lead to the idea of an 
isoform specificity for different target proteins, introducing another possibility of fine tuning 
and regulation of protein-protein interactions. However, the binding groove is highly 
conserved among the 14-3-3 isoforms (Figure 8) (Yaffe et al., 1997), and variability is 
achieved with just a few residues around the ligand binding site which may create a ligand 
preference for different isoforms (Vincenz & Dixit, 1996). In many cases, all 14-3-3 
isoforms are able to bind a phosphoresidue of a ligand with comparable affinities (Yaffe et 
al., 1997). Another possibility to achieve isoform specificity are posttranslational 
modifications of the 14-3-3 isoforms and isoform specific expression levels (Fu et al., 
2000). Regarding posttranslational modifications, acetylation of lysine residues close to 
the 14-3-3 binding pocket, such as K49 and K120, negatively influence binding of target 
proteins (Choudhary et al., 2009).  
During mouse embryogenesis and neuronal development different 14-3-3 isoforms show 
very dynamic expression patterns indicating that different 14-3-3 isoforms are required for 
different cellular processes (Meller et al., 1996; Watanabe et al., 1993). Moreover, in many 
cancer types aberrant expression of individual 14-3-3 isoforms have been identified 
(Hermeking, 2003). The expression of 14-3-3 zeta was found to be upregulated in many 
cancer cells, for example in patients with breast cancer (Neal et al., 2009). The 
upregulation of 14-3-3 zeta in this context was also correlated with a poor cancer prognosis 
of these patients (Neal et al., 2009). Interestingly, low expression of 14-3-3 isoforms 
gamma and theta are associated with markers for breath cancer (Song et al., 2012). In 
contrast, 14-3-3 sigma was reported to has a suppressive effect on cancer cell growth and 
tumor formation (Li et al., 2009). These are a few examples of effects caused by different 
expression levels of 14-3-3 isoforms implying that different expression levels may regulate 
14-3-3 proteins (Cau et al., 2018).  
The involvement of different 14-3-3 isoforms in cancer, as well as in neurodegenerative 
and other human diseases, indicate the importance of 14-3-3 modulation. The 
circumstances, that 14-3-3 proteins act in many cases as adaptor proteins raises interest 
in the use of active compounds against 14-3-3 to impact binding partners (Stevers et al., 
2018). In principle two strategies are considerable, inhibition (e.g. R18) or stabilization of 
the interaction (e.g. fusicoccanes) (Stevers et al., 2018; Thiel et al., 2012). In both cases, 
small molecules can be used to either block the 14-3-3 binding groove or to stabilize the 
interaction. Extensive research is ongoing to identify such small protein interactors, which 
can help to modulate 14-3-3 protein interactions (Cau et al., 2018).  
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1.4 Potassium ion channels 
Ion channels are integral membrane proteins which are inserted into the plasma 
membrane and are responsible for ion transfer over the lipid bilayer allowing cellular 
electrical excitability, signal transduction and muscle contraction (Bartos et al., 2015; 
Humphries & Dart, 2015). Potassium channels (K+) are a large family of ion channels found 
in a broad spectrum of organisms like mammals, plants, bacteria and viruses (Feliciangeli 
et al., 2015). Several different types of potassium channels are responsible to set the 
membrane resting potential in many different cell types (Humphries & Dart, 2015).  
The selectivity of K+ channels is mediated by a conserved sequence (T-X-G-X-G) located 
in a loop between transmembrane helixes (Sansom et al., 2002). The transmembrane 
helixes span the lipid bilayer and form together with the selectivity filter and a cage of eight 
oxygen residues the pore entry (Kim & Nimigean, 2016). The oxygen residues are placed 
in a way that allows optimal interaction with K+ ions to achieve selectivity (Kuang et al., 
2015; MacKinnon, 2003). The interaction of the oxygen residues dehydrates the K+ ion 
and allows passage through the pore (Kuang et al., 2015). The smaller Na+ ions cannot 
interact with the oxygen residues around the K+ pore and therefore do not enter the pore 
(Shrivastava et al., 2002). 
Overall K+ channels can be subdivided in three families: voltage gated (Kv) channels, 
inward rectifier (Kir) channels and two-pore domain potassium (K2P) channels (Goldstein 
et al., 2001; Reimann & Ashcroft, 1999) (Figure 10). Kv and Kir channels form tetramers 
while K2P channels dimerize in order to form a functional K+ channel (Kuang et al., 2015). 
The correct assembly of the four pore domains is essential for the channel function 
(Sansom et al., 2002).  
Kir channels mostly transport K+ ions from the outside to inside of the cell (Reimann & 
Ashcroft, 1999). Four different subgroups are subdivided within the Kir channel family: (1) 
classical lipid gated Kir channels, (2) G-protein gated Kir channels (3) ATP gated Kir 
channels and (4) K+ transport channels (Hibino et al., 2010). The basic structure of Kir 
channels contain two transmembrane segments flanking a pore forming loop (Figure 10). 
The transmembrane segment has cytoplasmic NH2 and COOH termini which contain 
several regulatory domains and allows modulation of Kir channel trafficking and function 
(Hibino et al., 2010). Functional Kir channels can be arranged in homo- or heterotetramers 
(Hibino et al., 2010). Besides an oligomerization function, Kir channels need 
phosphatidylinositol 4,5-bisphosphate (PIP2) as a cofactor (Huang et al., 1998).  
Kv channels are a very diverse group of K+ channels including 40 Kv channels which are 
classified into 12 different subgroups (Gutman et al., 2005). The basic structure of a Kv 
channel contains six transmembrane helices spanning the lipid bilayer and a NH2 and 
COOH termini. The pore forming domain is located between transmembrane domain 5 
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and 6, meanwhile the voltage sensor is located between transmembrane domain 4 and 5 
(Figure 10). The voltage sensor membrane depolarizes via a preserved domain of positive 
arginine or lysine residues which consequently opens the channel (Aggarwal & 
MacKinnon, 1996). Further regulation of Kv channels is mediated via the amino- and 
carboxy termini. The amino terminus is highly conserved among the huge variety of Kv 
channels and contains a tetramerization domain which is required for correct channel 
association into homo- or heterotetramers (Bocksteins et al., 2009; Kurata et al., 2002).  
K2P channels are a relatively newly discovered K+ channel family. The group of K2P 
channels contains 15 identified channels that are grouped into six different subgroups. All 
K2P channels contain four transmembrane domains, two of which are pore forming loops, 
one short cytoplasmic NH2- terminus and one longer COOH terminus (Figure10) 
(Renigunta et al., 2015). 
 
Figure 10. The K+ channels are subdivided into three main families.  
The board spectrum of K+ channels belong to three main groups according to structure, activation 
stimuli or behavior. (A) Kir channels are inwardly rectifier K+ channels, (B) Kv channels are voltage 
sensitive channels and (C) two-pore domain K+ channels (K2P) are channels which contribute to 
background leak currents during an action potential and are regulated via pH changes or 
mechanical forces in the membrane. Functional Kir and Kv channels form tetramers, whereas K2P 
channels form dimers. Figure adapted from (Makino et al., 2011).  
 
1.4.1 Two-pore potassium channels  
The six subgroups of K2P are the following: TWIK (two-pore domain weakly inward 
rectifying K+ channel), TREK (TWIK-related K+ channel), TASK (TWIK-related acid 
sensitive K+ channel), TRESK (TWIK-related spinal cord K+ channel), TALK (TWIK-related 
alkaline sensitive K+ channel) and THIK (tandem-pore domain halothane inhibited K+ 
channel) (Feliciangeli et al., 2015).  
The K2P channels are also called “open leak channels” because they have no voltage 
sensing domain and thereby are not regulated by the membrane potential (Duprat et al., 
1997; F. Lesage et al., 1996). However, these channels were identified to contribute to K+ 
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leak currents resulting in a generation of instantaneous and non-inactivating currents over 
the range of membrane potential (Feliciangeli et al., 2015). This enables K2P channels to 
contribute to the repolarization of the action potential and stabilize the negative resting 
membrane potential (Decher et al., 2011; Duprat et al., 1997; Jeevaratnam et al., 2018). 
In contrast, an inhibition of leak conductance leads to an increased resting membrane 
potential and delayed repolarization (Donner et al., 2011; Gurney & Manoury, 2009). The 
K2P channels are able to adapt to the intra- or extracellular ion concentration independent 
from the gradient of potassium ions over the cell membrane (Thomas & Goldstein, 2009).  
Even though K2P channels lack a canonical voltage sensing domain, they are able to sense 
voltage changes via the selectivity filter which is located in the pore (Schewe et al., 2016). 
Like other K+ channels, K2P channels are also regulated by two conserved gating 
mechanism. An inactivated gate with a closed selectivity filter facing the extracellular side 
of the lipid bilayer and an activated gate to the intracellular side (Mathie et al., 2010). Zinc 
and hydrogen ions regulate gating of K2P channels by interacting with the inactivated gate 
in many K2P channels (Mathie et al., 2010). 
K2P channels have been described to be regulated over various different stimuli, such as 
membrane stretching (Li et al., 2006), changes in extracellular pH values or by hydrophobic 
gating (Niemeyer et al., 2016). For example, the TRESK channel requires 
dephosphorylation for activation which is achieved by interaction with calcineurin. 
Therefore, TRESK channel activity is regulated by intracellular Ca2+ levels (Czirják et al., 
2004). On the other hand, stimulation of Gq-protein coupled receptors show an inhibitory 
effect on TASK channels in the brain (Chen et al., 2006) and heart (Putzke et al., 2007). 
In line with TASK channels, also TREK channels are inhibited by Gq-coupled activation 
(Mathie, 2007). 
Functional K2P channels assemble in dimers (Figure 11). Interestingly, homo- and 
heterodimers between different members of the K2P channel family were identified. Within 
a heterodimer each monomer contributes two-pore forming domains to form a pore with 
potential different affinities for stimulation or inhibition (Figure 11) (Niemeyer et al., 2016). 
Homo- and heterodimerization have been reported for several different K2P family 
members. For example, TWIK1 form together with TASK-1 or TASK-3 heterodimers with 
SUMOylating sensitivity (Plant et al., 2012). Also, heterodimers between THIK2 and THIK1 
were identified as an active K2P channel (Blin et al., 2014) or heterodimers for TWIK-1 and 
TREK1 which are responsible for passive conductance in astrocytes (Hwang et al., 2014). 
A functional heterodimer formed of TASK-1 and TASK-3 could be identified in different 
tissues and was found to contribute to K+ leak currents (Czirják & Enyedi, 2002; Enyedi & 
Czirják, 2010). Heterodimerization is a very effective way to generate channels with new 
or combined functions and behaviors resulting in a broad diversity. 
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Figure 11. Structure of K2P channel assembly. 
A functional K2P channel is a homo- or heterodimer. Each monomer (orange or blue) contributes 
four transmembrane domains and two-pore forming loops which are assembled into a function 
channel. The upper part of the representation shows the N-terminus of the channel and the lower 
part the C-terminus of the two subunits. Figure from (Renigunta et al., 2015). 
 
The K2P channels have been shown to be important regulators in various tissues with 
physiological and pathophysiological significances (Renigunta et al., 2015). K2P channels 
were first discovered in the brain, but some channels are also expressed in smooth muscle 
cells and in cardiomyocytes (Gurney & Manoury, 2009). The expression of TWIK, TASK, 
TREK and TRAAK channels was demonstrated at mRNA levels in rat hearts, whereas only 
TREK-1 and TASK-1 were identified on protein level (Gurney & Manoury, 2009; Liu & 
Saint, 2004; Putzke et al., 2007). Interestingly, human TREK-1 and TASK-1 channels are 
mostly expressed in the atrium, which makes them noteworthy for the treatment of atrial 
fibrillation (AF) (Gurney & Manoury, 2009). The cardiac action potential has a plateau 
phase between depolarization and repolarization of the cell which is characteristic for 
cardiomyocytes (Decher et al., 2015). Knock-down or knock-out of K2P channels in the 
heart results in a prolonged cardiac action potential, indicating their contribution to the 
plateau phase and the depolarization of cardiomyocytes (Limberg et al., 2011).  
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1.4.2 TASK ion channels 
The TASK channel family belongs to the K2P ion channel class and consist of three 
channels: TASK-1, TASK-3 and TASK-5. The TASK-1 channel was successfully cloned in 
1997 (Duprat et al., 1997) and since then a lot of research was done to analyse the function 
of TASK channels. The sub-family of TASK channels is acid sensitive resulting in activation 
by alkaline pH values and inhibition due to acidosis (Duprat et al., 1997). Physiological 
changes in the extracellular pH can take place during hypoxia or ischemia (Duprat et al., 
2007; Silver & Erecinska, 1990). 
TASK channels are, as all K2P channels, predominantly expressed in neurons and 
involved in the action potential generation (Renigunta et al., 2015). TASK-1 and TASK-3 
were found to directly contribute to the firing rate of neurons in the thalamus and are 
sensitive to anesthetics, resulting in an increased firing rate (Lesage 2003; Renigunta et 
al., 2015). Interestingly, the TASK-5 mRNA was found to be expressed in various tissues 
such as pancreas, liver, kidney and heart (Ashmole et al., 2001; Hopwood & Trapp, 2005). 
Heterologous expression of TASK-5 failed to generate whole-cell currents (Ashmole et al., 
2001; Kim & Gnatenco, 2001). TASK-5 channel distribution was found to be similar to 
TASK-1 in mammalian cells, but a heterodimeric TASK-1/TASK-5 channel could not be 
identified. It is still in question whether TASK-5 channels require other interactions partner 
to form a functional channel (Ashmole et al., 2001). Until know, the general assumption is, 
that TASK-5 channels are not functional (Lesage 2003). 
For TASK-1 and TASK-3 channels, homo- as well as heterodimers were identified in 
Xenopus laevis oocytes (Czirják & Enyedi, 2002). TASK-1/TASK-3 heterodimers showed 
in many cases intermediate behavior for chemical activators or inhibitors, thereby 
responding to AT(1a) angiotensin II receptor stimulation with weaker inhibition as 
homodimeric TASK-1 channel but greater as homodimeric TASK-3 channel. The same 
behavior was observed for the well investigated inhibitor ruthenium red (Czirják & Enyedi, 
2002). A potential heterodimerization between TASK-1 and TALK-2 was shown in 
pancreatic and mammalian cell lines with Förster resonance energy transfer (FRET) 
analysis. The sensitivity of the TASK-1/TALK-2 dimers to the extracellular pH and 
halothane was found to be unique for the hybrid (Suzuki et al., 2017).  
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1.4.2.1 Regulation of TASK channels by intracellular trafficking 
TASK channels are regulated like all K2P channels over various chemical and physical 
stimuli including pH changes, or by zinc and hydrogen ions. An additional way of post-
translational ion channel regulation is through intracellular trafficking which ensures 
localization in the plasma membrane. Trafficking of TASK channels is regulated by their 
distal C-terminus and the two adaptor proteins 14-3-3 and coat protein complex I (COPI) 
(Kilisch et al., 2015). The extreme C-terminus of TASK-1 and TASK-3 contains an 
overlapping COPI and 14-3-3 binding mode III motif. Interaction of these two binding 
partners is controlled by PKA phosphorylation (Mant et al., 2011). Mutagenesis studies of 
the C-terminus of TASK channels identified a di-arginine motif KRR as a COPI 
endoplasmic reticulum (ER) retention signal in TASK-1 and TASK-3 (Zuzarte et al., 2009). 
COPI binds the KRR signal in the unphosphorylated TASK channel and retains the 
channels in the early secretory pathway until PKA phosphorylation of TASK allows 14-3-3 
to bind which mediates forward trafficking (Figure 12). TASK channels were the first ion 
channels identified to interact with 14-3-3 (Rajan et al., 2002). With the help of mutagenesis 
studies, the last 40 aa of TASK channels were identified to contribute to 14-3-3 binding, 
whereas the last five aa were found to be essential for the interaction (Rajan et al., 2002). 
TASK channels with truncations in the C-terminus abolish 14-3-3 interaction and showed 
reduced or no currents measured by patch clamp (Rajan et al., 2002). This indicated that 
14-3-3 binding to TASK channels is important to regulate forward trafficking to the cell 
surface and exposure of the channel (Figure 12). 14-3-3 binding to the phosphorylated 
TASK channel mediates forward trafficking of TASK by two effects, it prevents COPI 
binding due to masking the COPI interaction site and binds the channel in a conformation 
that induces forward transport (Schwappach, 2008; Smith et al., 2011). Consequently, 
trafficking of TASK channels to the cell surface is regulated by protein kinases such as 
PKA and the corresponding phosphatase (Kilisch et al., 2015). 
  
Chapter I: Introduction 
 24 
 
Figure 12. Regulation of TASK channel expression at the cell surface by trafficking.  
Cell surface expression of TASK channels is regulated by phosphorylation dependent 14-3-3 or 
COPI interaction. COPI binds the unphosphorylated TASK channel and initiates retrograde 
trafficking to the ER. Phosphorylation of TASK allows 14-3-3 binding which is responsible for 
forward trafficking.  
 
14-3-3 binding to TASK channels is mediated via phosphorylated serine residues (S393 in 
TASK1 and S373 in TASK-3) (Figure 13). In line with the already known 14-3-3 COPI 
mediated trafficking of TASK channels, mutation of these serine residues abolish 
phosphorylation of the trafficking control domain and reduce surface expression and 
currents measured for TASK channels (Rajan, Preisig-Müller, et al., 2002; Zuzarte et al., 
2009). Interestingly, the TASK-1 channel contains a second PKA phosphorylatable serine 
residue (S392 in human TASK-1) in the extreme C-terminus (Mant et al., 2011) which is 
not present in TASK-3 (Figure 13).  
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Figure 13. Schematic representation of the TASK-1 and TASK-3 extreme C-terminus.  
The last 6 aa of TASK-1 and TASK-3 contain the trafficking control region with overlapping COPI 
and 14-3-3 binding motifs. Small sequence differences in this region cause differences in the 
regulation and trafficking of TASK-1 and TASK-3. 
 
This small sequence discrepancy between TASK-1 and TASK-3 channels causes 
differences in the trafficking control of both channels (Kilisch et al., 2016). First of all, higher 
14-3-3 binding affinity was measured for TASK-3 than for TASK-1 with fluorescent 
polarization titrations and surface plasmon resonance (SPR) analysis (Kilisch et al., 2016). 
Moreover, phosphorylation of the second serine residue in TASK-1, which is absent in 
TASK-3, inhibit 14-3-3 binding and prevent surface expression of TASK-1. 
Phosphorylation of both neighboring serine residues in TASK-1 inhibit 14-3-3 binding as 
well (Kilisch et al., 2016). These findings about post-translational regulation of TASK 
channels via trafficking implies that TASK-1 is more tightly regulated via the two 
phosphorylation residues. 
Overall, the localization and therefore the number of TASK channels expressed at the cell 
surface are regulated in a complex way in different states of ion channel expression, 
assembly and surface presentation. At the molecular level, a reduction in the open state 
can be done by different chemical and physical stimuli, at the transcriptional level, up- or 
downregulation of protein transcription or at the posttranslational level by modulation of 
intracellular trafficking (Kilisch et al., 2016). 
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1.4.2.2 Expression of TASK-1 and TASK-3 channels in the heart 
Although TASK-1 and TASK-3 channels belong to the same sub-family, just TASK-1 
shows robust protein expression in rodent hearts (Kim et al., 1999; Putzke et al., 2007) 
and in the human atrium (Decher et al., 2011). TASK-1 is mostly expressed in the ventricle 
and immunostaining experiments in cardiomyocytes showed the localization at the 
intercalated disc and t-tubule network (Jones et al., 2002). 
Putzke et al reported TASK-1 like currents in rat ventricular myocytes and suggested that 
TASK-1 currents contribute to the outward current during the plateau phase in the cardiac 
action potential and help to stabilize the resting membrane potential (Putzke et al., 2007). 
In line, inhibition of TASK-1 channels showed prolonged action potential (Putzke et al., 
2007). The same effect was found by blocking the pore of TASK-1 channel with a TASK-1 
specific inhibitor called A923 (Putzke et al., 2007). Action potential modeling and patch 
clamp experiments revealed that the impact of TASK-1 currents on the action potential 
duration is more obvious when the action potential is prolonged. This indicates that the 
small TASK-1 current plays a functional role in longer action potentials with a plateau 
shape (Putzke et al., 2007). 
TASK-3 is predominantly expressed in the brain and nervous system but mRNA levels 
were also identified in the heart (Callahan et al., 2004; Gurney & Manoury, 2009). 
Interestingly, Rinné et al performed immunocytochemistry analysis of TASK-3 in right 
human auricles revealing TASK-3 protein expression at the cell surface (Rinné et al., 
2015). However, single channel recordings in the cell-attached mode did not allow for the 
identification of TASK-3 homodimer channels. Instead, intermediate single channel 
conductance between TASK-1 and TASK-3 channels were measured indicating the 
presence of a heterodimer TASK-1/TASK-3 channel in cardiomyocytes (Rinné et al., 
2015). The TASK-1/TASK-3 dimer was found to be expressed at the cell surface and 
showed a reduced affinity for TASK-1 inhibitors indicating changed pharmacologic 
response (Rinné et al., 2015). 
 
1.4.2.3 TASK-1 regulation in the heart  
In 2007, Putzke et al reported that TASK-1 channels are regulated via the adrenergic 
pathway by alpha1-adrenoreceptors. They used the selective alpha-1-adrenoceptor 
agonist methoxamine to block alpha-1 adrenoceptors and measured strongly reduced 
outward currents at pH 6 in cardiomyocytes. This experiment showed that 
alpha-adrenergic stimulation inhibits TASK-1 channels (Putzke et al., 2007). From rat 
cardiomyocytes, it is known that alpha-adrenergic stimulation prolong action potential 
duration by reducing outward potassium currents (Ravens et al., 1989). Even though, 
treatment of rat cardiomyocytes with methoxamine reduced TASK-1 like currents, it is still 
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an open question, how big the relative contribution of the TASK-1 currents are to the 
general effect of alpha-adrenergic stimulation on action potentials in rat cardiomyocytes 
(Decher et al., 2014). 
Alpha1-adrenergic receptors are Gq-coupled receptors and upon activation they activate 
the phospholipase C which leads to hydrolysis of PIP2 (Gurney & Manoury, 2009). As a 
consequence, the local PIP2 levels are reduced in the plasma membrane (Stauffer et al., 
1998) which is associated with ion channel activity (Baukrowitz et al., 1998; Zhang et al., 
2003). PIP2 is as a phospholipid integral part of the plasma membrane and known to be 
involved in several signaling pathways. (McLaughlin et al., 2002). Interestingly, PIP2 was 
shown to activate TASK-1 channels and other members of the K2P channel family 
(TASK-3, TREK-1, TRAAK) (Lopes et al., 2005). In line, it was shown that PIP2 hydrolysis 
is responsible for inhibition of TASK channels and the strength of inhibition was determined 
by the level of agonist-induced inhibition (Lopes et al., 2005). The theory of PIP2 depletion 
being responsible for TASK-1 inhibition was contradicted in another study, where TASK-1 
currents were found to be unaltered upon PIP2 depletion (Lindner et al., 2011). The 
mechanism of TASK-1 inhibition due to Gq-coupled receptors are controversial in the field 
(Decher et al., 2014). Contrary to the results of Lopes et al, it was shown that the Gq-
receptor alpha-subunit (Gqa) directly inhibits TASK-1 (Chen et al., 2006), whereas a third 
study claims that phospholipase C inhibits TASK-1 (Schiekel et al., 2013). 
In the brain, TASK-1 and TASK-3 were also found to be inhibited by Gqa mediated 
receptors (Chen et al., 2006). Receptor mediated regulation of TASK-1 was found to be 
controlled via the first six aa of the COOH-terminal tail (VLRFMT) (Talley & Bayliss, 2002). 
A detailed understanding of the suppression effect of alpha-adrenergic stimulation on 
TASK-1 channels remains incomplete (Decher et al., 2014). 
 
1.4.2.4 Potential of TASK-1 in atrial fibrillation and heart failure  
Endothelin-1 (ET-1) is a peptide hormone secreted by endothelia cells and functions as a 
vasoconstrictor regulated by two G-protein-coupled receptors (Marasciulo et al., 2006). 
Increased ET-1 levels are associated with HF or myocardial infarction (Becker et al., 2000). 
ET-1 is associated with inhibition of steady-state outward currents in rat cardiomyocytes 
(James et al., 2001). In line with this, Schiekel et al were able to show that ET-1 inhibited 
TASK-1 currents as well, suggesting that the TASK-1 channel may be involved in the 
arrhythmogenic effects of ET-1 (Schiekel et al., 2013).  
AF is the most diagnosed form of arrhythmia with the potential of serious complications 
such as HF or stroke (Schmidt et al., 2011). Drugs to treat arrhythmias are not tolerant in 
all patients and cause side effects (Hancox et al., 2016; Schmidt et al., 2011; Wiedmann 
et al., 2016). It was shown that inhibition of TASK-1 channels prolonged action potential 
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duration (Limberg et al., 2011; Schmidt et al., 2019) and the exclusive expression in the 
atrium makes TASK-1 an interesting ion channel to treat AF (Limberg et al., 2011; Schmidt 
et al., 2014). TASK-1 mRNA and protein levels were found to be upregulated in patients 
suffering AF (Schmidt et al., 2015).  
The finding that chronic AF is associated with increased levels of TASK-1 leading to 
shortened action potential duration cause increased research in identifying potential and 
highly selective TASK-1 blockers (Schmidt et al., 2014; Şterbuleac 2019). In 2006, Cotton 
at al. presented doxapram as a TASK channel inhibitor (Cotten et al., 2006). They found 
that doxapram inhibits the TASK-1 homodimer channel and with a strongly reduced affinity 
also the TASK-3 homodimer channel (Cotten et al., 2006). Interestingly, an intermediate 
inhibitory effect of doxapram on the TASK-1/TASK-3 heterodimer was identified (Cotten et 
al., 2006). In 2007, Putzke et al presented the TASK-1 channel blocker A293 (Putzke et 
al., 2007). In Xenopus oocytes, low concentrations of A293 showed a high specificity for 
TASK-1 channels causing an increased action potential duration (Putzke et al., 2007). 
Another already presented TASK-1 inhibitor is A1899, which blocks the pore of TASK-1 
specifically with very high affinity (Kd in the nanomolar range) (Streit et al., 2011). Recently, 
the anti-arrhythmic drug ranolazine was shown to be an inhibitor of TASK-1 currents in 
mammalian cells and Xenopus oocytes (Ratte et al., 2019). This contributes to better 
understanding of the function of ranolazine and may help to consider ranolazine as a 
prototype drug (Ratte et al., 2019).  
 
1.4.2.5 TASK channel mutations and pathogenic heart phenotypes 
It was found that TASK-1 loss of function mutations cause pulmonary hypertensions 
(Gurney et al., 2003; Ma et al., 2013). Six TASK-1 loss of function mutations were 
characterized from two different patient cohorts and four mutations showed the phenotype 
of pulmonary hypertension (Ma et al., 2013). In addition, three of the TASK-1 mutation 
carriers showed arrhythmias (Ma et al., 2013). In another study, a large population of 
Danish patients with AF and an Australian cohort with AF within the family were analysed 
for mutations in TASK-1 (Liang et al., 2014). Two patients with genetic defects in the 
TASK-1 channel were identified form the two different patient cohorts. One patient showed 
a V123L mutation and the other one had two 5’UTR variants in the Kozak sequence of the 
TASK-1 gene (Liang et al., 2014). Both patients showed reduced cardiac TASK-1 currents 
in patch clamp analysis (Liang et al., 2014). The findings from TASK-1 mutations in 
patients are in contrast to the pharmacological analysis of TASK-1 channels with inhibitors 
which resulted in a prolonged action potential duration preventing AF (Limberg et al., 2011; 
Schmidt et al., 2014). However, the analysed patients also had additional mutations and 
were heterozygous for a single-nucleotide polymorphism already correlated with the 
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development of AF (Liang et al., 2014). The data obtained about the involvement of 
TASK-1 mutations in the development of AF so far, show indication that TASK-1 mutations 
contribute to arrhythmogenesis instead of being the exclusive cause for development of 
AF (Decher et al., 2014).   
Chapter I: Introduction 
 30 
1.5 Aim of this thesis  
The aim of this thesis was to analyse proteins and regulators which are involved in main 
processes of cardiac excitation and Ca2+ handling. Novel interaction partners for two 
important regulators involved in these processes, namely PLN and TASK channels, were 
identified.  
 
PLN is a main regulator of the Ca2+ pump SERCA responsible for correct Ca2+ handling in 
the heart (MacLennan & Kranias 2003). The SERCA/PLN interaction is regulated by 
phosphorylation of two different kinases (Coyler, 1998). A putative 14-3-3 interaction motif 
was identified in the cytosolic domain of PLN, including the phosphorylation residues 
(Arakel et al., 2014). 14-3-3 binding contain often phospho-residues and stabilize client 
proteins in a specific conformation or block alternative interaction partners (Fu et al., 2000). 
A potential 14-3-3/PLN interaction may stabilize PLN and influence the inhibitory effect on 
SERCA. Consequently, one main aim of this thesis was the analysis of a potential 14-3-3 
interaction with PLN. This aim was addressed with complementary experimental 
approaches: binding assays with recombinant 14-3-3 and cardiac lysate, proteomic mass 
spectrometry and immunoprecipitation experiments. After a novel interaction between 
14-3-3 and PLN was confirmed, the binding site was dissected with recombinant binding 
assays, surface plasmon resonance measurements and molecular dynamic simulation 
experiments. The physiological function of the 14-3-3/PLN interaction was analysed by 
following the hypothesis that 14-3-3 binding to PLN may protect PLN from fast 
dephosphorylation by phosphatases. Recombinant dephosphorylation assays were 
performed along with patch clamp experiments in cardiomyocytes. Finally, the 14-3-3/PLN 
interaction was investigated in a PLN R14del mutation (Haghighi et al., 2006) using 
recombinant binding assays and homo- and heterozygous disease mouse models.  
 
The class of pH sensitive TASK channels belong to the K2P ion channel family and 
contribute with K+ leak currents to the repolarization of the action potential (Duprat et al., 
1997). TASK channels were first identified and characterized in the brain (Duprat et al., 
1997; Enyedi & Czirják, 2010; Medhurst et al., 2001). Later, especially TASK-1, but also 
TASK-3 were identified in the heart (Gurney & Manoury 2009; Rinné et al., 2015). It is 
known that both channels are regulated by phosphorylation dependent interaction of 
14-3-3 and COPI (Kilisch et al., 2016). However, further regulation via A-kinase-anchoring 
protein or chaperones such as MAGUK or PDZ proteins, as already identified for other 
potassium channels, is unidentified so far (Mathie et al., 2010). In addition, little is known 
about TASK channel insertion in the plasma membrane (Mathie et al., 2010). Therefore, 
the second main goal of this thesis was the analysis of the cardiac proteome of TASK-1 
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and TASK-3. Binding experiments with recombinant TASK C-termini, considering different 
phosphorylation states, with cardiac lysate were performed followed by mass spectrometry 
analysis. Novel potential interaction partners were further investigated with different 
biochemical approaches. 
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2 Chapter II: Manuscript  
Major parts of my work contributed to a first author manuscript (aaz1436), which is 
currently edited and prepared for publication in Science Signaling (status June 2020). The 
protein-protein interaction discovered in this publication have been submitted to the IMEx 
consortium (http://www.imexconsortium.org) through IntAct and assigned the identifier 
IM-27195. The manuscript is part of my thesis in the following chapter 2, including a 
detailed table of my contribution. All data needed to evaluate the conclusions presented in 
the manuscript are present in the main or in the supplementary materials of the manuscript. 
Further experiments and projects, I investigated during my PhD studies, are presented in 
chapter 3 (Further analysis of the PLN/14-3-3 interaction) and chapter 4 (Identification of 
novel interaction partners for TASK channels in the heart). 
 
Figure contribution in the manuscript “14-3-3 binding creates a memory of kinase action 
by stabilizing the modified state of PLN”: 
 
Figure 1: 14-3-3 affinity purification experiment analysed by silver staining (JM) 
and immunoblotting (JM), data analysis (JM) 
 
Figure 2: PLN proximity proteomics (DKD), MS analysis (CL, HU), data analysis 
(CL, DKD) 
 
Figure 3: 14-3-3 affinity purification with heated cardiac membranes and 
immunoblotting (JM), recombinant binding assay upon PKA or CaMKII 
phosphorylation (JM), data analysis (JM) 
 
Figure 4: MD simulations for PLN pS16 or PLN pT17 with 14-3-3 (AB, MM); 
recombinant binding assay of PLN-GST variants mimicking DCM-
causing mutants (JM) 
 
Figure 5: recombinant de-phosphorylation assay of pT17-PLN-GST in the 
presence of 14-3-3 (JM), data analysis (JM) 
 
Figure 6: cardiomyocyte isolation (JM, KUF), immunoprecipitation from cardiac 
membranes (JM) and corresponding inputs were analysed by 
immunoblotting (JM), data analysis (JM) 
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Figure 7: recombinant purification of 14-3-3 (JM), measurement of  of CaT 
decay after ISO application in cardiomyocytes for 14-3-3 and control 
solution (JM, ST), measurement of  of CaT decay after ISO application 
in cardiomyocytes for R18, 14-3-3+R18, PLN pS16 and pT17 antibodies 
(ST), data analysis (ST), graphical representation shown in D (JM) 
 
Supplement  
Figure 1:  
14-3-3 affinity purification experiment analysed by immunoblotting (JM), 









recombinant binding assay upon CaMKII phosphorylation for all seven 




recombinantly purification 14-3-3 and PLN (JM); SPR experiments 
(JM), data analysis (JM, MK)  
 
Supplement 
Figure 5:  
MD simulations for PLN pS16 or PLN pT17 with 14-3-3 (AB, MM), data 




recombinant PKA phosphorylation of PLN-GST variants mimicking 




recombinant de-phosphorylation assay of pS16-PLN-GST T17A in the 




stimulation of cardiomyocytes and Ca transient recording with or without 
14-3-3 (JM, ST), relaxation of Ca transients under rapid removal of 





manuscript conceptualization (JM, MJS; SEL, BS), writing original draft 
(JM, SEL, BS), writing review and editing (JM, DKD, AB, CL, MM, CO; 
MJS, SEL, BS) 
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The cardiac membrane protein phospholamban (PLN) is a target of protein kinase A (PKA), 
at Ser16, and Ca2+/calmodulin-dependent protein kinase II (CaMKII), at Thr17. -adrenergic 
stimulation and PKA-dependent phosphorylation of Ser16 acutely stimulates the 
sarcoplasmic reticulum calcium pump (SERCA) by relieving an inhibitory effect of PLN on 
SERCA. CaMKII-dependent phosphorylation may lead to longer lasting SERCA 
stimulation and sustain (mal)adaptation of calcium handling. Here, we demonstrated that 
phosphorylation at either Ser16 or Thr17 converted PLN into a target for the phosphoadaptor 
protein 14-3-3 with different affinities. Proximity labelling in live cardiomyocytes identified 
14-3-3 proteins within nanometers of PLN and endogenous 14-3-3 coimmunoprecipitated 
with pentameric PLN from cardiac membranes. There were differences in the molecular 
contacts of the phosphopeptides phosphorylated at Ser16 or Thr17 within the binding groove 
of 14-3-3, as predicted by molecular dynamics simulations, resulting in varied binding 
affinities. We showed that 14-3-3 binding protected either PLN phosphosite from 
dephosphorylation. During  -adrenergic stimulation of isolated adult cardiomyocytes, 
endogenous 14-3-3 proteins were recruited to the membrane fraction. Functionally, the 
binding of exogenously added 14-3-3 to PLN phosphorylated at Ser16 produced by -
adrenergic stimulation prolonged SERCA activation, presumably by protecting pSer16-
containing PLN pentamers from dephosphorylation. Phosphorylation of Ser16 was 
disrupted by the cardiomyopathy-associated ∆Arg14 mutation, implying that Thr17 
phosphorylation by CaMKII may become crucial for 14-3-3 recruitment to ∆Arg14 PLN. In 
line with PLN as a dynamic hub in the control of Ca2+ handling, our results identify 14-3-3 








The cardiac excitation-contraction cycle relies critically on the spatio-temporal control of 
intracellular Ca2+ release and sequestration in the sarcoplasmic reticulum (SR) (1). In 
cardiomyocytes, the RyR Ca2+ release channel and the Ca2+ pump SERCA cooperate in 
large protein assemblies to ensure the physiological plasticity of Ca2+ handling (2). The 
small membrane protein phospholamban (PLN) negatively regulates SERCA pumps and 
thereby affects the reuptake kinetics of Ca2+ into the SR. The protein is dispensable in mice 
perhaps because it regulates only 40% of the SERCA pumps (3, 4). Yet, mutations found 
heterozygously in patients with inherited dilated cardiomyopathy suggest that humans 
require the full complement of PLN (5-7). Protein kinase A (PKA)-dependent 
phosphorylation targets PLN on Ser16, relieves the inhibitory effect of PLN on SERCA, and 
hence stimulates SERCA (8, 9). During -adrenergic stimulation, this mechanism results 
in increased force generation and an accelerated relaxation of cardiac muscle. The 
adjacent Thr17 is targeted by Ca2+-calmodulin-dependent kinase (CaMKII) under a variety 
of stimuli (10, 11) although phosphorylation of Ser16 is sufficient to mediate the effects of 
-adrenergic signal transduction (12). Aside from its regulation by phosphorylation, PLN 
exists in an equilibrium between two assembly states, a monomeric and a pentameric form, 
which can be observed as an SDS-resistant pentamer (9, 13-14) consistent with the high 
stability of the oligomer observed by FRET in living cells (15). This equilibrium and a 
spectrum of conformations assumed by the cytoplasmic domain of PLN are central to the 
regulatory effect of Ser16 or Thr17 phosphorylation on PLN (13, 15) and may hence be 
targeted by other modulatory mechanisms including protein-protein interactions (16). 
Indeed, the regulatory subunit of protein phosphatase 1c (PP1c), the membrane protein 
PPP1R3A (2, 17), recruits not only the phosphatase but two additional proteins that inhibit 
PP1c, inhibitor-1 (I-1) and the small heat shock protein Hsp20.  
In previous work on cardiac ATP-sensitive potassium channels (KATP), we 
dissected arginine (Arg)-based trafficking motifs in KATP subunits (18). Arg-based motifs 
bind the vesicle coat complex COPI and in many cases also 14-3-3 phosphoadaptor 
proteins. 14-3-3 proteins are encoded by a family of seven related genes, which historically 
have been called isoforms (19-21). They bind to various client proteins by engaging with 
target sequences that often but do not always contain phosphoresidues. Binding may 
stabilize specific conformations of a client protein or sterically block alternative protein-
protein interactions. As a result, the subcellular localization, stability, or posttranslational 
modification state of the client protein may be affected by 14-3-3 binding. Client binding 
involves a highly conserved ligand binding groove of 14-3-3 proteins. The relative 
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abundance and biological relevance of the isoforms, which differ most in their N- and C-
terminal regions, remains poorly understood. 
The molecular interactions of Arg-based motifs with COPI and 14-3-3 are crucial to 
the proper assembly, subcellular localization, and regulation of membrane proteins that 
present Arg-based signals (22, 23). For KATP and the two-pore domain potassium channel 
TASK-1 (24), interactions with COPI and 14-3-3 are regulated by PKA-dependent 
phosphorylation. Based on its N-terminal sequence (Fig. 1A), we predicted that PLN is a 
membrane protein with an Arg-based signal that may be regulated in a similar manner (18) 
and set out to test whether PKA-phosphorylated PLN could bind to 14-3-3 proteins. We 
discovered that two distinct phosphosites, phosphorylated (p) Ser16 and pThr17, engaged 
14-3-3 with different affinities. We propose that this differential binding adapts the lifetimes 
of the respective phosphostate to its specific biological purpose. 
  




14-3-3 binds to SDS-resistant PLN pentamers 
PLN is a major target of PKA in cardiomyocytes (25) and its PKA consensus sequence 
and a putative 14-3-3 binding site (18) are highly conserved (Fig. 1A). To test whether 
PKA-phosphorylated pSer16-PLN interacted with 14-3-3, we incubated recombinantly 
expressed 14-3-3 immobilized on a matrix with solubilized cardiac membranes or 
cytosolic fractions prepared from mouse ventricular tissue (Fig. 1B). The R18 peptide is a 
high-affinity 14-3-3 ligand (26, 27) that is routinely used to verify the specific interaction of 
a protein with 14-3-3. Structural models of R18 bound to 14-3-3 obtained by X-ray 
crystallography demonstrate that R18 occupies the canonical peptide-binding groove of 
14-3-3 and hence blocks other ligands from binding. Silver staining (Fig. 1C) of the eluate 
revealed the presence of bound proteins from the membrane fraction, which we probed by 
Western blotting using an antibody recognizing generic PKA-dependent phosphosites (Fig. 
1D, fig. S1A). The strongest band detected was consistent with the presence of a PKA-
phosphorylated PLN pentamer in the 14-3-3 eluate, which can be observed by SDS-PAGE 
under denaturing conditions (14), possibility due to its high stability (15). To test whether 
this band corresponded to PLN, we probed the eluates using specific antibodies against 
PLN (Fig. 1E,F, fig. S1B) and pSer16-PLN (Fig. 1G,H, fig. S1C,D). Because preincubation 
with R18 reduced PLN binding to background levels (Fig. 1F and H) this experiment 
identified SDS-resistant PLN pentamers as 14-3-3 ligands that use the canonical ligand-
binding groove. PLN monomers, which were present in the solubilized membranes, were 
not found in the 14-3-3 eluates (Fig. 1D,E,G).  
In situ biotinylation reveals that PLN is situated in close proximity to 14-3-3 in 
cardiomyocytes  
To complement this analysis with a method that enables the detection of 14-3-3 in 
proximity to PLN in situ, we fused an engineered ascorbate peroxidase (V5-APEX2) to the 
PLN N-terminus and expressed the fusion protein in neonatal rat cardiomyocytes (NRCMs; 
Fig. 2A, fig. S2A) using cytosolic GFP (fig. S2B) or PLN lacking the cytosolic N-terminus 
(fig. S2B,C) as negative controls for background binding to the avidin matrix and 
nonspecific APEX2-mediated labelling, respectively. V5-APEX2-PLN localized to SR 
membranes as expected (fig. S2A). Six of seven 14-3-3 proteins in the family were 
specifically labelled when APEX2 fused to full-length PLN was exposed to biotinphenol 
and H2O2 (Fig. 2B, Data File S1), including 14-3-3, which was the bait in our 14-3-3 affinity 
purification (Fig. 1B). PLN itself was strongly enriched in both controls as expected based 
on auto-labelling within V5-APEX2-PLN and on the oligomeric states of PLN. On the other 
hand, the functionally best characterized interaction of PLN with SERCA pumps (8) could 
Chapter II: Manuscript 
 40 
not be detected, presumably because SERCA2a is a highly abundant cardiac protein 
leading to substantial background in the biotin-affinity step of the protocol (fig. S2B,C) and 
because the transmembrane segment of PLN may remain in close proximity to SERCA2a 
in SR membranes (fig. S2C). Similarly, another membrane protein that associates with 
PLN, the PP1c regulating protein PPP1R3A (2, 17), could not be detected although soluble 
proteins that interact with PPP1R3A, PP1c itself and Hsp20, were biotin-labelled (Fig. 2B, 
Data File S1). These two proteins acted as positive controls for the proximity proteomics 
approach and their detection underscored that proximity labelling could be due to indirect 
interactions within larger protein complexes. Hence, the enrichment of six out of seven 
14-3-3 isoforms could not be interpreted beyond proximity because 14-3-3 proteins exist 
as different heterodimers. Binding to PLN could occur through one specific isoform that 
engages in different heterodimers. However, the peptide-binding groove of 14-3-3 proteins 
is highly conserved and PLN may directly engage with different 14-3-3 proteins, as occurs 
with many other 14-3-3 ligands (28). We conclude that PLN and several endogenous 
14-3-3 proteins are present within nanometers of each other in cardiomyocytes and that 
direct or indirect interactions may explain this proximity. 
14-3-3 enriches PLN pentamers more efficiently than PLN monomers 
Our specific enrichment of SDS-resistant PLN pentamers that contain PKA-
phosphorylated PLN by 14-3-3 (Fig. 1G) implies an avidity effect in which the two ligand-
binding grooves present in the 14-3-3 dimer support binding of 14-3-3 to PLN with a higher 
apparent affinity than the binding parameters of one peptide ligand binding to a single 
binding site would allow (29, 30). To further test this idea, we converted the majority of 
PLN present in solubilized mouse cardiac membrane into the monomeric form by gentle 
heating (14). In the heated membrane input, the monomer was the predominant species. 
However, only 10% of this monomeric PLN was enriched by 14-3-3 whereas 30% of the 
pentamer present in the solubilized membranes before heating was bound (Fig. 3A,B). 
This result supports the concept that an avidity effect is relevant to the interaction between 
PLN and 14-3-3. 
Next, we tested direct binding of 14-3-3 to PLN in an in vitro system. A recombinant 
protein consisting of the first 31 N-terminal residues of PLN fused to GST did not bind to 
14-3-3 despite efficient phosphorylation of Ser16 by purified PKA catalytic subunit in vitro 
(Fig. 3C,D). This finding may reflect a low affinity of the interaction between pSer16-PLN 
and one 14-3-3 ligand-binding groove. However, when we exchanged the neighboring 
residue Thr17 with an alanine, the enrichment of pSer16-T17A-PLN-GST for 14-3-3 was 
more efficient (Fig. 3C,D). These data confirm that pSer16 contributes to a 14-3-3 binding 
site that is weakened by the neighboring Thr17. The low affinity of 14-3-3 binding to the 
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monomeric pSer16-PLN-GST construct is consistent with the presence of pSer16-PLN in 
the 14-3-3 interacting SDS-resistant pentamers but not the monomers (Fig. 1G,H) and the 
observed avidity effect (Fig. 3A,B). 
14-3-3 binds with higher affinity to pThr17-PLN than to pSer16-PLN 
After conversion of PLN into monomers by heating, 10% of PLN monomers and 30% of 
the SDS-resistant pentamers, which have previously been interpreted as a biochemical 
correlate of endogenous pentamers (9,14), were enriched on the 14-3-3 matrix (Fig. 3A,B). 
The kinase CaMKII targets Thr17 (8, 9), which is adjacent to Ser16 targeted by PKA. 
Because specific antibodies detecting pThr17-PLN are available (fig. S1C,D), we probed 
solubilized cardiac membranes that had been heated or not as well as the respective 
eluates from the 14-3-3 matrix (Fig. 3E,F). This antibody was less efficient at detecting 
monomers compared to pentamers in the input. However, the pThr17 monomer and 
pentamer were equally enriched by the 14-3-3 matrix leading us to infer that monomeric 
pThr17-PLN could bind to 14-3-3 with higher affinity than pSer16-PLN. We observed robust 
binding of PLN-GST phosphorylated in vitro with CaMKII to 14-3-3 (Fig. 3G,H). This result 
indicates that either phosphosite generates a 14-3-3 target motif but with apparently 
different affinities when monomeric PLN is offered as a target.  
We found that all seven 14-3-3 isoforms bound to pThr17-PLN-GST (fig. S3). 
Although this result does not reflect the interactions between endogenous cardiomyocyte 
proteins, it does show that direct binding of 14-3-3 to PLN can occur . We also measured 
14-3-3 binding to immobilized pSer16- or pThr17-PLN-GST by SPR ((24); fig. S4A). We 
determined an equilibrium dissociation constant (KD) of 4 µM (fig. S4B,C) for the binding 
of 14-3-3 to pThr17-PLN-GST. It was difficult to obtain reliable sensograms for PKA-
phosphorylated WT (fig. S4D). Hence, we cannot provide equilibrium dissociation 
constants for these binding events but conclude that the respective affinities are 
substantially lower than those observed for pThr17-PLN. 
pSer16 and pThr17 determine the conformation of the PLN/14-3-3 complex 
Possible differences in the molecular contacts between the distinct PLN phosphoforms 
and 14-3-3σ were addressed by molecular dynamics (MD) simulations, exploiting the 
conserved mechanism of 14-3-3σ and 14-3-3 for phospho-dependent ligand binding (31). 
This approach was also justified by our observation that 14-3-3σ bound to immobilized 
pThr17-PLN-GST (fig. S3) and that all 14-3-3 proteins engaged with pThr17-PLN. 
Unrestrained MD trajectories were generated for 250 ns on each system. For the 
14-3-3σ/pSer16-PLN complex, the all-atom root mean square deviations (RMSD) (fig. S5A) 
suggested that conformational convergence is achieved during MD simulation time 
whereas the comparison of the root mean square fluctuation (RMSF) between 14-3-3σ 
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residues from the complex and apo 14-3-3σ (fig. S5B) showed that residues with the 
highest fluctuation belonged to loops 64-88 and 208-219 (fig. S5B,C). Notably, the 
conformational freedom of residues 118-190 that belonged to the 14-3-3σ amphipathic 
groove was constrained by the phosphopeptide. Moreover, by cluster analysis of the 
phosphopeptide and residues within 6 Å (fig. S5C-D), we found that the most abundant 
population of MD frames had a peptide conformation (Fig. 4A) that was comparable to that 
observed in X-ray crystallographic structures (32). Indeed, pSer16 is located in the 
amphipathic groove and establishes hydrogen bonds to Lys49 (2.97 Å), Arg129 (1.81 Å), and 
Tyr130 (1.86 Å) consistent with a mode II binding motif (33). 
Similar results were obtained for the 14-3-3σ/pThr17-PLN complex (Fig. 4B, figs. 
S5E-G). The first cluster featuring a population of 45.6% of MD frames was taken as the 
most representative model (fig. S5H) for further investigation and comparison with the 
14-3-3σ/pSer16-PLN complex. The structure of both peptides in their respective 14-3-3σ 
complexes does not completely overlap because the first three helices of 14-3-3σ/pSer16-
PLN complex show a more opened conformation compared to those in the 14-3-3σ/pThr17-
PLN complex (Fig. 4C). Similar to pSer16-PLN, pThr17-PLN occupies the canonical central 
position in the amphipathic groove (32, 33) and establishes H-bond interactions with Lys49 
(3.94 Å), Arg56 (1.83 Å), Arg129 (1.68 Å), and Tyr130 (1.64 Å). Notably, the spatially similar 
placement of pSer16 and pThr17 within the groove shifts the conformation of the rest of the 
PLN peptide. As a result, the remaining portion of the pThr17 phosphopeptide is elongated 
within the groove, placing Ile18, Glu19, and Met20 of PLN in different molecular environments 
as revealed by electrostatic rendering of 14-3-3 (Fig. 4A,B).  
At least one arginine residue located at the -4, -3 or -2 position relative to the 
phosphoresidue is a key feature of the canonical 14-3-3-binding phosphopeptide motif 
(34). This residue stabilizes the phosphopeptide conformation by forming hydrogen bonds 
and intramolecular salt bridge with the phosphate group (35). In pSer16-PLN, this role is 
taken by Arg14 in the -2 position (Fig. 4A) whereas Arg13 (-3 position) is pointing away from 
the phosphate group. In contrast, there is no arginine close to the phosphoresidue for 
pThr17-PLN in complex with 14-3-3 (Fig. 4B). Instead, Arg14 is pointing away from the 
phosphoresidue consistent with some previously characterized 14-3-3σ/phosphopeptide 
complexes (36) and Arg13 contacts the solvent. Hence, its position is not reliable in the 
current model. Calculation of the peptide’s delta energy of binding to 14-3-3σ along MD 
trajectories confirmed the binding assay data, showing that pThr17-PLN has a greater 
affinity for the protein than the pSer16-PLN peptide (-9.17 ± 2.17 kcal/mol and -4.43 ± 1.22 
kcal/mol, respectively). Although the precise atomic determinants of the different stabilities 
await further characterization, modification of PLN by either PKA or CaMKII determines 
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the conformation in which 14-3-3 binds to the resulting phosphoform and therefore the 
stability of the complex.  
Disease-causing ∆Arg14 PLN recruits 14-3-3 exclusively through pThr17 
Arg13 and Arg14 are multifunctional residues in the PLN N-terminus because they are also 
essential elements of an Arg-based COPI-interacting motif (18). Indeed, ∆Arg14 PLN 
leaves the endoplasmic reticulum (ER) whereas WT PLN is retained (37). In addition, Arg14 
is crucial for the PKA consensus motif resulting in the phosphorylation of Ser16. However, 
Arg14 is lost as a consequence of a tri-nucleotide deletion in an inherited form of dilated 
cardiomyopathy (DCM; (5)). We concluded that this disease-associated variant of PLN 
lacks the low-affinity 14-3-3 binding site provided by pSer16-PLN (Fig. 3C, fig. S6). 
However, we found that the CaMKII-dependent binding site provided by pThr17 was not 
altered in this disease-causing variant because we observed robust phosphorylation and 
14-3-3 binding to pThr17-∆Arg14-PLN (Fig. 4D). A second disease variant associated with 
familial forms of DCM is R9C (7), which is not predicted to participate directly in the 14-3-3-
binding phosphopeptide motif. Accordingly, mutating Arg9 to cysteine or alanine did not 
affect the binding of pThr17-PLN to 14-3-3 (Fig. 4D). These results imply that CaMKII-
mediated phosphorylation of Thr17 is the only way by which PLN can recruit 14-3-3 in 
∆Arg14-carrying patients. 
14-3-3 slows the kinetics of PLN dephosphorylation 
14-3-3 binding has been suggested to protect against dephosphorylation by steric masking 
(23, 38). We measured the effect of 14-3-3 binding on the kinetics of the 
dephosphorylation. of immobilized pThr17-PLN-GST or pSer16-T17A-PLN-GST by alkaline 
phosphatase (Fig. 5A, fig. S7A). We observed a substantial increase in the lifetime of 
pThr17 or pSer16 when 14-3-3 was present (Fig. 5B, fig. S7B). Concomitantly with 
dephosphorylation, binding of 14-3-3 slowly decreased from either PLN phosphoform as 
expected (Fig. 5C,D, fig. S7A). We conclude that occupancy by 14-3-3 controls 
phosphatase access and thereby the lifetime of the posttranslational modification on either 
Ser16 or Thr17 of PLN. 
Signal-transduction recruits 14-3-3 to PLN-containing membranes in cardiomyocytes 
PLN is an abundant cardiac membrane protein and a major target of PKA-mediated 
regulation during -adrenergic stimulation (25). To determine the cellular consequences of 
PLN phosphorylation and 14-3-3 binding, we stimulated -adrenergic signal transduction 
in isolated adult rat cardiomyocytes using the agonist isoprenaline and assessed whether 
the predicted increase in pSer16-PLN led to the recruitment of 14-3-3. The N-terminus of 
PLN is short and 14-3-3 may occlude the antibody epitope. Nevertheless, we generated a 
rabbit antibody that immunoprecipitated SDS-resistant PLN pentamers (Fig. 6A). Detection 
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of precipitated PLN used commercially available antibodies against PLN raised in mouse 
and against 14-3-3 raised in rabbit. In HeLa cell and total ventricular lysate, this antibody 
detected two bands most likely reflecting 14-3-3 (its primary sequence is ~ten residues 
longer than that of all other isoforms (39)) (Fig. 6B). Untreated and isoprenaline-treated 
ventricular cardiomyocytes (Fig. 6C, panels labelled “total”) showed comparable levels of 
PLN in the membrane fraction (Fig. 6D). Membranes from isoprenaline-treated 
cardiomyocytes showed a substantial increase in pSer16-PLN (Fig. 6E) and modestly 
increased levels of 14-3-3 (Fig. 6F). We performed coimmunprecipitation experiments 
which suggested that endogenous PLN was associated with endogenous 14-3-3 proteins 
(Fig. 6C, panels labelled “IP: PLN”). Whether this association is direct cannot be definitively 
concluded from these experiments, although this interpretation is supported by the direct 
binding shown in vitro (Fig. 3C,D) and by the preferred binding of 14-3-3 dimers to SDS-
resistant PLN pentamers, suggesting an avidity effect (Fig. 3A,B).  
We sought to further corroborate the idea that isoprenaline stimulation resulting in 
an increase in pSer16-PLN might elicit biological effects by 14-3-3 binding and ensuing 
stabilization of the phosphoform of PLN as observed in vitro (Fig. 5A). Adult 
cardiomyocytes were patch-clamped and Ca2+ transients evoked at 0.5 Hz (fig. S8A). As 
expected, acute (10 s) stimulation with the adrenergic agonist isoprenaline elicited an 
apparent accelerated recovery of Ca2+ transients as quantified by the time-constant tau of 
Ca2+ transient decay (fig. S8B) due to PKA-dependent PLN phosphorylation and SERCA 
stimulation. We dialyzed cells with an intracellular pipette solution containing recombinant 
14-3-3, which slowed the recovery of the time-constant decay of the Ca2+ transients back 
to the baseline as observed before isoprenaline stimulation (Fig. 7A, fig. S8C,D). This 
effect was blocked by R18 (Fig. 7B) suggesting that it depended on the interaction of 
14-3-3 with a target protein through its ligand-binding groove. To support the notion that 
this effect of 14-3-3 occurred through PLN and SERCA, we showed that in mouse 
myocytes at 35°C the contribution of the Na+/Ca2+ exchanger is negligible and SERCA 
dominates the Ca2+ transient recovery (fig S8E-G). 
To test whether the effect of 14-3-3 on the recovery of the time-constant could be 
explained by binding to pSer16-PLN, we compared the effect of two phospho-specific 
antibodies directed against pSer16-PLN or pThr17-PLN (Fig. 7C, fig. S1C,D). Although the 
latter did not affect recovery, the pSer16 antibody led to a prolonged slowing of the recovery 
of the time-constant, similar to that caused by 14-3-3. During isoprenaline stimulation, 
pSer16 PLN is expected to be the dominant phosphoform of PLN. Furthermore, pThr17-PLN 
may already be saturated with endogenous 14-3-3 due to the higher binding affinity (Fig. 
3E-H). We would predict that the pThr17 antibody or 14-3-3 would prolong the lifetime of 
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pThr17-PLN and hence SERCA stimulation under conditions in which PLN becomes 
acutely and abundantly phosphorylated at this site. The comparison of the effect of the two 
antibodies during -adrenergic stimulation and concomitant PKA activation suggests that 
pSer16-dependent, acute recruitment of a large antibody protein or 14-3-3 to PLN can affect 
the biological outcome of -adrenergic stimulation by prolonging the isoprenaline-
stimulated state of SERCA in cardiomyocytes. Taken together, we predict that affinity and 
avidity effects combine to finetune the stability of PLN-14-3-3 complexes (Fig. 7D), 
resulting in different degrees of protection from phosphatase action.  




PLN is a key regulator of SERCA. Inherited disorders that result in PLN dysfunction 
demonstrate a critical role of this regulation in humans. Despite its short sequence, the N-
terminus of PLN is emerging as a hub where interactions with proteins distinct from the 
kinases and phosphatases that modify PLN in response to cardiac signal transduction may 
enhance or attenuate PLN’s potential to inhibit SERCA (16). We identified 14-3-3 
phosphoadaptor proteins as PLN interactors through several independent lines of 
evidence. First, 14-3-3 affinity purification enriched SDS-resistant PLN pentamers from 
solubilized cardiac membranes (Fig. 1E, 3A). APEX2-peroxidase based proximity labelling 
demonstrated that 14-3-3 proteins are localized within nanometers of PLN in living 
cardiomyocytes (Fig. 2B). We coimmunoprecipitated PLN with 14-3-3 (Fig. 6C) from 
isolated cardiomyocytes. Although these complementary approaches do not demonstrate 
a direct interaction between PLN and 14-3-3, we argue that a direct interaction is plausible 
because Ser16 and Thr17 are located in putative 14-3-3 binding sites (18, 34), because we 
showed a direct interaction in a phosphorylation dependent manner (Fig. 3C,G), and 
because MD simulations yielded plausible structural models for the respective PLN-
derived phosphopeptide in the ligand-binding groove of 14-3-3 (Fig. 4A-C). 
14-3-3 proteins are dimeric and, hence, susceptible to avidity effects when binding 
to multimeric targets. Indeed, we found that SDS-resistant pentameric but not monomeric 
PLN bound 14-3-3 when phosphorylated by PKA (Fig. 1E, 3A). The SDS-resistant PLN 
pentamers were previously interpreted to be proxies of physiological pentamers (9,14). 
Even if our binding experiment performed in a mild detergent (ComplexioLyte48) and 
subsequent analysis by SDS-PAGE captured only a fraction of all PLN pentamers, the 
experiment showed unequivocally that PLN pentamers can recruit 14-3-3. However, we 
reconstituted the interaction between CaMKII-phosphorylated PLN and 14-3-3 using a 
recombinant non-oligomeric protein (Fig. 3G,H). Hence, we propose a model (Fig. 7D) in 
which the relative abundance of pSer16 and pThr17 phosphosites determines the 
occupancy of PLN pentamers by 14-3-3. Acute PKA-mediated phosphorylation of PLN 
during -adrenergic stimulation is expected to raise the apparent affinity for 14-3-3. Indeed, 
we observed prolonged SERCA activity due to 14-3-3 binding after -adrenergic 
stimulation in cardiomyocytes (Fig. 7A). Because 14-3-3 binding slowed the 
dephosphorylation of PLN phosphosites in vitro (Fig. 5A,B, fig. S8C,D), we propose that 
the biological effects of 14-3-3 binding are due to blocking the access of PP1c to the 
phosphosite thereby maintaining PLN in the inactive, phosphorylated and SERCA in the 
active state. Consistently, we mimicked the effect of 14-3-3 after acute -adrenergic 
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stimulation in cardiomyocytes by the addition of a specific anti-pSer16-PLN antibody (Fig. 
7C). Binding of 14-3-3 dimers to the pSer16-PLN pentamers may also stabilize the 
pentameric form of PLN and hence reduce the pool of monomeric form that is thought to 
be the major species that inhibits SERCA (15). 
The affinity of the respective protein-protein interaction between 14-3-3 and pSer16- 
or pThr17-PLN translates into a molecular “memory” of which kinase created the 14-3-3 
binding site on PLN. At the molecular and atomic level, this memory is because the 
respective phosphoresidues, which are specific products of either PKA or CaMKII, fit into 
the same position of the 14-3-3 ligand-binding groove (Fig. 4A,B). Consequently, the 
surrounding side chains of the PLN N-terminus slot into different, energetically more or 
less favorable positions of the binding groove. For example, comparison of pSer16-PLN 
with pSer16-T17A-PLN (Fig. S5) indicated that the side chain of Thr17 reduced the energy 
of binding when Ser16 was phosphorylated. When Thr17 was phosphorylated, Ile18 occupied 
the corresponding position, which avoided placing the polar side chain of Thr17 in this 
environment and hence resulted in an energetically more favorable fit.  
Biologically, a shorter memory for PKA-mediated phosphorylation is consistent with 
the role of this modification in the acute and reversible adaptation of intracellular Ca2+ 
handling to the cAMP signal elicited by -adrenergic agonists. CaMKII activation in 
cardiomyocytes integrates changes in intracellular Ca2+ concentrations and other 
parameters such as redox potential (40). In fact, CaMKII activity can become independent 
of acute changes in intracellular Ca2+. The kinase has many targets in addition to 
intracellular Ca2+ handling proteins, such as ion channels that control cardiomyocyte 
excitation and proteins that mediate the transcriptional activation of a hypertrophic gene 
program. The slower effects of CaMKII on gene expression could represent a biological 
rationale for the longer-lasting memory associated with PLN modification by CaMKII 
kinase, which translates to a higher affinity of 14-3-3 binding to pThr17-PLN. This 
mechanism may ensure the adaptation of intracellular Ca2+ handling to the hypertrophic 
state. Expression of CaMKII itself is elevated in heart failure (41) and the kinase has 
attracted attention as a potential therapeutic target (42). Our insight into CaMKII-
dependent 14-3-3 recruitment to PLN may help to understand the effects of CaMKII 
inhibitors that are currently under development. 
Two forms of genetic PLN-dependent DCM alter the N-terminus of PLN with 
different effects on phosphorylation and 14-3-3 binding. Our data can therefore help to 
extend current models (7, 43, 44) of the molecular basis of ∆Arg14- and R9C-PLN. On the 
one hand, ∆Arg14-PLN cannot be modified by PKA (fig. S6) and hence lacks the low-affinity 
14-3-3 binding mode. This may make CaMKII activation upon sustained -adrenergic 
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stimulation and 14-3-3 binding to PLN through pThr17 more crucial. On the other hand, the 
introduction of a reactive cysteine side chain instead of Arg9 leads to disulfide bridges that 
stabilize the PLN pentamer and render it less accessible to PKA (44). Access of 14-3-3 to 
the pertinent phosphopeptide in such disulfide-stabilized PLN pentamers would also be 
impaired resulting in an inability to differentially stabilize the pentamer according to kinase 
action. The precise consequences of either DCM mutation on 14-3-3 recruitment to PLN 
will have to be biochemically investigated in the corresponding heterozygous disease 
models. 
In conclusion, PLN represents yet another fascinating example in which the action 
of 14-3-3 proteins modulates the outcome of signal transduction events by recognizing the 
phosphorylation and oligomerization state of a target protein. Steric masking of the 
phosphosite and potentially stabilization of the pentamer through 14-3-3 binding may 
influence not only the access of other proteins such as phosphatases, but also the 
dynamics of PLN itself. In line with the different delta energies of binding in the two 
molecular registers of 14-3-3 binding, these effects and their duration seem to be finetuned 
according to the kinase that modified PLN. 
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Materials and Methods 
 
Purification of proteins 
Recombinant Gluthathione-S-transferase (GST)- or Maltose binding protein (MBP)-tagged 
proteins (expressed from the plasmids listed in supplementary table S1) were expressed 
and purified from E. coli strain BL21 Rosetta. Protein expression was induced in 2YT media 
(2YT mix, AppliChem) using 1 mM isopropyl-beta-D-thiogalactopyranosid (IPTG) for 3 h at 
30°C. Cells were harvested and lysed in GST buffer (20 mM HEPES pH 6.8, 150 mM 
KOAc, 5 mM Mg(OAc)2, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol 
(DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), pH 6.8). Crude cell lysate was 
centrifuged at 100.000 g for 30 min at 4°C. The supernatant was incubated with 1 ml 
washed glutathione sepharose beads (GE Healthcare) for GST-tagged proteins or 1 ml 
amylose resin (New England Biolabs) for MBP-tagged proteins for 1h at 4°C under gentle 
rotation. The bead slurry was transferred to gravity columns and washed with 3 column 
volumes GST buffer pH 7.4, followed by one column volume of 1 mM adenosine 
triphosphate (ATP) in GST buffer pH 7.4 and a final wash step in GST buffer pH 7.4. Bound 
GST-tagged proteins were eluted with GST elution buffer (20 mM HEPES pH 6.8, 150 mM 
KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1 mM DTT, 15 mM L-Glutathione, pH 8.5), 
meanwhile bound MBP-tagged proteins were eluted with MBP elution buffer (20 mM 
HEPES pH 6.8, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1 mM DTT, 20 mM D-
Maltose, pH 7.5). The MBP-tag was cleaved with FactorXa enzyme for 16 h at 25°C 
according to the supplier’s recommendation (Merck MilliPore). After cleavage, proteins 
were separated by size exclusion chromatography on an Äkta purifier (GE Healthcare) and 
a Superdex75 size exclusion column in GST buffer pH 7.5. 
 
Heart membrane preparation 
Mice hearts were defrosted on ice, fat tissue was removed, and mice hearts were washed 
in tissue homogenization buffer (50 mM NaCl, 320 mM Sucrose, 2 mM EDTA, 20 mM 
HEPES, pH 7.4) supplied with protease and phosphatase inhibitors (Roche). Hearts were 
cut into small pieces and lysed with a MiccraD-1 homogenizer for 30 sec followed by 
douncing for 30 strokes. Cytosol and membranes were separated by centrifugation at 
100.000 g for 30 min at 4°C. The supernatant was the cytosolic fraction. The purified 
membrane fraction was resuspended once, washed in homogenization buffer, and 
collected by centrifugation at 100.000 g for 30 min. 
 
Heart membrane solubilization 
Purified heart membranes were solubilized in ComplexioLyte 48 (Logopharm) buffer for 30 
min on ice. 1 ml ComplexioLyte 48 was used to solubilize membranes with a protein 
content of 1 mg. Solubilized membranes were centrifuged for 30 min at 55.000 g, 4°C. The 
supernatant contained solubilized proteins which were used for pull-down experiments or 
trichloroacetic acid (TCA) precipitated for Western blot analysis.  
 
Separation of PLN pentamer into monomer in cardiac membranes by heating 
Mouse heart membranes were purified as described above. Solubilized mouse heart 
membranes were diluted 1:5 in GST buffer (20 mM HEPES pH 6.8, 150 mM KOAc, 5 mM 
Mg(OAc)2, 1 mM EDTA, 1 mM DTT, pH 7.4) supplemented with protease and phosphatase 
inhibitors and divided into two Eppendorf tubes. One tube was stored on ice meanwhile 
the other one was heated at 75°C for 20 min. After heating, the membranes were 
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centrifuged at 20.000 g for 10 min at 4°C. Both solubilizes membrane preparations were 
used as inputs for pull-down experiments (Fig. 3 A,B).  
 
Phos-tag polyacrylamide gel electrophoresis (PAGE) 
Phos-tag acrylamide (NARD institute) was used at a concentration of 5 µM according to 
the supplier’s information. 
 
Western Blot detection 
Primary antibodies were diluted 1:1000 in blocking buffer (5% w/v milk powder, 1x TBS, 
0,1% Tween) and incubated overnight at 4°C or for 2-3 h at room temperature (RT). 
Western blots were imaged with an LICOR Odyssey CLx imaging system using IRDye 
LICOR secondary antibodies. Secondary antibodies were diluted 1:10.000 in blocking 
buffer and incubated for 1h at room temperature.  
 
14-3-3 pull-down experiments from mouse cardiac membranes and cytosol 
Solubilized cardiac membranes or cytosol and recombinant purified MBP, or MBP-14-3-3 
bait protein was used for pull-down experiments. 50 µg MBP or MBP-14-3-3 protein was 
immobilized to 5 µl amylose resin bead slurry (New England Biolabs) in GST buffer (20 
mM HEPES pH 6.8, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1 mM DTT, pH 7.5) 
supplied with protease and phosphatase inhibitors for 45 min at 4°C under gentle rotation. 
Immobilized bait protein was washed 3 times in GST buffer, followed by blocking in 4% 
bovine serum albumin (BSA) dissolved in GST buffer and supplied with protease and 
phosphatase inhibitors for 30 min at 4°C under gentle rotation to block unspecific binding 
sites. For the MBP-14-3-3 protein, which was blocked with R18 trifluoroacetate inhibitor, 
5 µM R18 trifluoroacetate was supplied during immobilization and blocking. After blocking, 
the resin-bound bait proteins were washed 3 times in GST buffer and added to prepared 
solubilized cardiac membranes or cytosol, which were previously diluted 1:5 in GST buffer 
pH 7.5. After 1 h incubation at 4°C under gentle rotation, the resin-bound 14-3-3 was 
washed 4 times in GST buffer followed by elution with 1x SDS sample buffer (containing 
100 mM DTT). The pull-down experiment was analyzed by SDS-PAGE or Phos-tag-PAGE 
followed by silver staining or Western blot detection using primary antibodies described in 
supplementary table S2.  
 
APEX2 proximity labeling in neonatal rat cardiomyocytes 
Neonatal rat cardiomyocytes (NRCMs) were isolated from 0 to 3 days old Wistar rats and 
5x105 cells per well were seeded on 6-well plates. NRCMs were cultivated in heavy, 
medium and light (Eurisotop) SILAC medium (Thermo Fisher Scientific) under humidified 
conditions at 37 °C. After 13 days, NRCMs were transduced with adenoviral vectors (V5-
APEX2-PLN, V5-APEX2-PLN(Δ1-29), or eGFP) with a MOI of 10 for 48 h. The proximity 
labeling was conducted as described elsewhere (45). Briefly, the cells were incubated for 
30 min with 0.5 mM biotinphenol at 37 °C followed by 1 mM H2O2 for 1 min at room 
temperature. Cells were washed with quenching buffer (5 mM Trolox, 10 mM NaN3, 10 mM 
Na-ascorbate in PBS) and harvested in RIPA buffer (0.5 % Na-deoxycholate, 50 mM 
Tris/HCl pH 7.5, 150 mM NaCl, 0.2 % SDS, 1 % Triton, 10 mM NaN3, 5 mM Trolox, 10 mM 
Na-ascorbate, 1 mM PMSF, complete mini). Cells were lysed by passing 10 times through 
a 27 G needle and centrifuged at 13000 x g for 10 min. Protein concentrations were 
determined with the Pierce 660 nm Protein Assay Kit (Thermo Fisher Scientific). The 
lysates of heavy, medium and light labelled NRCM were mixed in a ratio of 1:1:1 for a total 
of 250 µg protein. Biotinylated proteins were enriched by avidin pulldown assay (Thermo 
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Fisher Scientific). Eluted proteins were analysed by LC-MS/MS and MaxQuant. For 
quantification, log2 fold changes of ratios of PLN/eGFP and PLN/PLN(Δ1-29) were 
calculated and proteins that differed positivly from 0 according to a one sample t-test 
(p<0.01) were plotted. The experiment was conducted in three biological and two technical 
replicates with label switch. 
 
LC-MS/MS analysis 
Proteins were separated on 4-12 % Bis-Tris Minigels, visualized with Coomassie blue stain 
and sliced into 11 sections of equal size regardless of staining. After reduction with DTT, 
alkylation with 2-iodoacetamide, and overnight digestion with trypsin, digest peptides 
mixtures were extracted and dried in a speedvac (46). For mass spectrometric (MS) 
analysis, samples were enriched on a self-packed reversed phase-C18 precolumn (0.15 
mm ID x 20 mm, Reprosil-Pur120 C18-AQ 5 µm, Dr. Maisch) and separated on an 
analytical reversed phase-C18 column (0.075 mm ID x 200 mm, Reprosil-Pur 120 C18-
AQ, 3 µm, Dr. Maisch) using a 30 min linear gradient of 5-35 % acetonitrile/0.1% formic 
acid (v:v) at 300 nl min-1). The eluent was analyzed on a Q Exactive hybrid 
quadrupole/orbitrap mass spectrometer (ThermoFisher Scientific) in data-dependent 
acquisition mode. Each experimental cycle contained a full MS scan (350-1600 m/z, 
resolution setting 70,000 FWHM, AGC target 1*10e6, maximum fill time of 60 ms) and up 
to 12 MS/MS experiments (z=2-5, 2*10e4 trigger threshold, dynamic exclusion window 15 
s, 2.0 FWHM isolation width, normalized collision energy 25%, resolution setting 17,500 
FWHM, AGC target 2*10e5, maximum fill time 60 ms). Two technical replicates per sample 
were acquired. Raw data were processed using MaxQuant Software version 1.5.2.8 (Max 
Planck Institute for Biochemistry). The arginine R10/R6 and lysine K8/K4 labels including 
the ‘re-quantify’ option were specified for relative protein quantitation. 
 
Immunofluorescence 
NRCMs were isolated from 1 to 3 days old Wistar rats and plated on coverslips coated with 
collagen. After 15 days of cultivation and 48 h post transduction cells were fixed in 4 % 
PFA for 5 min. Next, cells were incubated in blocking/permeabilization buffer for 4 h (10 % 
bovine calf serum, 0.2 % Triton in PBS). Primary antibodies were diluted in blocking buffer 
and incubated over night at 4 °C as follows: V5 1:1000 (R960-25, Invitrogen); SERCA2a 
1:500 (A010-20, Badrilla). Subsequently, samples were washed three times in blocking 
buffer and incubated with secondary antibodies diluted 1:1000 and incubated over night at 
4 °C: anti-mouse (Alexa Fluor 568, Thermo Fisher Scientific) and anti-rabbit (Alexa Fluor 
633, Thermo Fisher Scientific). After washing, samples were embedded in mounting 
medium (ProLong Gold antifade reagent, Thermo Fisher Scientific). For imaging we used 
a Zeiss LSM 880 system with a Plan-Apochromat 63x/1.4 Oil DIC objective. Raw images 
were processed in ImageJ/Fiji (http://imagej.nih.gov/if/). 
 
Binding assay using purified PLN-GST constructs and 14-3-3 
10 µg purified PLN-GST variants were phosphorylated with recombinant PKA catalytic 
subunit (New England) or CaMKII (delta) kinases (Thermo Fisher Scientific) accordingly to 
the supplier’s information at 30 °C for 1 h. Phosphorylated bait proteins were bound to 5 µl 
glutathione sepharose beads (GE Healthcare) in GST buffer (20 mM HEPES, 150 mM 
KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1 mM DTT, 0.1% TritonX-100, pH 7.5) for 45 min at 
4°C under gentle rotation. Resin-bound bait proteins were incubated with equimolar 
amounts of recombinant purified 14-3-3 protein in GST buffer for 1 h at 4°C under gentle 
rotation. The resin-bound bait was washed 4 times in GST buffer and eluted in 1 x SDS 
sample buffer (supplied with 100 mM DTT). The binding assay was analyzed on SDS-
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PAGE which was transferred to nitrocellulose and probed with the indicated primary 
antibodies (compare Supplementary Table S2). Phosphorylation of bait proteins was 
analysed on Coomassie stained Phos-tag-PAGE and SDS-PAGE gels.  
 
Surface Plasmon Resonance  
Binding affinities of recombinant 14-3-3 protein to the cytosolic domain of recombinant 
purified PLN-GST were determined with surface plasmon resonance (SPR). SPR 
experiments were carried out on a Reichert SR 7500DC biosensor instrument at 20°C and 
a flow rate of 40 µl/min in SPR buffer (150 nM NaCl, 20 mM HEPES, 0,005% (v/v) Tween 
20, pH 7.5). All experiments were done in a buffer containing 20 mM HEPES pH 7.5, 150 
mM NaCl, 0.005% Tween-20 (v/v). A HC-1000 SPR sensor chip was activated with 1-
ethyl-3-83-dimethylaminopropyl)-carbodiimide and N-hydroxysuccinimide (EDC-NHS) 
(Xantec Biotechnologies) according to the supplier’s instruction. Followed by covalent 
binding of a GST antibody (Carl Roth, 3998.1) to the chip surface at a flow rate of 15 µl/min 
and a concentration of 30 µg/ml to a surface density of 4000-8000 µRIU (refractive index 
units, depending on the maximal capacity of each chip). After antibody coupling, the chip 
surface was deactivated by quenching with 1 M ethanolamine pH 8.5 for 180s at a flow 
rate of 30 µl/min. PLN-GST fusion proteins were phosphorylated with recombinant PKA 
catalytic subunit (New England Biolabs) or CaMKII (delta) (Thermo Fisher Scientific) 
kinase according to the manufacturer’s instruction for 1 h at 30°C and immobilized to the 
chip surface at a flow rate of 30 µl/min and to a surface density of 200-400 µRIU. The 
14-3-3 analyte was serially diluted and injected over the sensor chip surface at a flow rate 
of 40 µl/min. Association was done for 4.5 min and dissociation was subsequently done 
for 7 min. The dilution series ranged from 0.390 mM to a final concentration of 50 µM. Data 
analysis was performed with Scrubber 2.0c. Equilibrium binding isotherms were analysed 
with GraphPad Prism 6.0. 
 
Cardiomyocytes isolation and stimulation with isoprenaline  
All animal procedures were reviewed and approved by the Institutional Animal Care and 
Use Committees of the University Medical Center Göttingen in compliance with the 
humane care and use of laboratory animals. Hearts were perfused by Langendorff solution 
(120.4 mM NaCl, 17.7 mM KCl, 0.6 mM KH2Po4, 0.6 mM Na2HPO4, 1.2 mM MgSO4, 10 
mM HEPES, 4.6 mM NaHCO3, 30 mM taurine, 10 mM 2,3-butanedione-monoxime, 5.5 
mM glucose, pH 7.4) with a flow of 4 ml/min for a period 4 min at 37°C. To digest the tissue 
the heart was perfused with perfusion buffer supplemented with collagenase type II (2 
mg/ml) and CaCl2 (40 µM) for 8 min. The heart was removed from the Langendorff 
perfusion apparatus, placed in collagenase solution and the tissue was mechanically 
disrupted with a scissor and by resuspension with a pipette. The collagenase was stopped 
with bovine calf serum (10%) and CaCl2 (12.5 µM). Isolated cardiomyocytes were collected 
by filtration with a 100 µM cell sieve and centrifugation at 22 g for 1.5 min. Isolated 
cardiomyocytes from one animal were split into two Eppendorf tubes in experimental buffer 
(10 mM HEPES, 136 mM NaCl, 40 mM KCl, 1 mM MgCl2, 10 mM Glucose, 1 mM CaCl2, 
pH 7.35) and one tube was treated with 100 nM isoprenaline for 30 sec meanwhile the 
other was not treated. After isoprenanline stimulation the cells were collected by 
centrifugation and resuspend in sucrose homogenization buffer ((50 mM NaCl, 320 mM 
Sucrose, 2 mM EDTA, 20 mM HEPES, pH 7.4) supplied with protease and phosphatase 
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Immunoprecipitation 
Isoprenanline (100 nM, 30 sec) stimulated cardiomyocytes were thawed and membranes 
were separated as described above (see heart membrane preparation). Cardiomyocytes 
were lysed and crude membranes were separated from the cytosolic fraction by 
centrifugation. Purified membranes were washed and solubilized in 500 µl ComplexioLyte 
48 (Logopharm) for 30 min on ice. After solubilization the samples were centrifuged at 
55.000 g for 30 min at 4°C. 30% of the solubilized membrane fraction was removed and 
complemented with 5x SDS sample buffer (250 mM Tris-HCl pH 6.8, 10% SDS, 0.5% 
bromphenolblue, 50% glycerol) to a final concentration of 1 x and analysed by Western 
blotting detecting the indicated antigens using primary antibodies listed in supplementary 
table S2. The remaining solubilized membranes were diluted 1:5 in GST buffer (20 mM 
HEPES pH 6.8, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1 mM DTT, pH 7.5) and 
5 µl PLN total antibody (r-IgG) was added. The antibody was incubated for 4 h at 4°C under 
gentle rotation. Washed Sepharose A (GE Healthcare) was added to the samples and 
incubated overnight at 4°C under gentle rotation. Finally, the beads were washed 2 times 
in GST Buffer and eluted in 1 x SDS sample buffer. The SDS sample buffer was not 
supplemented with DTT to avoid reducing conditions. The samples were separated on 
SDS-PAGE gels, transferred to nitrocellulose, and analysed using the indicated primary 
antibodies.  
 
Dephosphorylation of pThr17- or pSer16-T17A-PLN-GST with or without bound 14-3-3 
10 µg recombinant purified PLN-GST protein was used per sample and time point. Bait 
protein was phosphorylated with CaMKII kinase (delta) (Thermo Fisher Scientific) or PKA 
(New England Bioland) accordingly to the supplier’s information at 30°C for 1 h. 
Phosphorylated recombinant protein was bound to 5 µl glutathione sepharose beads (GE 
Healthcare) in GST buffer (20 mM HEPES pH 6.8, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM 
EDTA, 1 mM DTT, 0.1% TritonX-100, pH 7.5) for 45 min at 4°C under gentle rotation 
followed by 3 wash steps in GST buffer. The immobilized bait protein was divided in two 
Eppendorf tubes. To one tube equimolar amounts of recombinant purified 14-3-3 protein 
was added in GST buffer and allowed to bind for 1 h at 4°C under gentle rotation. After 
binding, the bait proteins were washed 4 times in GST buffer. The resin-bound proteins 
were transferred to alkaline phosphatase buffer (Thermo Fisher Scientific) and treated with 
8 units alkaline phosphatase (Fast AP, Thermo Fisher Scientific) according to the 
supplier’s information for 0, 5, 10, 25 min at 30°C. After each incubation time point, the 
resin-bound bait protein was washed two times in GST buffer and eluted in 1 x SDS sample 
buffer (supplied with 100 mM DTT). The experiment was analyzed on SDS-PAGE or Phos-
tag-PAGE. SDS-PAGE were transferred to nitrocellulose membranes and analysed for 
pSer16 or pThr17-PLN as appropriate using the antibodies listed in Supplementary Table 
S2. Phos-tag gels were stained with Coomassie.  
 
Mouse cardiomyocyte isolation and cell culture for patch-clamp experiments 
Cells were isolated from hearts of 9-11 week old male mice (c57bl6) by standard 
collagenase digestion as previously described (47). All animal procedures were reviewed 
and approved by the Institutional Animal Care and Use Committees of King’s College 
London in compliance with the humane care and use of laboratory animals. Myocytes were 
pelleted by gravity and washed at room temperature with modified M199 (Earle's Salts) 
culture medium (Thermo Fisher Scientific) containing (per 500ml bottle): 0.113g creatine; 
0.313g taurine; 0.198g carnitine; 5ml penicillin/streptomycin (final concentration 1%). Cells 
were then pelleted, re-suspended in fresh media and transferred to laminin covered 
coverslips (15mm diameter No1) in 12-well plates at an approximate final density of 150 
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myocytes/coverslip. Cells were incubated for 24 hours (37°C, 5% CO2) prior to use in 
electrophysiological experiments. 
Measurement of intracellular [Ca2+] and patch-clamp Experiments 
Membrane currents were measured at 35°C in whole-cell ruptured-patch configuration 
using voltage-clamp with simultaneous intracellular Ca2+ measurement as previously 
described (48). Patch-Clamp experiments were performed using an Axopatch 200B 
amplifier, Digidata 1322A data acquisition and pClamp9.2 software (Molecular Devices, 
Sunnyvale, CA). Borosilicate glass microelectrodes had tip resistances of 1-2 MΩ when 
filled with pipette solution containing (in mmol/L): EGTA 0.024, Fluo-3 0.025, GTP-Tris 0.1, 
HEPES 10, K-aspartate 92, KCl 48, Mg-ATP 1, Na2-ATP 4; (pH=7.25 at 35°C). During 
experiments myocytes were superfused at 35°C with a Tyrode’s containing (in mmol/L): 
CaCl2 1, glucose 10, HEPES 10, KCl 4, MgCl2 1, NaCl 136, probenecid 2; (pH=7.35 at 
35°C). Cells were kept at a holding potential of -80mV and Ca2+ transients were stimulated 
through the pipette at 0.5 Hz as previously described [2]. In addition to including Fluo3 in 
the pipette solution, myocytes were also pre-incubated with Fluo-3-acetoxymethyl ester 
(Fluo3 AM; Invitrogen, Thermo Fisher Scientific; 1 mM solution in DMSO). Briefly, the 
cardiomyocyte staining solution was prepared by adding 5 µl of 1 mmol/l Fluo3 solution (in 
DMSO) to 1 ml of bath solution and 160 µl deionised water to limit the osmotic effects of 
DMSO. Cardiomyocytes were incubated in staining solution for 40 minutes followed by 
washing in bath solution (20 min) before use in voltage-clamp experiments. Optical 
measurements were performed using an Evolve 512 camera (Photometrix) and PTI 
EasyRatio Pro software (HORIBA Scientific). To avoid over-loading the computer memory 
(due to high speed acquisition at ~200 Hz), Ca2+ transients were recorded in groups of 5 
interspersed by 40 s intervals during which cells were continuously paced but data were 
not recorded. Purified 14-3-3 (2 µM) or 14-3-3 (2 µM blocked with R18 peptide as 
described for the pull-down assay) in other experiments 2.5 µg/ml of either anti-Ser16 or 
anti-Thr17 antibody was added to the in intracellular pipette solution and dialyzed into the 
cell interior.  
 
Data analysis and statistics 
In mouse myocytes the contribution of Na+/Ca2+ exchange to the recovery of the Ca2+ 
transient is minimal. Li et al using mouse myocytes at 23oC estimate that SERCA is 
responsible for 90% of the Ca2+ transient recovery, with Na+/Ca2+ exchange contributing 
only 9% (49). In our studies at 35oC (at which active processes may be even more 
dominant), we found that the rapid removal of extracellular Na+ (<50msec exchange time) 
prior to a Ca2+ transient did not affect the recovery of the transient (see Figure S8G). This 
finding suggested that at 35oC the recovery of the Ca2+ transient was dominated by 
SERCA. This recovery phase could therefore be accurately described by a single 
exponential fit and the time-constant of this Ca2+ transient recovery (t) could be used as 
an index of SERCA activity. Ca2+ transients were automatically fitted using custom 
software written in Matlab (MathWorks, Inc, USA). Time-constants obtained for each of 5 
sequential Ca2+ transients in each group were averaged to get a single  value at each 
time point. To minimise differences caused by cell variability data obtained in each 
individual cell were normalized to the maximum response amplitude. Differences between 
experimental groups were tested with two-way ANOVA mixed model test, followed by a 
Tukey’s multiple comparison test. 
 
Computational modelling 
The 3D structure of 14-3-3σ in complex with pSer16-PLN peptide (RRApSTIEMP – Uniprot 
identifier P26678) was generated by homology modelling using the PrimeX software, 
version v5.5 (Schrodinger (50)). Input coordinates of the template systems were retrieved 
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from PDB codes 3MHR and 4DAT that contain the phosphopeptides complexed to 
14-3-3σ. With the purpose of modelling the longest peptide sequence, amino acids from 
the C-terminus to the phosphosite and from the phosphosite to the N-terminus were taken 
from 4DAT and 3MHR respectively. The homology model was relaxed through molecular 
dynamics (MD) simulations carried out by Amber18 program. The force field ff14SB (51) 
was used to parametrize protein and peptide while the general amber force field (GAFF) 
was used for non-standard residues. Parameters for the phosphoserine residue were 
retrieved from the AMBER Parameter Database (52). For MD simulation purposes the 
system was solvated in a cubic box of TIP3P water molecules buffering 10 Å from the 
surface. Periodic boundary conditions were applied. In order to keep the system electrically 
neutral, the total charge was neutralized by the addition of Na+ counter-ions. Following 
previous work (53, 54), the solvent and Na+ ions were energy-minimized for 1500 steps 
using the steepest descent (SD) algorithm and a further 3500 steps using the conjugate 
gradient (CG) algorithm while keeping the solute as fixed. The solvated solute was then 
energy-minimized for 1500 steps using the SD and 3500 steps using the CG before being 
heated at constant volume using the Langevin thermostat from 0 to 300 K over 150 ps. A 
density equilibration was carried out at constant pressure (NPT ensemble) for 150 ps, 
before running the production of unbiased MD trajectories for 250 ns (timestep was 2 fs). 
MD trajectories were processed by the cpptraj software (55) and analysed in terms of root 
mean square deviation (RMSD) or residue fluctuation (RMSF) and cluster analysis. The 
same parameters were used to relax the apo 14-3-3σ by MD simulations. The same 
procedure as described above was used to generate the 3D structure of 14-3-3σ in 
complex with pThr17-PLN peptide (RASpTIEMP). Electrostatic surface potential was 
computed with APBS version 27 (56) and visualized in VMD molecular graphic software 
(57). The delta energy of binding was computed by the Molecular Mechanics Poisson-
Boltzmann Surface Area (MM-PBSA) approach using the MMPBSA.py script in AMBER18 
(58). Theoretical affinity results are presented as the delta energy of binding +/- standard 
error of the mean (SEM) (59). 
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Supplementary Materials 
fig. S1. Cardiac cytosolic fractions do not show a signal for 14-3-3-bound PLN.  
fig. S2. Confocal imaging showing the colocalization of APEX2-PLN or APEX2-PLN (∆1-
29) and SERCA2a in NRCMs. 
fig. S3. All seven 14-3-3 isoforms bind pThr17-PLN-GST.  
fig. S4. Determination of the equilibrium dissociation constant for 14-3-3 binding to 
pThr17-PLN. 
fig. S5. MD simulation of the 14-3-3σ-pSer16-PLN complex and the 14-3-3σ-pThr17-PLN 
complex. 
fig. S6. PKA does not phosphorylate ∆Arg14-PLN monomers. 
fig. S7. 14-3-3 binding protects pSer16-T17A-PLN protects from fast dephosphorylation. 
fig. S8. Effect of 14-3-3 and Na+-free superfusion on the kinetics of isoprenaline-induced 
Ca2+ transients in isolated cardiomyocytes. 
table S1. Plasmids used in this study. 
Table S2. Antibodies used in this study. 
Data File S1. Biotinylated proteins detected by in-vivo proximity labelling using V5-
APEX2-PLN. 
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Fig. 1. 14-3-3 binds PLN pentamers from cardiac membranes. (A) Schematic 
representation of PLN indicating the PKA consensus site and a putative 14-3-3 binding 
site (18). (B) Scheme for the 14-3-3 affinity purification protocol. (C) Representative silver-
stained gel revealing proteins from the membrane fraction co-purifying with 14-3-3 and 
background according to workflow shown in (B) (n = 3 mice/group). (D) Presence of PKA-
phosphorylated proteins in the 14-3-3-bound membrane fraction (n = 3 mice/group). See 
fig. S1A for the full blot including the cytosol fraction. (E) Immunoblotting of the 14-3-3-
bound membrane fraction with a PLN antibody (n = 6 mice/group). See fig. S1B for the full 
blot including the cytosol fraction. (F) Quantification of experiments shown in (E). (G) 
Detection with phospho-specific anti-pSer16 reveals the presence of pSer16-PLN in the 
14-3-3-bound proteins from the membrane fraction (n = 5 mice/group). (H) Quantification 
of experiments shown in (G). In (F) and (H) data are presented as box and whisker plots 
with mean and median. A one-way ANOVA analysis showed significant differences 
between the MBP, 14-3-3+R18 and 14-3-3 group in (F) (p=<0.0001) and in H (p=<0.0002). 
A Tukey test revealed significant differences in (F) between 14-3-3+R18 compared to 
14-3-3 (*** p=0.0002) and between MBP compared to 14-3-3 (*** p=0.0003) as well as in 
(H) between 14-3-3+R18 compared to 14-3-3 (*** p=0.0009) and MBP compared to 14-3-3 
(*** p=0.0003). H.s., Homo sapiens; M.m., Mus musculus; R18, R18 trifluoroacetate; WB, 
Western blot; M, monomer; P, SDS-resistant pentamer; a.u., arbitrary units. 
 
Fig. 2. PLN proximity proteomics enriches six out of seven 14-3-3 isoforms. (A) Scheme 
of proximity proteomic strategy: N-terminal fusion of the V5-APEX2 peroxidase to full-
length PLN was compared to PLN lacking 29 residues of the N-terminus. (B) Enrichment 
of 14-3-3 isoforms (orange circles), PP1c, and Hsp20 with full-length PLN was identified 
by proximity proteomics in living NRCMs (see Data File S1 for enriched proteins). 
Enrichment compared to two different negative controls is shown – cytosolic GFP to 
assess background binding to the biotin affinity matrix and N-terminally truncated PLN (1-
29) to assess specific binding to the exposed region of the membrane protein (n = 5 
independent experiments from 3 NRCM preparations). In (B), only proteins that positively 
differed from 0 according to a one sample t-test (p < 0.05) in the ratios for both full-length 
PLN/eGFP and full-length PLN/PLN 1-29 mutant are shown. 14-3-3 was only 
significantly enriched over eGFP (p < 0.05) but not over PLN 1-29 mutant (p=0.07). See 
fig. S2B and S2C for the intensity of detected proteins. APEX, ascorbate peroxidase; 
SILAC, stable isotope labeling by amino acids in cell culture; , 14-3-3 delta; , 14-3-3 eta; 
, 14-3-3 epsilon; , 14-3-3 gamma; , 14-3-3 sigma; , 14-3-3 tau; , 14-3-3 zeta. 
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Fig. 3. 14-3-3 preferentially binds PLN pentamer and pThr17-PLN has a higher 14-3-3 
binding affinity than pSer16-PLN. (A) Effect of heating cardiac membranes to convert PLN 
pentamers to monomers on binding of PLN to 14-3-3 (n = 7 mice/group). (B) Quantification 
of experiments shown in (A). The proportion of the respective form in the eluate was 
determined in relation to the pentamer or monomer signal from the input. (C) Binding assay 
using recombinant, monomeric PLN-GST and the indicated variants to assess 14-3-3 
binding after PKA-dependent phosphorylation in vitro (n = 3 independent experiments). (D) 
Quantification of experiments shown in (C) using normalized values of 14-3-3 intensity and 
of the slower migrating band in Phos-tag gels. (E) The experiments shown in (A) were 
probed for pThr17-PLN on independent Western blots (n = 5 mice/group). (F) Quantification 
of experiments shown in (E). The proportion of the respective form in the eluate was 
determined in relation to the pentamer or monomer signal from the input. (G) Binding assay 
using recombinant, monomeric PLN-GST and the indicated variants to assess 14-3-3 
binding after CaMKII-dependent phosphorylation of PLN-GST (n= 3 independent 
experiments). (H) Quantification of experiments shown in (G) using normalized values of 
the 14-3-3 intensity and of the slower migrating band in the Phos-tag gel. Data in (B), (D), 
(F), and (H) are presented as box and whisker plots with mean and median. A one-way 
ANOVA analysis showed significant differences between groups in (B) (p=<0.0001) and in 
(F) (p=<0.0001), and a Tukey test showed significant differences in (B) between pentamer 
-75°C and monomer +75°C (* p=0.0143). The multiple comparison test showed no 
significant difference in (F) between pentamer -75°C and monomer +75°C (p=0.5587). M, 
monomer; P, SDS-resistant pentamer; pPLN, phosphorylated PLN; WB, Western blot. 
 
Fig. 4. 14-3-3 contacts PLN in two distinct conformations. (A) Overview of a 14-3-3σ 
monomer bound to pSer16-PLN based on the model obtained by MD simulations. 14-3-3σ 
is shown as a colored surface according to the electrostatic potential computed by APBS 
(negative potential in red, positive in blue), and peptides are depicted as cyan sticks (n = 
2 independent experiments with conformational sampling of 250 ns). (B) Overview of a 
14-3-3σ monomer bound to pThr17-PLN as obtained by MD simulations. Visualization as 
in (A) (n = 2 independent experiments with conformational sampling of 250 ns). (C) 
Superimposition of 14-3-3σ/ pSer16-PLN complex (white cartoon/cyan sticks) and 14-3-3σ/ 
pThr17-PLN (pink cartoon/purple sticks) shown in (A) and (B). (D) In vitro phosphorylation 
of the indicated PLN-GST variants mimicking DCM-causing mutants using CaMKII (n = 5 
independent experiments). pPLN, phosphorylated PLN; WB, Western blot.  
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Fig. 5. 14-3-3 protects PLN from dephosphorylation. (A) De-phosphorylation of pThr17-
PLN-GST in the presence of 14-3-3 as monitored by anti-pThr17-PLN Western blot (n= 6 
independent experiments). (B) Quantification of experiments shown in (A) using values of 
the PLN pThr17 intensity at different time points normalized to the PLN pThr17 intensity at 
time point 0 (no 14-3-3). (C) Experiments as shown in (A) illustrating the phosphorylation 
state of PLN-GST (Phos-tag gel), total PLN-GST (SDS PAGE), and bound 14-3-3 
(Western blot). (D) Quantification of bound 14-3-3 from experiments shown in (A) and (C) 
using values of the 14-3-3 intensity at different points normalized to the 14-3-3 intensity at 
time point 0. Data in (B) and (D) are presented as box and whisker plots with mean and 
median. A paired t-test showed no significant difference between the samples with or 
without 14-3-3 at 0 min (p=0.2141). A significant difference was shown between the 
samples with or without 14-3-3 at 5 min (* p=0.0181), at 10 min (* p=0.0136) and at 25 min 
(* p=0.0370). FastAP, alkaline phosphatase; min, minutes, Norm, normalized. 
 
Fig. 6. 14-3-3 is enriched in mouse cardiac membranes after isoprenaline stimulation. (A) 
Immunoprecipitation from cardiac membranes using PLN (rabbit-IgG) antibody. Detection 
with PLN (mouse-IgG) antibody (n = 2 mice/group). (B) 14-3-3 pan 14122 antibody 
characterization using HeLa cell and heart lysate. Upper band indicates a slower migrating 
14-3-3-positive band, presumably 14-3-3 epsilon based on predicted molecular weights. 
Asterisk indicates cross-reacting protein. (n = 2 mice or independently transfected cell 
populations/group). (C) Detection of PLN associated 14-3-3 after isoprenaline stimulation 
in cardiomyocytes. IP = Immunoprecipitation of PLN with PLN (rabbit-IgG) antibody from 
isoprenaline stimulated cardiomyocytes; total = 15% input membranes. Top two panels: 
anti-14-3-3 detection of PLN IP (run without DTT) and cardiac inputs (run with DTT); middle 
three panels: anti-PLN (mouse IgG) or anti-Na/K detection of PLN IP (run without DTT) or 
cardiac inputs (run with DTT); lower two panels: anti-pSer16-PLN or anti-Na/K detection of 
cardiac inputs (n = 4 mice/group). Asterisk indicates cross-reacting protein. (D-F) 
Quantification of experiments shown in (C). Data are presented as box and whisker plots 
with mean and median. A paired t-test showed no significant difference in (D) (p=0.8771) 
but a significant difference was found in (E) (* p=0.0338) and in (F) (* p=0.0222). 14-3-3 
detected in membranes from Pln-/- mice (negative control for IP) is shown in purple in (F). 
IP, immunoprecipitation; IgG, immunoglobulin G; m-IgG, mouse immunoglobulin; r-IgG, 
rabbit immunoglobulin; M, monomer; P, pentamer; WB, Western blot; total, total amount 
of protein used as input; NaK, Na/K ATPase; ISO, isoprenaline. 
 
Fig. 7. 14-3-3 prolongs SERCA stimulation after -adrenergic activation in mouse 
cardiomyocytes. The data in (A – D) were obtained under control conditions or in the 
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presence of the tested peptides or antibodies in the patch pipette solution. Ca2+ transients 
were recorded at 0.5 Hz stimulation rate, as it is shown in fig. S8A,C. The time constant 
(τ) of Ca2+ transient decay was measured every 55s. To obtain an individual reading, we 
averaged τ values calculated by single exponential fitting of decay phase for 3 Ca2+ 
transients, recorded at each time point. The changes in the SERCA function followed the 
application of 10 nM isoprenaline for 10 sec. To compensate for the cell-to-cell variability 
in the absolute magnitude of isoprenaline peak response, the relative response from 
baseline was normalized to the peak response in each cell. (A) Ca2+ transient decay in 
cardiomyocytes patched with control pipette solution (7 cells from 4 isolations) or with 
pipette solution containing 14-3-3 (2µM) (n=7 cells from 5 isolations). A two-way ANOVA 
mixed-model analysis revealed significant differences between curves (p=0.0024). A 
multiple comparison test showed significant differences only at the last time point (* 
p=0.033). (B) Ca2+ transient decay in cardiomyocytes patched with control pipette solution 
(7 cells from 4 isolations) or pipette solution containing R18 (2µM) (n=8 cells from 4 
isolations) or a mixture of 14-3-3 (2µM) and R18 (2µM) (n=6 cells from 4 isolations). 
Two-way ANOVA indicated no significant differences between the three tested conditions 
(control, R18 inhibitor and 14-3-3 blocked with R18) either using mixed-model analysis 
(p=0.6365). (C) Ca2+ transient decay in cardiomyocytes patched with control pipette 
solution (n = 7 cells from 4 isolations) or with pipette solution containing 2.5 µg/ml of either 
anti-pSer16 (n = 6 cells from 5 isolations) or anti-pThr17 antibody (n = 6 cells from 4 
isolations). A two-way ANOVA mixed-model analysis revealed significant differences 
between the curves of the three tested conditions (p=0.0131). Multiple comparison tests 
showed significant differences between anti-pSer16 and anti-pThr17 antibodies at 380s (* 
p=0.0143) and further 440s (* p=0.0053). Between control and anti-Ser16 group, significant 
differences were observed at 380s (* p=0.0495) and at 440s (* p=0.0268). All other 
changes were not significant. (D) Scheme illustrating the dependence of the apparent 
binding affinity of dimeric 14-3-3 protein on the number and kind of different phospho-
residues present in the PLN pentamer. Affinity and avidity effects combine with each other 
resulting in increased 14-3-3 binding to PLN and protection from the phosphatase PP1. 
ISO, isoprenaline; s, seconds; R18, R18 trifluoroacetate; Ab, antibody, PP1, protein 
phosphatase 1. 
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fig. S1. Cardiac cytosolic fractions do not show a signal for 14-3-3-bound PLN. (A) 
Presence of PKA-phosphorylated proteins in the 14-3-3-bound membrane fraction but not 
in the cytosolic fraction (n = 3 mice/group). (B) Detection of 14-3-3-bound proteins from 
membrane or cytosolic fractions from cardiomyocytes with a PLN antibody (n = 6 
mice/group). (C,D) Recombinant PLN WT, S16A, or T17A proteins were phosphorylated 
with either PKA (C) or CaMKII (D). The phosphorylated samples were resolved by SDS-
PAGE and probed with pSer16-PLN or pThr17-PLN antibodies (n = 2 independent 
experiments). R18, R18 trifluoroacetate; WB, Western blot. 
  




fig. S2. Confocal imaging showing the colocalization of APEX2-PLN or APEX2-PLN (∆1-
29) and SERCA2a in NRCMs. (A) NRCMs cultured for 15 days were transduced with 
adenoviruses (Ad5) expressing either APEX2-PLN or APEX2-PLN(∆1-29). NRCMs were 
fixed with 4% paraformaldehyde, immunostained for V5 (red) and SERCA2a (green), and 
imaged by confocal microscopy (Zeiss LSM 880, 63x/1.4 Oil DIC objective). Dashed boxes 
indicate areas of magnified views (representative of 2 independent experiments). Scale 
bars 10 µm. (B, C) Log(2) dot plots showing all detected proteins for the ratio V5-APEX2-
PLN/eGFP (B) or V5-APEX2-PLNΔ(1-29)/eGFP (C) (n=5 independent experiments from 3 
NRCM preparations). , 14-3-3 delta; , 14-3-3 eta; , 14-3-3 epsilon; , 14-3-3 gamma; , 
14-3-3 sigma; , 14-3-3 tau; , 14-3-3 zeta. 
 
  




fig. S3. All seven 14-3-3 isoforms bind pThr17-PLN-GST. Detection of PLN bound 14-3-3 
isoforms with silver-stained SDS-PAGE. Unphosphorylated PLN-GST was used as 
negative control for the binding of 14-3-3 and 14-3-3. Equal 14-3-3 inputs were 
confirmed on SDS-PAGE and PLN pThr17 phosphorylation using activated CaMKII kinase 
was confirmed on a Phos-tag gel (n = 3 independent experiments). , 14-3-3 beta; , 








fig. S4. Determination of the equilibrium dissociation constant for 14-3-3 binding to pThr17-
PLN. (A) Scheme of surface plasmon resonance experiment using pSer16- or pThr17-PLN-
GST. (B) Binding isotherm obtained from the experiment schematized in (A) and 
dissociation constant for 14-3-3 (without MBP-tag) binding pThr17-PLN determined by a 
sigmoidal dose-response curve fit (n = 3 independent experiments). Error bars depict +/-
SEM. (C, D) Sensograms underlying (B) for pThr17-PLN (C) and unphosphorylated PLN 
exposed to the same concentrations of 14-3-3 (D). KD, equilibrium dissociation constant; 
pSer16, PLN phosphorylated at Ser16; pThr17, PLN phosphorylated at Thr17; koff, 
dissociation rate constant. 
  




fig S5. MD simulation of the 14-3-3σ-pSer16-PLN complex and the 14-3-3σ-pThr17-PLN 
complex. (A) RMSD of all-atom of 14-3-3σ protein and the peptide as a function of the MD 
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curve) in comparison with 14-3-3σ apo (blue curve) obtained during the 250 ns simulation 
(n= 2 independent experiments). (C) Overview of 14-3-3σ monomer bound to pSer16-PLN 
(cyan sticks). Residues showing high conformational freedom in MD simulation are 
depicted in purple and green (loops 64-88 and 208-219, respectively). Residues 118-190 
of the amphipathic groove are highlighted in ice blue. (D) Distribution of clusters over 5 
population groups. Conformations of the 14-3-3σ-pSer16-PLN complex were clustered 
along MD trajectory frames. (E) RMSD of all-atom of 14-3-3σ protein and the peptide as a 
function of the MD simulation time. (F) RMSF of the protein residues of 14-3-3σ/pThr17-
PLN complex (blueviolet curve) in comparison with 14-3-3σ apo (blue curve) obtained 
during the 250 ns simulation (n = 2 independent experiments). (G) Overview of 14-3-3σ 
monomer bound to pThr17-PLN (purple sticks). Residues unfavourable for stability during 
the simulation are depicted in purple and green. The amphipathic groove is highlighted in 
ice blue. (H) Distribution of average cluster over 5 population groups. Conformations of the 
14-3-3σ-pThr17-PLN complex were clustered along MD trajectory frames. 14-3-3, 14-3-3 
sigma; RMSD, all-atom root mean square deviations; RMSF, root mean square fluctuation. 
 
  




fig S6. PKA does not phosphorylate ∆Arg14-PLN monomers. In vitro phosphorylation of the 
indicated PLN variants using PKA (n = 3 independent experiments), visualized on Phos-tag 
gel or SDS-PAGE gel. pPLN, phosphorylated PLN. 
 
  




fig S7. 14-3-3 binding protects pSer16-PLN protects from fast dephosphorylation. (A) 
Dephosphorylation of pSer16-PLN T17A-GST in the presence of 14-3-3 was analysed by 
Western blot with anti-pSer16-PLN and 14-3-3 pan H8 antibodies (n = 5 independent 
experiments). In addition, pSer16-PLN was also monitored on Phos-tag gel and SDS-PAGE 
gel. (B) Quantification of slower-migrating band observed in Phos-tag-PAGE normalized 
to slower-migrating band at time point 0 (no 14-3-3) shown in (A). Data is presented as 
box and whisker plot with mean and median. A paired t-test showed no significant 
difference between the samples with or without 14-3-3 at 0 min (p=0.4279), at 10 min 
(p=0.0540) or at 25 min (p=0.0947). A significant difference was observed at 5 min (** 
p=0.0061). FastAP, alkaline phosphatase; min, minutes; pPLN, phosphorylated PLN. 
 
  




Fig S8. Effect of 14-3-3 and Na+-free superfusion on the kinetics of isoprenaline-induced 
Ca2+ transients in isolated cardiomyocytes. (A) Ca2+ transients were stimulated at 0.5 Hz 
by patch pipette and Ca2+ transients recorded discontinuously (due to memory buffering 
limitations of the video capture system). A 10 sec pulse of isoprenaline (ISO, 10 nM) was 
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applied at the time point indicated. Representative traces from 7 myocytes isolated from 4 
mice recorded with control pipette solution. (B) Ca2+ transient profiles averaged from 3 
consecutive Ca2+ transients recorded at the points marked 1, 2 and 3 in (A). Data were 
normalized to maximum amplitude before plotting. (C) Ca2+ transients recorded as in (A) 
with a pipette solution containing 2µM of 14-3-3 in the whole-cell configuration. 
Representative of 7 myocytes isolated from 5 mice. (D) Ca2+ transient profiles averaged 
from 3 consecutive Ca2+ transients recorded with 14-3-3 in the pipette at the points marked 
1, 2 and 3 in (C). Data were normalized to maximum amplitude before plotting. (E) 
Recovery of the Ca2+ transient in mouse myocytes at 35oC was unaffected by the rapid 
removal of extracellular Na+. Myocytes were stimulated throughout at 0.5 Hz by patch 
pipette and Ca2+ transients recorded. At the time points indicated, extracellular Na+ was 
rapidly and transiently replaced with an equimolar amount of mannitol. Representative of 
5 myocytes isolated from 2 mice. (F) Magnified section of pane (E) showing Ca2+ transient 
profiles immediately before and during perfusion with the Na+-free solution. Representative 
of 5 myocytes isolated from 2 mice. (G) The final two Ca2+ transients in normal Tyrode 
(blue) and the first two transients in Na+-free (red) were baseline corrected, normalized 
and averaged. Because Na+-free perfusion inevitably loads the cell with Ca2+ and causes 
an inotropy and diastolic shortening from which the cell ultimately does not recover. For 
this reason, only the first two Na+-free transients were analyzed. Similar results were 
observed in 4 other cells. Isoprenaline, ISO. 
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table S1. Plasmids used in this study. 
Plasmid name Description Restriction sites Source 
pMal2CX 
Bacterial expression 
vector for N-terminal MBP-
tagged proteins 






vector for MBP-14-3-3 
EcoRI - HindIII M. Kilisch 
pMal2CX 14-3-3 
Bacterial expression 
vector for MBP-14-3-3 
EcoRI - HindIII M. Kilisch 
pMal2CX 14-3-3 
Bacterial expression 
vector for MBP-14-3-3 
EcoRI - HindIII M. Kilisch 
pMal2CX 14-3-3 
Bacterial expression 
vector for MBP-14-3-3 
EcoRI - HindIII J.Menzel 
pMal2CX 14-3-3 
Bacterial expression 
vector for MBP-14-3-3 
EcoRI - HindIII M. Kilisch 
pMal2CX 14-3-3 
Bacterial expression 
vector for MBP-14-3-3 
EcoRI - HindIII M. Kilisch 
pMal2CX 14-3-3 
Bacterial expression 
vector for MBP-14-3-3 
EcoRI - HindIII M. Kilisch 
pMal2CX - GST 
modified 
Bacterial expression for C-
terminal tagged GST 
proteins (MBP-tag 
removed) 
NdeI - BamHI J. Menzel 
pMal2CX modified 
PLN N31 WT 
Bacterial expression 
vector for PLNcyt-linker-
GST N31 WT 
NdeI-XhoI J. Menzel 
pMal2CX modified 
PLN N31 S16A 
Bacterial expression 
vector for PLNcyt-linker-
GST N31 S16A 
NdeI-XhoI J. Menzel 
pMal2CX modified 
PLN N31 T17A 
Bacterial expression 
vector for PLNcyt-linker-
GST N31 T17A 
NdeI-XhoI J. Menzel 
pMal2CX modified 
PLN N31 S10A 
Bacterial expression 
vector for PLNcyt-linker-
GST N31 S10A 
NdeI-XhoI J. Menzel 
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pMal2CX modified 
PLN N31 R9C 
Bacterial expression 
vector for PLNcyt-linker-
GST N31 R9C 
NdeI-XhoI J. Menzel 
pMal2CX modified 
PLN N31 R9A 
Bacterial expression 
vector for PLNcyt-linker-
GST N31 R9A 
NdeI-XhoI J. Menzel 
pMal2CX modified 
PLN N31 Arg14 
Bacterial expression 
vector for PLNcyt-linker-
GST N31 R14del 
NdeI-XhoI J. Menzel 
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table S2. Antibodies used in this study. 
Name Raised in Supplier Cat. No. Dilution Technique PID* 
14-3-3 pan (H8) mouse Santa Cruz sc-1657 1:1000 Western 16 
14-3-3 pan rabbit Abcam ab14112 1:1000 Western 974 
GST rabbit Carl Roth 3998.1 200 nM SPR 66 
Na/K ATPase  mouse Santa Cruz 
sc-
21712 
1:1000 Western 20 
p-PKA substrate rabbit 
Cell 
Signaling 
9624 1:500 Western 522 
PLN mouse Abcam ab2865 1:1000 Western 520 
PLN rabbit Lehnart lab - 5 µl IP - 
PLN pSer16 rabbit Badrilla A010-12 1:1000 Western 519 
PLN pThr17 rabbit Badrilla A010-13 1:1000 Western 975 
SERCA2a rabbit Badrilla A010-20 1:200 IF 976 
V5 mouse Invitrogen R960-25 1:200 IF 977 
*persistent identifier generated by ePIC (https://www.pidconsortium.net) 
 https://hdl.handle.net/11022/umg-sfb1002-antibody-primary-XXX 
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Data File S1. In vivo proximity labeling. List of biotinylated proteins detected with a 
significance of p<0.01 by in vivo proximity labeling using V5-APEX2-PLN.  
 
The file can be found under this link: 
https://owncloud.gwdg.de/index.php/s/v18RVghJqu0uE5w 
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3 Chapter III: Further analysis of the PLN/14-3-3 interaction  
3.1 Introduction 
Every heartbeat is an interplay between contraction and relaxation. This is regulated by 
complex cardiac signaling pathways and the flux of ions as well as other intracellular 
secondary messengers, like cAMP and Ca2+ (MacLennan & Kranias 2003). Cardiac 
contraction is induced by an electrical stimulus that travels from the atria to the ventricle 
and from cardiomyocyte to cardiomyocyte due to voltage-sensitive ion channels (Bartos et 
al., 2015). Cardiomyocyte membrane depolarization activates, amongst other ion 
channels, voltage gated Ca2+ channels which lead to an influx of Ca2+ ions into the 
cytoplasm (Fearnley et al., 2011). The increased cytoplasmic Ca2+ levels activates the 
Ca2+-release channel RyR which releases large amounts of Ca2+ from the SR into the 
cytoplasm (Laver, 2007). The large intracellular Ca2+ concentration leads to muscle 
contraction (Potter & Gergely, 1974). After contraction, Ca2+ is released by PMCAs and 
NCX located at the plasma membrane or by SERCA located at the SR (Calderón et al., 
2014). More than 70% of the intracellular Ca2+ is transported by SERCA back into the SR 
in humans (MacLennan & Kranias 2003). As Ca2+ is an important regulator of the 
excitation-contraction coupling in the heart, all factors which regulate Ca2+ handling in 
cardiomyocytes have a great impact on heart function.  
SERCA is mainly responsible for the transport of Ca2+ ions into the SR and for the 
relaxation of the heart after each contraction. SERCA is a single polypeptide with a 
molecular mass of 110 kDa and belongs to the P-type ATPase family such as PMCA and 
sodium/potassium ATPase (Na/K ATPase) (Sweadner & Donnet, 2001). As an ATPase 
pump SERCA transports two Ca2+ ions against a calcium gradient into the SR upon the 
hydrolysis of one ATP molecule (Periasamy & Kalyanasundaram, 2007). Hydrolysis of an 
ATP molecule transfers the phosphate to an aspartate residue located in the catalytic 
domain of SERCA, resulting in a reversible conformational change (Sweadner & Donnet, 
2001). SERCA is encoded by three genes, SERCA 1, 2 and 3 that are highly conserved 
and localized on different chromosomes. The SERCA isoform variability is enhanced by 
alternative splicing resulting in ten different isoforms expressed in humans. Two of these 
are expressed in muscle cells and only SERCA2a is expressed in cardiac muscle 
(Periasamy & Kalyanasundaram, 2007).  
SERCA2a activity itself is modulated via a small tail-anchor protein PLN, which is able to 
directly bind to SERCA’s transmembrane domain. The interaction between PLN and 
SERCA is regulated by the phosphorylation of PLN (Gustavsson et al., 2013). 
Unphosphorylated PLN binds SERCA and reduces SERCA’s affinity to Ca2+ causing the 
inhibitory effect. Upon phosphorylation of PLN the interaction between PLN and SERCA 
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is disturbed and as a consequence SERCA transports Ca2+ ions back into the SR 
(MacLennan & Kranias 2003). Therefore, PLN is a reversible inhibitor of SERCA and has 
influence on the heart relaxation rate. 
PLN itself is a small protein of 52 amino acids and very abundant in the heart (Traaseth et 
al., 2008). The cytosolic region of PLN has two potential phosphorylation sites, S16 and 
T17 residues, which can be phosphorylated by PKA or by CaMKII respectively (Mattiazzi 
& Kranias, 2014). CaMKII kinase needs to be auto-phosphorylated in order to be active, 
which is achieved by high intracellular Ca2+ levels or by high cAMP levels after beta-
adrenergic stimulation (Mattiazzi et al., 2005). Upon beta-adrenergic stimulation, both 
phospho-residues in PLN become phosphorylated and contribute equally to total PLN 
phosphorylation (Mundiña-Weilenmann et al., 1996). It was reported that both residues 
can be phosphorylated individually and independent from each other in vitro (Mundiña-
Weilenmann et al., 1996). For the S16 phospho-site a predominant role in PLN regulation 
was suggested based on experiments showing that S16 phosphorylation is sufficient for 
maximal cardiac response upon highest beta adrenergic stimulation (Mattiazzi & Kranias, 
2014). For the T17 phospho-residue it was shown, that upon phosphatase inhibition and 
increased Ca2+ levels, T17 was phosphorylated by CaMKII in-vivo independently, without 
S16 phosphorylation (Mattiazzi et al., 2005; Mattiazzi & Kranias, 2014). In addition, there 
is another phosphorylatable residue in PLN (S10) which is targeted by PKC. However, 
phosphorylation of S10 in PLN has not been associated with a physiological effect or 
SERCA inhibition (Coyler, 1998). 
Two physiological forms of PLN are present in the heart, a monomeric or pentameric 
conformation which are in an intracellular equilibrium (Smeazzetto et al., 2013; Wittmann 
et al., 2015). The oligomerization state of PLN plays, along with PLN phosphorylation, an 
important role in SERCA regulation. Initially, it was reported that only monomeric PLN 
directly interacts with SERCA and thus has an inhibitory effect on it (Kimura et al., 1997). 
In 2015 Wittmann et al showed that PKA has a higher affinity for PLN pentamers than for 
PLN monomers, resulting in a delayed phosphorylation of monomers and a prolonged 
interaction between monomeric PLN and SERCA. These findings indicate indirect effects 
of the PLN pentamer on the SERCA/PLN interaction (Wittmann et al., 2015). While PKA 
and CaMKII are responsible for the phosphorylation of PLN, the phosphatase PP1 is 
responsible for its dephosphorylation which makes PP1 an important regulator of the 
PLN/SERCA interaction as well (Kranias & Hajjar, 2012).  
The human PLN gene is highly conserved among mammals (Han et al., 2018; McTiernan 
et al., 1999). Yet, gene knockout of PLN has various effects in mammals. In mice it leads 
to hyperdynamic hearts, but has little consequence overall (Haghighi et al., 2003). In 
contrast, in humans all identified mutations in the PLN gene were identified in 
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heterozygous patients. For a leucine 39 stop (L39Stop) mutation two homozygous patients 
were identified, both developed lethal DCM underlying the importance of PLN in human 
hearts (Haghighi et al., 2003). Several disease-associated mutations were identified in the 
human PLN gene, causing serious contraction problems with the progression to HF and a 
high risk of early death (Young et al., 2015). One mutation is the deletion of the R14 residue 
in PLN, which forms a part of the PKA consensus motif. Therefore, the absence of R14 
will impair PKA binding and subsequent phosphorylation of S16 in R14del patients 
(Ceholski et al., 2012; Haghighi et al., 2006). In a heterozygous disease background, the 
R14del mutation was identified to be a very strong SERCA inhibitor causing cardiac 
remodeling over time (Haghighi et al., 2006; Hof et al., 2019). Expressed in mammalian 
cells, R14del PLN was found to be located at the plasma membrane interacting with the 
Na/K ATPase (Haghighi et al., 2012). The second disease mutation is a arginine to 
cysteine mutation at position 9 (R9C) which was identified in several families with dilated 
cardiomyopathy (Ha et al., 2011). The R9C mutation was initially found to trap PKA and 
therefore prevents phosphorylation of S16 (Schmitt et al., 2003). Later it was reported, that 
hydrophobic interactions cluster PLN R9C proteins tightly together into inactive pentamers 
(Ha et al., 2011). In line with this observation, it was found that PKA phosphorylation was 
disrupted as well as the SERCA interaction (Ha et al., 2011). 
 
The PLN/SERCA interaction is regulated by several factors such as the PLN monomer to 
pentamer ratio, different kinases, and several interaction partners. As already described in 
chapter 2, I identified the phospho-adaptor protein 14-3-3 as a novel interaction partner of 
PLN. 14-3-3 proteins are a family of universal regulators involved in numerous regulatory 
functions via a broad number of ligands (Sluchanko, 2018). Seven different 14-3-3 
isoforms are expressed in humans (Fu et al., 2000). In many cases 14-3-3 proteins bind 
the ligands by recognizing phosphorylated residues, but phosphorylation is not always 
required (Fu et al., 2000). The 14-3-3 interaction can have several functions such as 
stabilization of phosphorylated proteins, stabilization of protein-protein interactions, 
conformational alterations, or different subcellular localization of ligands (van Heusden, 
2005). 
In this chapter, I further characterized the 14-3-3/PLN interaction with the main focus on 
the role of 14-3-3 in the R14del PLN disease mutation.  
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3.2 Material and Methods  
3.2.1 Chemicals 
Chemicals used in this study were purchased from Sigma Aldrich, Carl Roth, Roche, GE 
HealthCare, AppliChem, Merck, and Serva. Restriction enzymes were purchased from 
Thermo Fisher Scientific. DNA oligonucleotides and phosphorylated oligonucleotides were 
synthesized by Sigma-Aldrich. Phusion DNA polymerase was homemade. PKA catalytic 
subunit was purchased from New England Biolabs. CaMKII delta kinase was purchased 
from Thermo Fisher Scientific. T4 DNA ligase and corresponding buffer was purchased 
from Thermo Fisher Scientific. FastAP Thermosensitive Alkaline Phosphatase was 
purchased from Thermo Fisher Scientific. FactorXa cleavage enzyme was purchased as 
a Cleavage Capture Kit from Merck Millipore. Phos-tag™ acrylamide was purchased from 
NARD institute. Protease and phosphatase inhibitors were purchased from Roche. 
Dulbecco’s modified eagle medium (DMEM), reduced serum medium (Opti-MEM, Gibco), 
Trypsin-EDTA (0.05%) and Lipofectamine 2000 transfection reagent were purchased from 
Thermo Fisher Scientific.  
 
3.2.2 Mouse models  
Wild-type (Black6), Pln +/+ (Black6J), Pln∆R14/∆R14 (C57B16/N), Pln+/∆R14 (C57B16/N) and  
Pln-/- (Black6N) mice were used. The Pln-/- mouse was provided by the lab of Prof. Dr. 
Stephan Lehnart and previously described (Kiriazis et al., 2002). The Pln∆R14/∆R14 and 
Pln+/∆R14 mice were generated by the laboratory of Prof. Dr. Herman Silljé and already 
characterized (Eijgenraam et al., 2020). All mice were male and aged between 8-12 weeks. 
The only exception was the Pln∆R14/∆R14 mouse, where the animals were females and 3 
weeks old. Animals were anesthetized with isoflurane and killed by cervical dislocation. 
Cardiomyocytes were isolated or organs were dissected and stored by -80°C. All animal 
procedures were performed under revision of the Animal Care and Use Committees of the 
University Medical Center Göttingen or University Medical Center Groningen.  
 
3.2.3 Human atrial tissue samples 
Right atrial appendages were obtained from 4 normal sinus rhythm patients undergoing 
cardiac surgery and kindly provided by the laboratory of Prof. Dr. Niels Voigt. Experimental 
protocols were approved by the ethics committee of the Göttingen University (No. 4/11/18). 
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3.2.4 Methods 
3.2.4.1 Molecular cloning 
Several protein expression plasmids for expression in bacteria and mammalian cells were 
generated with the use of well-established molecular cloning techniques based on the 
1987 first established polymerase chain reaction (PCR) technique by K.B. Mullis. This 
technique was further development to insert point mutations, deletions and affinity 
sequences with the help of oligonucleotide-driven mutagenesis. Molecular cloning 
techniques such as PCR, restriction enzyme digest, purification of DNA and transformation 
in Escherichia coli (E.coli) were performed according to standard methods. Generated 
expression plasmids, oligonucleotides and restriction enzymes used in this study can be 
found in table 4-5.  
 
3.2.4.2 Polymerase chain reaction  
For the enzymatic amplification of DNA and the generation of expression vectors different 
PCR reactions were used together with specific designed oligonucleotides. Two different 
types of oligonucleotides were designed: oligonucleotides including enzymatic restriction 
sites and oligonucleotides which carry a specific point mutation (see table 4-5). PCR 
reactions were performed according to standard protocols and for each reaction optimized. 
  
Table 1. Standard PCR reaction mix and amplification cycles.  
*where TM (°C)=4x(G+C) + 2x(A+T). 
Component Concentration 
10x Phusion Poly. 
buffer mix 
1x 












Sterile dH2O to 50 µl 
 
Temperature Time Cycles 
95 °C 2 min X 1 
95 °C 30 sec 
X 35 55-65°C 30 sec 
72°C 1 min/kb 
72°C 10 min X 1 
4°C - - 
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All PCR reactions were prepared on ice accordingly to the pipette scheme described in 
table 1. After amplification PCR products were analysed on 1-2% agarose gels depending 
on the size of the fragment. The agarose solution was supplemented with SafeView (abm), 
a fluorescence dye with an emission wavelength of approximate 490 nm, to visualize DNA-
bands upon irradiation with UV-light. Prior to electrophoreses, samples were diluted with 
6x sample buffer (0.2% bromophenol blue, 0.2% xylene cyanol, 60% glycerol, 60 mM 
EDTA) and loaded on the gel together with a 100 bp or 1 kb marker, followed by 
electrophoresis at 200 V in 1x TAE buffer (40 mM Tris/HCl pH 8.0, 20 mM actetic acid, 
1 mM EDTA). Subsequently, gel bands according to the correct size of the PCR product 
were excised from the gel and purified using a PCR clean up kit (High Pure Kit, Roche) 
following the manufactures instructions.  
 
3.2.4.3 Restriction enzyme digest 
PCR products and recipient plasmid DNA vectors were digested with one or multiple 
restriction enzymes. In general, all digests were pipetted on ice and carried out in a total 
reaction volume of 30 µl. Purified DNA products obtained by PCR were digested with 
10 units of restriction enzyme(s) in the respective buffer according to the manufacture’s 
instruction for 1 h at 37°C.  
The digestion of 1-2 µg plasmid DNA was performed as already described for the insert, 
followed by a dephosphorylation reaction. To avoid that the linearized vector re-anneals in 
the ligation reaction, the phosphate groups were removed with 1 unit of Fast Alkaline 
Phosphatase for 10 min at 37°C. Whenever possible, restriction enzyme digests were 
carried out with multiple restriction enzymes in one reaction. Digested DNA inserts, as well 
as vectors, were analysed by gel electrophoresis, visualized and extracted from the 
agarose gel as described in section 3.2.4.2. Digested and purified DNA fragments of the 
expected size were used for ligation. 
 
3.2.4.4 Ligation 
Ligation reactions were done with 100 ng linearized vector and 5-fold molar excess of 
linearized and purified insert. These products were mixed in 3 µl 10x T4 DNA ligase buffer, 
2 units T4 DNA ligase and diluted to a final reaction volume of 30 μL with sterile dH2O. 
Ligation reactions were performed at 18°C for 16 h or at RT for 1-2 h. In both cases the 
ligase was heat inactivated at 65 °C for 10 min. Ligated products were stored at 4°C until 
further use.  
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3.2.4.5 Transformation of bacterial cells by electroporation 
DNA was transformed into bacteria via electroporation. Therefore, 0.5 ng of plasmid DNA 
was transformed in either electro-competent Electro Ten Blue cells (Agilent Technologies) 
for amplification of plasmid DNA or in BL21 pRosetta for protein expression. In preparation, 
cuvettes (Gene Pulser Cuvettes, BioRad) were cooled on ice, the competent cells were 
thawed on ice, SOC medium (20 g/L tryptone, 5g/L yeast extract, 0.5 g/L yeast extract, 
0.5 g/L NaCl, 2.5 mM KCL, 10mM MgCl2, 20 mM glucose) for the reconstitution was pre-
warmed to 37°C and the electroporator was set at 25 µF and 2.25 V. Plasmid DNA was 
added into the electro-competent cell aliquot (50 µl), mixed and filled into the cuvette. The 
cuvette was placed in the electroporator and a pulse at 2.25 V was initiated. After the pulse, 
the cells were resuspended in 1 ml pre-warmed SOC medium, transferred to a tube and 
incubated at 37°C for 30 min under gentle shaking. Finally, the cells were centrifuged in a 
table centrifuge at full-speed for 1 min, the supernatant was removed, the cell pellet was 
dissolved in sterile dH2O and streaked out on a LB-Agar plate with corresponding antibiotic 
selector. Plates were incubated at 37°C overnight.  
 
3.2.4.6 Amplification of plasmid DNA 
Single colonies obtained on agar plates after transformation of amplified plasmid DNA in 
ElectroTen blue cells were inoculated under sterile conditions in 5 ml LB media under the 
respective antibiotic selection. Cultures were incubated overnight at 37°C under agitation. 
Bacteria cells were harvested by centrifugation in a table centrifuge at full speed for 2 min. 
The supernatant was removed and plasmid DNA was amplified with a NucleoSpin DNA 
amplifier kit (Machery Nagel) according to the manufacture instructions. Extracted DNA 
was dissolved in 50 µl dH2O and stored at 4°C. When larger DNA yields were required, 
the same protocol was performed with a 100 ml bacteria culture and NucleoBond Xtra Midi 
kit (Machery-Nagel). 
 
3.2.4.7 PCR site-directed mutagenesis  
Single point mutations or deletions were introduced in oligonucleotides which were able to 
anneal with the target region of the gene of interest. In general, the site-directed 
mutagenesis PCR was pipetted on ice and carried out in a total reaction volume of 50 µl 
according to the pipetting scheme in table 2. After the PCR reaction, the entire samples 
were mixed with 6x sample buffer and analysed by gel electrophoresis as described in 
section 3.2.4.2. The purified DNA was digested with 1 µl DpnI enzyme in the corresponding 
buffer at 37°C for 2-4 h. After the digest, 3 µl of the plasmid DNA was transferred in 
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ElectroTen blue cells by electroporation and positive clones were confirmed by 
sequencing.  
 


















3.2.4.8 Expression and affinity-purification of GST-tag proteins 
Recombinant glutathione-S-transferase (GST)- tagged proteins were expressed and 
purified from E.coli strain BL21 Rosetta. Protein expression was done in 2 YT media (2YT 
mix, AppliChem) and induced with 1 mM IPTG for 3 h at 30°C. Cells were harvested and 
lysed in GST Lysis buffer (20 mM HEPES pH 6.8, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM 
EDTA, 1 mM DTT, 1 mM PMSF). Crude cell lysate was centrifuged at 100.000 g for 30 min 
at 4°C. The supernatant was incubated with 1 ml washed glutathione sepharose beads 
(GE Healthcare) for GST-tagged proteins for 1 h at 4°C under gentle rotation. The bead 
slurry was transferred to gravity columns and first washed with 3 column volumes GST 
buffer pH 7.4, followed by one column volume 1mM ATP dissolved in GST buffer pH 7.4 
and a final wash step in GST buffer pH 7.4. Bound GST-tagged proteins were eluted with 
GST elution buffer (20 mM HEPES pH 8.5, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 
1 mM DTT, 15 mM L-Glutathione). Eluted proteins were dialyzed overnight in GST buffer 
pH 7.4. After dialysis proteins were centrifuged in a table-top centrifuge at full speed for 
10 min at 4°C to remove precipitated proteins. Protein concentrations were measured with 
Component Concentration 
10x Phusion Poly. 
buffer mix 
1x 












Sterile dH2O to 50 µl 
Temperature Time Cycles 
95 °C 2 min x 1 
95 °C 30 sec 
x 18 52-56°C 30 sec 
72°C 1 min/kb 
72°C 12 min x 1 
4°C - - 
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Bradford and the purified proteins were aliquoted and stored by -80°C. Every aliquot was 
thawed once.  
 
3.2.4.9 Expression and affinity-purification of MBP-tag proteins 
Recombinant MBP-tagged proteins were expressed and amplified from E.coli strain BL21 
Rosetta. Proteins expression, lysis and purification was done as already described (section 
3.2.4.8) with the following modifications: Lysis was performed in GST buffer pH 7.4 and 
the supernatant was incubated with Amlyose affinity resin (New England Biolabs). After 
washing, the purified proteins were eluted from the resin with 20 mM Maltose Elution buffer 
(20 mM HEPES pH 7.4, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1 mM DTT, 20 mM 
D-Maltose). 
 
3.2.4.10 SDS PAGE electrophoresis 
SDS PAGE gel electrophoresis was performed accordingly to the 1970 developed method 
from Laemmli where proteins are separated respective to size and charge. Glas plates and 
spacer were cleaned, assembled and placed in a gel casting station (Hoeffer). 3.5 ml 
resolving gel was casted into the assembled glass plates per gel and covered with 0.5 ml 
isopropanol to get an even surface. The gel was allowed to polymerize for 30 min, the 
isopropanol was removed and the surface was washed with H2O a couple of times before 
the stacking gel (4%) was casted. The combs were added to the stacking gel and the gel 
was allowed to polymerize. The height of the stacking gel was always 1.5 cm. The gels 
were electrophoresed in SDS running buffer (5 mM Tris, 50 mM Glycine pH 8.3, 0,02 % 
SDS) at 15 mA (constant amperage) for 120 min. 
 
3.2.4.11 Phos-tag-PAGE electrophoresis 
Phos-tag SDS-PAGE was used to visualize phosphorylated residues in proteins of interest, 
by retarding the migration of phosphorylated proteins on a SDS-PAGE gel (leads to a shift). 
Therefore, standard SDS-PAGE gels (section 3.2.4.10) were supplemented with 50 µM 
Phos-tag acrylamide and 50 µl MnCl2. Phos-tag-PAGE gels were electrophoresed at 
15 mA (constant amperage) for 120 min. After electrophoresis, the gels were either 
Coomassie (section 3.2.4.12) stained or transferred to a nitrocellulose membrane by 
electroblotting (section 3.2.4.13).  
 
3.2.4.12 Coomassie staining of SDS-PAGE 
SDS PAGE or Phos-tag-PAGE gels were visualized after the run with Coomassie brilliant 
blue G-250. After the gel run, the gels were carefully removed and soaked for 10 min in 
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destainer solution (30% ethanol, 10% acidic acid, diluted with MilliQ-H2O). This step can 
improve the intensity of the bands. Afterwards the gels were placed in Coomassie solution 
(45% Coomassie brilliant blue G-250, 20% CH2COOH, diluted in MilliQ-H2O), boiled in the 
microwave for around 30 seconds and incubated on a shaker for 30 min. After staining, 
the gel was rinsed with H2O and destained in destainer solution for 30 min. The gels were 
stored in H2O.  
 
3.2.4.13 Western blot transfer with electro blotting  
After electrophoresis of SDS-PAGE gels, the gels were carefully removed and briefly 
rinsed in Transfer buffer (25 mM Tris pH 8.3, 192 mM Glycine). In general, transfer was 
done with the wet blot technique and nitrocellulose membrane (Amersham, Hybond-ECL, 
GE Healthcare). The blotting chamber, cassettes and sponges were washed and 
incubated in cold transfer buffer for 5 min. The sandwich was assembled in the following 
way: a sponge was placed in a blotting cassette, followed by blotting paper (Whatman), 
the nitrocellulose membrane, the SDS-PAGE gel, another layer of blotting paper and 
another sponge. The cassette was placed in the transfer chamber so that the membrane 
was directed towards the anode. The transfer was done in cold transfer buffer at 60V, 0.5 
mA for 70 min at RT. After the run, the membrane was removed and blocked in milk 
blocking solution (5% milk powder dissolved in 1x TBS supplemented with either 0.1% 
Tween-20 or 0.02% NP-40, depending on the antibody) for 1h at RT. Finally, the primary 
antibody was diluted in blocking buffer and added to the membrane overnight at 4°C or for 
at least 3h at RT.  
 
3.2.4.14 Western blot transfer with electro blotting for Phos-tag-PAGE 
After electrophoresis the Phos-tag-PAGE was washed twice in transfer buffer with 1 mM 
EDTA for 5 min and washed twice more in transfer buffer without EDTA. The Phos-tag-
PAGE was transferred to a nitrocellulose membrane in a blotting tank at 15 V, 75 mA for 
18 h at 4°C.The nitrocellulose membrane was then blocked in a suitable blocking solution 
and incubated in primary antibody.  
 
3.2.4.15 Western Blot detection 
After primary antibody incubation, the membrane was washed 3 times in washing buffer 
(1x TBS supplemented with either 0.1% Tween-20 or 0.02% NP-40) for 10 min each at 
RT. Then the fluorescent labeled secondary antibody (LiCOR) was diluted 1:10.000 in 
blocking solution and incubated on the membrane for 1-1.5 h at RT under light exclusion. 
After secondary antibody incubation, the membrane was washed again 3 times in washing 
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buffer for 10 min each at RT. Western blots were developed with the Odyssey CLx LiCOR 
imaging system.  
 
3.2.4.16 Cell culture – passaging of mammalian cells  
HeLa and HEK293T cells were cultured in DMEM (Dulbecco’s modified eagel medium 
Gibco) at 37°C. Cells were cultured until 70-80% confluency was reached. Briefly, all work 
was done under a sterile hood and all equipment used for passaging cells was sterilized 
with 70% ethanol directly before use. All media were pre-warmed to 37°C before use. The 
medium was carefully aspirated from the plate and the cells attached to the bottom of the 
petri dish were washed in 10 ml 1x PBS. After washing, 2 ml trypsin (for 10 cm dish) was 
added and the plate was turned to cover the surface with trypsin. The plate was incubated 
at 37°C for 5 min. Followed by resuspension of the cells in 10 ml DMEM medium was 
added and the cell suspension was pipetted up and down in a 10 ml pipette to avoid cell 
clumps. Finally, the cell suspension was plated on a new plate. To maintain cells in culture, 
they were plated on a 10 cm dish or a 20 cm dish. For transfection cells were plated in 6-
well plates. 
 
3.2.4.17 DNA transfection of mammalian cells  
Cells were always seeded one day before transfection to be 80% confluent at the time 
point of transfection. On the day of transfection, media was removed and pre-warmed Opti-
MEM was added. Lipofectamine 2000 and the plasmid were prepared in Opti-MEM 
medium as described in table 3.  
 
Table 3. Pipetting scheme to transfect mammalian cells. 

















10 cm 10 1000 30 1000 14 
6-well 2 200 6 200 2.8 
12-well 0.85 85 2.55 85 1.2 
24-well 0.5 50 1.5 50 0.7 
 
The prepared lipofectamine solution in tube 1 and the plasmid solution in tube 2 were 
incubated at RT for 5 min. Tube 1 and 2 were mixed and incubated for 15 min at RT and 
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finally added to the cells. Cells were incubated for 6h, then trypsinized and diluted 1:5 in 
DMEM medium. Cells were harvested 48 hours after transfection. 
 
3.2.4.18 Immunofluorescence 
Cells were seeded before all IF experiments in a 6-well or 12-well plate in DMEM. Medium 
was aspirated and each well was washed at least twice in 1x PBS (use 1ml per well for a 
12 well dish). Cells were fixed for 20 min with 4% paraformaldehyde in 1x PBS (pH 7.4) 
and afterwards washed twice with PBS. Cells were permeabilized for 10 min with 0.3% 
TritonX-100, 0,05% SDS in 1x PBS at RT. After permeabilization, the cells were washed 
twice in PBS followed by blocking against unspecific antibody binding with 10% fetal bovine 
serum (FCS) diluted in 1x PBS. Blocking was done for 30 min at RT or overnight at 4°C. 
The primary antibody was diluted in 5% FCS and incubated overnight at 4°C. After primary 
antibody incubation, each well was washed 3 times in 1x PBS followed by secondary 
antibody incubation. The secondary antibody was diluted in 5% FCS 1:10.000 and 
incubated for 1h at RT under light exclusion. After secondary incubation, each well was 
washed 3 times in 1x PBS. For mounting the coverslips, each coverslip was briefly washed 
in dH2O to remove salts from the PBS and directly mounted on the coverslip in a 
Mowiol/DAPI drop. The mounted coverslips were dried at 37°C for at least 1 h or overnight 
at RT. The cells were imaged with a LSM-510 microscope (Zeiss).  
 
3.2.4.19 TCA precipitation of proteins  
Prepared solubilized heart membranes or cytosol or complete lysate was precipitated by 
adding TCA up to a final concentration of 12.5% and incubated on ice for 30 min, followed 
by centrifugation at 11.000 g for 7 min at 4°C. The supernatant was discarded and the 
pellet was washed two times with ice-cold acetone. After the last washing step, the 
supernatant was removed and the pellet was dried at 37°C for 10 min. Finally, SDS sample 
buffer (2% SDS, 0.1% bromophenol blue, 10% glycerol, 50 mM Tris-HCl pH 6.8) 
supplemented with 100 mM DTT was added and the pellet was dissolved at 30°C for at 
least 10 min.  
 
3.2.4.20 PKA or CaMKII phosphorylation of recombinant protein 
10 µg recombinant purified PLN-GST mutants were phosphorylated with recombinant PKA 
(NEB) or CaMKII kinases (Thermo Scientific) according to the suppliers information at 
30°C for 1 h. CaMKII kinase was auto-phosphorylated before use according to suppliers 
information at 30°C for 10 min. Phosphorylated protein was either used for further 
Chapter III: Further analysis of the PLN/14-3-3 interaction 
 99 
experiments or solved in 1 x SDS sample buffer and analysed by SDS-PAGE and Phos-
tag-PAGE. 
 
3.2.4.21 Phosphorylation with cardiac cytosol 
10 µg recombinant purified PLN-GST mutants were immobilized to 5 µl glutathione 
sepharose beads (GE Healthcare) in GST buffer (20 mM HEPES pH 7.5, 150 mM KOAc, 
5 mM Mg(OAc)2, 1 mM EDTA, 1 mM DTT) for 45 min at 4°C under gentle rotation.  
For the preparation of cardiac cytosol, a mice heart disrupted with a MiccraD-1 tissue 
homogenizer in homogenization buffer (50 mM NaCl, 320 mM Sucrose, 2 mM EDTA, 
20 mM HEPES pH 7.4, 1x protease inhibitor, 1 x phosphatase inhibitor). The lysate was 
centrifuged at 100.000 g for 30 min. The supernatant after centrifugation is the cytosol, 
which was diluted 1:5 in GST buffer supplemented with 1x protease inhibitor, 
1 x phosphatase inhibitor and 1 x EM (EM, an ATP regeneration system (10 mM 
phosphocreatine, 0.5 mM ATP, 0.5 mM GTP, 50 µg/ml creatine phosphokinase). The resin 
bound PLN-GST mutant proteins were incubated for 1 h in cardiac cytosol at 4°C under 
gentle rotation. The resin bound proteins were collected and washed 4 times in GST buffer, 
followed by elution with 1x SDS sample buffer supplied with 100 mM DTT. The 
phosphorylation assay was analysed on Coomassie stained SDS-PAGE and Phos-tag-
PAGE.  
 
3.2.4.22 Binding assay with recombinant PLN-GST constructs and 14-3-3 
gamma 
10 µg recombinant purified PLN-GST mutants were phosphorylated with recombinant PKA 
(NEB) or CaMKII kinases (Thermo Scientific) according to the suppliers information at 
30°C for 1 h. Phosphorylated bait proteins were bound to 5 µl glutathione sepharose beads 
(GE Healthcare) in GST buffer (20 mM HEPES pH 7.5, 150 mM KOAc, 5 mM Mg(OAc)2, 
1 mM EDTA, 1 mM DTT, 0.1% TritonX-100) for 45 min at 4°C under gentle rotation. Resin-
bound bait proteins were incubated with equimolar amounts of recombinant purified 14-3-3 
protein in GST buffer for 1 h at 4°C under gentle rotation. The resin-bound bait was washed 
4 times in GST buffer and eluted in 1 x SDS sample buffer (supplied with 100 mM DTT). 
The binding assay was analysed on SDS-PAGE, which was transferred to nitrocellulose 
and probed with the 14-3-3 pan antibody (Santa Cruz) and on a Coomassie stained Phos-
tag-PAGE.  
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3.2.4.23 Separation of heart membranes and cytosol 
Binding experiments with recombinant 14-3-3 proteins were done with mice or human 
heart membranes and cytosol. Hearts or tissue samples were thawed on ice, fat tissue 
was removed and the heart was cut in small pieces. The tissue was mechanically disrupted 
with a MiccraD-1 homogenizer for 30 sec in tissue homogenization buffer (50 mM NaCl, 
320 mM Sucrose, 2 mM EDTA, 20 mM HEPES, pH 7.4, 1x protease inhibitor, 
1 x phosphatase inhibitor). Lysed tissue was dounced for 30 strokes on ice. The lysate 
was centrifuged at 100.000 g for 30 min at 4°C to separate membrane and cytosol. The 
supernatant is the cytosolic fraction and the pellet is the membrane fraction. The 
membranes were either stored at -80°C in tissue homogenization buffer with protease and 
phosphatase inhibitors or directly solubilized (section 3.2.4.24). The cytosol was cleared 
with another centrifugation step at 100.000 g for 30 min and either stored at -80°C or on 
ice until further use.  
 
3.2.4.24 Heart membrane solubilization 
Separated heart membranes were washed once in tissue homogenization buffer (50 mM 
NaCl, 320 mM Sucrose, 2 mM EDTA, 20 mM HEPES, pH 7.4, 1x protease inhibitor, 
1 x phosphatase inhibitor). 1 mg of washed crude membrane was solubilized in 1 ml 
ComplexioLyte48 (Logopharm) solubilization buffer on ice for 30 min, followed by 
centrifugation at 55.000 g for 30 min at 4°C. The supernatant contains solubilized heart 
membrane proteins, the detergent was diluted 1:5 with GST buffer pH 7.4 (20 mM HEPES 
pH 7.4, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1 mM DTT, 1x protease inhibitor, 
1x phosphatase inhibitor). Solubilized heart membranes were used for pull-down 
experiments or for Western blot analysis. 
 
3.2.4.25 14-3-3 pull-down experiment with heart membranes 
The pull-down experiments were done with solubilized heart membranes or cytosol and 
recombinant purified MBP-14-3-3 bait protein. 50 µg of bait protein was recombinantly 
phosphorylated with either PKA (NEB) or CaMKII kinase (Thermo Fisher) as described in 
section 3.2.4.20. Phosphorylated proteins were immobilized to 5 µl amylose resin bead 
slurry (NEB) in GST buffer (20 mM HEPES pH 7.5, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM 
EDTA, 1 mM DTT) supplied with protease and phosphatase inhibitors for 45 min at 4°C 
under gentle rotation. Immobilized bait protein was washed 3 times in GST buffer, followed 
by blocking in 4% BSA dissolved in GST buffer and supplemented with protease and 
phosphatase inhibitors for 30 min at 4°C under gentle rotation to block unspecific binding 
sites. After blocking, the resin-bound bait proteins were washed 3 times in GST buffer and 
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added to prepared solubilized heart membranes or cytosol. After 1 h incubation at 4°C 
under gentle rotation the resin-bound bait was washed 4 times in GST buffer followed by 
elution with SDS-sample buffer (containing 100 mM DTT). The pull-down experiment was 
analysed on SDS-PAGE transferred to nitrocellulose and detected with anti-PLN total, PLN 
pS16 and PLN pT17 antibodies. 
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Table 4. Plasmids generated and used in chapter III. 





Bacterial expression vector 
for N-terminal MBP-tagged 
proteins 






Bacterial expression vector 
for MBP-14-3-3 gamma 
Insert at EcoRI 
- HindIII 
J. Menzel 
pMal2CX - GST 
modified 
Bacterial expression for C-
terminal tagged GST proteins 
(MBP-tag removed) 




Bacterial expression vector 








Bacterial expression vector 








Bacterial expression vector 








Bacterial expression vector 








Bacterial expression vector 








Bacterial expression vector 








BamHI - XhoI Invitrogen 
pCDNA3.1 PLN 
N31 WT opsin 
Mammalian expression 
vector for PLNcyt-WT-opsin 
Insert at 




N31 S10A opsin 
Mammalian expression 
vector for PLNcyt-S10A opsin 
Insert at 
BamHI - XhoI 
J. Menzel 
pCDNA3.1 PLN 
N31 S16A opsin 
Mammalian expression 
vector for PLNcyt-S16A opsin 
Insert at 
BamHI - XhoI 
J. Menzel 
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pCDNA3.1 PLN 
N31 R9C opsin 
Mammalian expression 
vector for PLNcyt-R9C opsin 
Insert at 







vector for PLNcyt-R14del 
opsin 
Insert at 
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Table 5. Oligonucleotides used for PCR’s. 
Name Description Sequence (5’-3’) 
14-3-3 gamma-
FP 
Used to generate 
14-3-3 gamma, 
forward primer 
GGA TTT CAG AAT TCA TGG TGG ACC 
GCG AGC AAC TGG TGC AGA AAG CCC 
14-3-3 gamma-
RP 
Used to generate 
14-3-3 gamma, 
reserve primer 
GGG CTT TCT GCA CCA GTT GCT CGC 
GGT CCA CCA TGA ATT CTG AAA TCC 
BamHI-PLN For 
Used to generate 
pCDNA3.1 PLN, 
forward primer 
GCG GCG GGA TCC ATG GAA AAA GTG 
CAA TAC CTC AC 
opsin-XhoI-Rev 
Used to generate 
pCDNA3.1 PLN, 
reverse primer 
CGG CGG CTC GAG TCA GCC CGT CTT 
GTT GGA G 
pCDNA.3.1-
PLN-S10A For 
Used to generate 
mammalian PLN 
S10A, forward primer 
GGA AAA AGT GCA ATA CCT CAC TCG 
CGC CGC TAT CAG GAG AGC CTC CAC 
pCDNA.3.1-
PLN-S10A Rev 
Used to generate 
mammalian PLN 
S10A, reverse primer 
GTG GAG GCT CTC CTG ATA GCG GCG 
CGA GTG AGG TAT TGC ACT TTT TCC 
pCDNA.3.1-
PLN-S16A For 
Used to generate 
mammalian PLN 
S16A, forward primer 
CTC GCT CGG CTA TCA GGA GAG CCG 




Used to generate 
mammalian PLN S16 
construct, reverse 
primer 
GCT TGC TGA GGC ATT TCA ATA GTG 








ATA CTA CAT ATG ATG GAA AAA GTG 
CAA TAC CTC 
PLNcyt-linker-
XhoI-Rev 




CCG CCG CTC GAG GCT GCC GCC 
GCC GCC GCT GCC GCC GCC GCC 
GCT GCC GCC GCC GCC GCT GCC 
GCC GCC GCC TAG GTT CTG GAG ATT 
CTG ACG TGC TTG C 
Overlapping 
PLN For 




GGC GGC GGC GGC AGC GGC GGC 
GGC GGC AGC GGC GGC GGC GGC 
AGC ATG TCC CCT ATA CTA GGT TAT 
TGG AAA ATT AAG GGC C 








GCC GCC GCT GCC GCC GCC GCC 








GGA AAA AGT GCA ATA CCT CAC TCG 
CGC CGC TAT CAG GAG AGC CTC CAC 
PLNcyt-S10A 
Rev 




GTG GAG GCT CTC CTG ATA GCG GCG 
CGA GTG AGG TAT TGC ACT TTT TCC 
PLNcyt-S16A 
For 




CTC GCT CGG CTA TCA GGA GAG CCG 








GCT TGC TGA GGC ATT TCA ATA GTG 








GCT CGG CTA TCA GGA GAG CCT CCG 








CGT GCT TGC TGA GGC ATT TCA ATG 
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Table 6. Antibodies used in chapter III.  
Name Supplier Cat. No. Dilution Technique Clonality 
14-3-3 pan 
(H8) 
Santa Cruz sc-1657 1:1000 WB polyclonal 
p-CAMKII 
(Thr286) 












E8032S 1:10000 WB monoclonal 
Na/K ATPase 
alpha 




- 1:1000 WB polyclonal 




PLN pS16 Badrilla A010-12 1:1000 WB polyclonal 




- 1:200 IF polyclonal 
SERCA Santa Cruz sc-8093 1:1000 WB polyclonal 
Rab7 Cell signaling  9367 1:200 IF polyclonal 
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3.3 Results 
3.3.1 Recombinant PLN is phosphorylated at S16 by PKA and at T17 by CaMKII 
I identified a novel interaction between PLN and the phospho-adaptor protein 14-3-3 using 
binding assays with solubilized mouse heart membranes as input (see chapter 2, figure 1). 
PLN has two main phosphorylation sites within the N-terminus, the S16 and T17 residues. 
Phosphorylation of PLN disrupts its interaction with SERCA and leads to an inhibitory effect 
on SERCA. Therefore, phosphorylation of PLN is important for Ca2+ handling in 
cardiomyocytes. To determine the 14-3-3 binding site, recombinant PLN protein variants 
relevant for PLN phosphorylation were designed (Table 7). The cytosolic region of PLN 
(31 aa) was fused to a linker and a GST-tag separated by a flexible linker (Table 7). 
Phospho-dead mutants for the three phosphorylatable residues were generated as well as 
two human-disease causing mutations (Table 7).  
 
Table 7. PLN protein variants designed for bacterial expression.  
The first 31 N-terminal amino acids were fused with a linker and a GST-tag. Different mutations 
regarding the different phosphorylation sites in PLN (S10A, S16A, T17A) as well as two disease-
causing mutations (R9C, R14del) were generated. The di-arginine ER-retention signal in the PLN 
sequence is marked in green and the 14-3-3 target site is highlighted in orange. The single amino 
acid mutations inserted in the constructs are shown in red. 
Peptide name Amino acid sequence 
PLNcyt-linker-GST WT MEKVQYLTRSAIRRASTIEMPQQARQNLQNL-linker-GST 
PLNcyt-linker-GST R9C MEKVQYLTCSAIRRASTIEMPQQARQNLQNL-linker-GST 
PLNcyt-linker-GST R14del MEKVQYLTRSA_IRASTIEMPQQARQNLQNL-linker-GST 
PLNcyt-linker-GST S10A MEKVQYLTRAAIRRASTIEMPQQARQNLQNL-linker-GST 
PLNcyt-linker-GST S16A MEKVQYLTRSAIRRAATIEMPQQARQNLQNL-linker-GST 
PLNcyt-linker-GST T17A MEKVQYLTRSAIRRASAIEMPQQARQNLQNL-linker-GST 
 
The recombinant PLN protein variants were expressed and purified from E. coli, analysed 
on Coomassie stained SDS-PAGE (Figure 14) and confirmed by Western blot using a PLN 
antibody (Figure 14). The PLN antibody (2D12, abcam) could not detect the R9C variant, 
probably because the R9 residue is part of the epitope recognized by the antibody. Besides 
the PLN R9C mutant, all recombinant purified PLN variants were detected by the PLN 
antibody (Figure 14).  
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Figure 14. Purification of recombinant PLNcyt-linker-GST proteins.  
Purified proteins were analysed on a Coomassie stained SDS-PAGE and verified by Western 
blotting with an anti-PLN antibody.  
 
Recombinant phosphorylation of the purified PLN constructs was required for detailed 
analysis of the PLN 14-3-3 interaction in-vitro. Therefore, purified PLN WT, S10A, S16A 
and T17A variants were phosphorylated using the recombinant kinases. The purified PLN 
mutant proteins were in-vitro phosphorylated with either recombinant catalytic subunit of 
PKA (Figure 15A) or recombinant CaMKII (Figure 15B). Samples were then subjected to 
Phos-tag-PAGE and SDS-PAGE and stained in Coomassie solution for analysis. 
Phosphorylated residues form complexes with MnCl2 in a Phos-tag-PAGE and therefore 
run slower through the gel, which lead to an upward shift (Kumar, 2018). PLN WT was 
phosphorylated after PKA treatment which was visible by a shift on the Phos-tag-PAGE 
that is absent in samples lacking PKA treatment (Figure15A). PLN S10A and T17A were 
phosphorylated after PKA treatment as well but not the PLN S16A protein (Figure 15A). In 
parallel, the PLN constructs were in-vitro phosphorylated with CaMKII and analysed on 
Coomassie stained Phos-tag-PAGE and SDS-PAGE (Figure 15B). PLN WT, PLN S10A, 
and PLN S16A constructs were phosphorylated, but not the PLN T17A protein (Figure 
15B). Altogether, recombinant phosphorylation of PLN variants confirmed that PKA 
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Figure 15. PKA specifically phosphorylates S16 and CaMKII kinase T17 in PLN.  
Purified PLN mutant variants were in-vitro phosphorylated with either (A) PKA or (B) CaMKII kinase. 
Results were analysed on Coomassie stained Phos-tag-PAGE or SDS-PAGE. Phosphorylated PLN 
(pPLN) is indicated. 
 
Phosphorylation of recombinantly purified PLN proteins as seen with in-vitro supplied PKA 
or CaMKII kinases were corroborated by phosphorylating them with kinases present in 
mouse heart cytosol. Prepared cytosol contains native catalytic subunits of PKA as well as 
CaMKII kinase. The cytosol was supplied with an ATP regeneration system (“energy mix”; 
EM) to keep the kinases functional. The recombinantly purified PLN proteins were 
incubated in heart cytosol, followed by analysis on Coomassie stained Phos-tag-PAGE 
and SDS-PAGE (Figure 16). All different PLN variants were phosphorylated as indicated 
by the shift on the Phos-tag-PAGE (Figure 16). Upon closer inspection, it was noticeable 
that the PLN WT protein showed two phosphorylation bands in comparison with the other 
PLN variants. Even though, the upper band was very weak this result indicated that the 
PLN WT construct was double phosphorylated by PKA and CaMKII kinase after incubation 
with heart cytosol. Meanwhile the PLN S16A and T17A mutants were single 




































PKA phosphorylation CaMKII phosphorylation 
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Figure 16. Double phosphorylation of purified PLN WT protein with native kinases from heart 
cytosol.  
The cytosol was supplied with an ATP regeneration system (EM). Cytosol without EM was used as 
a negative control. Phosphorylated recombinant PLN variants were analysed on Coomassie stained 
Phos-tag-PAGE and SDS-PAGE. Single phosphorylated PLN (pPLN) and double phosphorylated 
PLN (pp-PLN) are indicated. 
 
Altogether, recombinant in-vitro phosphorylation of PLN variants using recombinant PKA 
or CaMKII showed that PKA specifically phosphorylated the S16 residue in PLN, 
meanwhile CaMKII phosphorylated T17 in PLN. Recombinant PLN protein variants were 
also phosphorylated with native PKA and CaMKII kinase from mouse tissue, confirming 
that PLN can be double phosphorylated, meanwhile the PLN S16A and T17A variants 
were both single phosphorylated. 
 
3.3.2 14-3-3 is unable to bind double phosphorylated PLN at S16 and T17 
The binding affinities of 14-3-3 to the two different phosphorylation sites in recombinant 
PLN proteins were already analysed in chapter 2. I was able to show that 14-3-3 binds the 
two different phosphorylated residues in PLN with different affinities (chapter 2, figure 3). 
In brief, phosphorylated T17 showed a higher affinity to 14-3-3 than phosphorylated S16 
in PLN. Next, I wondered whether 14-3-3 could interact with the double phosphorylated 
PLN protein, namely phosphorylated at S16 and T17 at the same time. To this end, 
recombinant PLN-GST protein variants were phosphorylated with both PKA and CaMKII 
kinases simultaneously followed by 14-3-3 binding. The 14-3-3 interaction was detected 
by Western blotting with a 14-3-3 antibody and Coomassie stained SDS-PAGE and Phos-
tag-PAGE showing the efficiency of in-vitro phosphorylation (Figure 17). 14-3-3 binding 
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(Figure 17). Phos-tag gels indicate that the S16 as well as the T17 residues were 
phosphorylated in the respective mutants and the WT was double phosphorylated. 
However, the phosphorylation efficiency was best for the T17A mutant and both S16A and 
WT showed lower phosphorylation efficiencies. Taken together, 14-3-3 can bind the single 
phosphorylated S16 or T17 residues in PLN, but not to the double phosphorylated 
monomeric PLN.  
 
Figure 17. Double phosphorylation of pS16 and pT17 residue in monomeric PLN prevents 
14-3-3 binding.  
Recombinant PLN-GST protein variants were recombinantly phosphorylated with PKA and CaMKII 
kinases at the same time, followed by 14-3-3 binding and analysis by Western blot, Coomassie 
stained Phos-tag-PAGE and SDS-PAGE. Phosphorylated PLN (pPLN) is indicated. 
 
3.3.3 PLN R14del mutation is either mislocated or aggregates in the homozygous 
mouse model 
Two mutations in the PLN sequence, R14del and R9C mutation, lead to severe dilated 
cardiomyopathy in heterozygous patients. 14-3-3 was already identified to also interact 
with recombinant PLN R9C and R14del disease-related mutations (chapter 2, figure 4D). 
Patients who suffer the R14del mutation are missing the arginine 14 residue, which is 
located in the PKA consensus motif. Therefore, PKA is unable to phosphorylate S16. PLN 
phosphorylation by CaMKII remains unaffected by this mutation (Haghighi et al., 2006). I 
could already show that CaMKII kinase phosphorylation is a requirement for 14-3-3 
interaction with the R14del PLN mutation (chapter 2, figure 4D). PLN R14del homozygous 
(Pln∆R14/∆R14) and heterozygous (Pln+/∆R14) mouse models have been developed at the lab 
of Prof. Dr. Herman Silljé (Eijgenraam et al., 2020). Furthermore, the lab of Prof. Dr. 
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Pln∆R14/∆R14 mice were always compared to a PLN WT mouse (Pln+/+), corresponding to 
littermates without the Pln∆R14/∆R14 mutation introduced into the genome. I obtained 
ventricular tissue samples from the aforementioned mouse models to analyze PLN steady-
state levels and the phosphorylation state of PLN. Ventricular samples were subjected to 
subcellular fractionation followed by the analysis of the steady-state levels of PLN and 
14-3-3 by Western blot. The rationale behind this experiment was the hypothesis that 
phospho-PLN is a major 14-3-3-binding protein in cardiac membranes and that less 
phosphorylated PLN would translate into lower 14-3-3 steady-state levels.  
The amount of total PLN protein was strongly reduced in Pln∆R14/∆R14 mice membranes in 
comparison to Pln+/+ animals as indicated by Western blotting (Figure 18). This loss was 
also reflected in both phosphorylated forms of PLN, i.e. the pS16 and the pT17. Meanwhile 
the Pln+/+ control samples showed phosphorylation at both phospho-sites (Figure 18). In 
parallel, I was interested in knowing whether the steady-state level of SERCA, as a known 
interaction partner of PLN, was affected by the absence of PLN. Interestingly, SERCA 
steady-state levels were also reduced in the Pln∆R14/∆R14 mouse in comparison with Pln+/+ 
control animals (Figure 18).  
Altogether, PLN and SERCA steady-state levels were strongly reduced in the Pln∆R14/∆R14 
mouse membranes from ventricles.  
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Figure 18. PLN steady-state levels were reduced in Pln∆R14/∆R14 mouse heart membranes.  
WT (Pln+/+), PLN K.O. (Pln -/-), and PLN R14del homozygous (Pln∆R14/∆R14) mice membranes were 
analysed by Western blotting with PLN, phosphorylated S16, phosphorylated T17 or SERCA2a 
antibodies. Equal loading of membrane samples was confirmed by Western blotting for Na/K 
ATPase (NaK). PLN monomer (M) and pentamer (P) are indicated. 
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Having found that the PLN steady-state-levels were strongly reduced in the Pln∆R14/∆R14 
mouse model, I was interested whether the 14-3-3 steady-state-levels were also 
influenced in the disease model. In addition, I analysed phosphorylated CaMKII (pCaMKII) 
steady-state levels in the Pln∆R14/∆R14 mouse model since the PKA interaction site is 
disrupted in the R14del PLN mutation. Again, subcellular fractions were prepared from the 
ventricular tissue samples of the mouse models and the 14-3-3 and pCaMKII levels at 
steady-state were analysed by Western blot (Figure 19). 14-3-3 as well as pCaMKII 
steady-state-levels were not influenced in the Pln∆R14/∆R14 mouse neither in membranes 
(Figure 19A) nor in cytosol (Figure 19B). Equal loading of membrane or cytosol samples 
were controlled by analysing Na/K ATPase in membranes (Figure 19A) and 
glycerinaldehyde-3-phosphate-dehydrogenase (GAPDH) in the cytosol (Figure 19B). 
These results indicated that neither 14-3-3 nor activated pCaMKII steady-state levels are 
altered due to the PLN R14del mutation. 
 
Figure 19. 14-3-3 and pCaMKII steady-state levels were unaltered in Pln∆R14/∆R14 mouse heart 
membranes and cytosol.  
Analysis of 14-3-3 and pCaMKII steady-state levels in WT (Pln+/+) and PLN R14del homozygous 
(Pln∆R14/∆R14) mice membranes (A) and cytosol (B) analysed by Western blot with 14-3-3 and 
pCaMKII antibodies. Equal loading of membrane and cytosol samples were confirmed with Western 
blotting for Na/K ATPase and GAPDH respectively. 
 
Finally, a 14-3-3 binding experiment with the Pln∆R14/∆R14 mouse model and corresponding 
controls was performed, to investigate whether the R14del PLN protein is still able to bind 
14-3-3. Strongly reduced levels of PLN R14del protein were detected in the analysis of 
PLN protein steady-state levels (Figure 18). However, solubilized membranes from the 
Pln∆R14/∆R14 and Pln+/+ mouse models were used for an affinity purification experiment and 
incubated with recombinant MBP-14-3-3 gamma protein. Recombinant MBP and MBP-
14-3-3 gamma bound to the 14-3-3 blocking peptide R18 served as negative controls of 
Chapter III: Further analysis of the PLN/14-3-3 interaction 
 115 
the experiment. Eluates were analysed by Western blot with PLN antibody and phospho-
PLN antibodies (Figure 20). As expected, the PLN pentamer was enriched with 
recombinant 14-3-3 protein from Pln+/+ mouse membranes (Figure 20). Very small 
amounts of the PLN R14del pentamer were enriched from membranes of the Pln∆R14/∆R14 
disease model (Figure 20). PLN pentamers enriched from Pln+/+ mouse membranes 
contained both phosphorylated S16 and T17 residues (Figure 20). However, no 
phosphorylated residues could be observed in the R14del PLN pentamers enriched from 
the membranes of the Pln∆R14/∆R14 disease mouse. This observation is hard to interpret due 
the very reduced amounts of enriched PLN R14del pentamers since both antibodies 
detecting phospho-PLN were less sensitive. 
 
Figure 20. R14del PLN pentamers were enriched with recombinant 14-3-3 gamma from the 
Pln∆R14/∆R14 mouse model. 
Binding assay with solubilized WT (Pln+/+) and PLN R14del homozygous (Pln∆R14/∆R14) mice 
membranes and recombinant MBP-14-3-3. MBP and MBP-14-3-3 blocked with R18 were negative 
controls. Eluates were probed by Western blot for enriched PLN, PLN pS16 and pT17 proteins with 
corresponding antibodies. PLN monomer (M) and pentamer (P) are indicated. 
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In summary, PLN steady-state levels were found to be strongly reduced in the Pln∆R14/∆R14 
disease mouse which indicates either mislocalization or aggregation of the mutant protein. 
However, 14-3-3 and pCaMKII steady-state levels were not influenced in the Pln∆R14/∆R14 
disease mouse. Even though, PLN R14del was severely reduced at steady-state level in 
the homozygous mouse tissue, I was able to enrich small amounts of R14del PLN 
pentamers in binding experiments with recombinant MBP-14-3-3 gamma. This suggests 
that the PLN R14del protein is able to bind 14-3-3 and confirms results from in vitro-binding 
assays performed in chapter 2 (Figure 4D). 
 
3.3.4 PLN R14del mutation is either mislocated or aggregates in the heterozygous 
mouse model 
I also analysed the interaction between 14-3-3 and PLN in a PLN R14del heterozygous 
(Pln+/∆R14) mice model. Patients suffering from the PLN R14del mutation are heterozygous 
carriers. Until today, no homozygous carrier has been identified (Haghighi et al., 2006).  
Ventricular tissue from the Pln+/∆R14 mouse model was analysed to assess the steady-state 
level of PLN as well as the PLN phosphorylation status. A PLN WT mouse (Pln+/+) was 
used as a control as well as a PLN K.O. mouse (Pln-/-). First, membranes and cytosol were 
separated from all ventricular heart samples and analysed by a Western blot for total PLN 
and phosphorylated states of PLN (Figure 21). PLN monomers and pentamers were 
detected for both the Pln+/+ and the Pln+/∆R14 mice (Figure 21). For two samples from 
Pln+/∆R14 (2 and 3), the steady-state level of PLN was reduced (Figure 21) in comparison 
to the controls. The steady-state level of PLN in the Pln+/∆R14 sample 1 showed comparable 
PLN levels to the Pln+/+ control animals (Figure 21). The same irregularity was observed 
for PLN phosphorylated at S16 (Figure 21) and T17 (Figure 21). Mentionable, no difference 
in PLN protein expression levels of pS16 or pT17 phosphorylation were observed for the 
Pln+/∆R14 disease model in comparison with control animals.  
Overall, slightly reduced PLN steady-state levels were detected in the Pln+/∆R14 disease 
model but the PLN phosphorylation status was not altered in the Pln+/∆R14 mouse in 
comparison with control animals.  
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Figure 21. PLN steady-state levels and phosphorylation distribution was not altered in 
Pln+/∆R14 mouse heart membranes.  
WT (Pln+/+), PLN K.O. (Pln-/-), and PLN R14del heterozygous (Pln+/∆R14) mice membranes were 
analysed by Western blot and analysed for PLN, PLN pS16 and PLN pT17 with specific antibodies. 
Equal loading of membrane samples was confirmed with Western blotting for Na/K. PLN monomer 
(M) and pentamer (P) are indicated. 
 
In addition to the analysis of PLN steady-state levels in Pln+/∆R14 animals, I was interested 
whether known PLN interaction partners such as SERCA, 14-3-3, or pCaMKII are 
influenced due to the heterozygous PLN R14del mutation. Therefore, steady-state levels 
of 14-3-3, SERCA and pCaMKII kinase, were analysed by Western blotting from separated 
membranes and cytosol prepared from Pln+/∆R14 and Pln+/+ control animals (Figure 22). In 
the membrane fractions from both Pln+/∆R14 and Pln+/+ mice, very reduced amounts of 
14-3-3 protein was detected (Figure 22A). In the corresponding cytosolic fractions, 14-3-3 
was detected in both Pln+/∆R14 and Pln+/+ animals. Yet, the 14-3-3 steady-state levels did 
not show drastic differences between them that could be attributed to the R14del mutation 
(Figure 22B). Phosphorylated CAMKII kinase levels were found to be strongly reduced in 
isolated membrane and cytosolic fractions from both Pln+/∆R14 and Pln+/+ animals (Figure 
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22A) indicating that the mutation does not increase steady-state levels of pCaMKII. 
SERCA steady-state levels were not influenced by the R14del PLN mutation in the Pln+/∆R14 
disease animals (Figure 22A). Equal loading of samples was controlled by analysing Na/K 
ATPase in membranes (Figure 22A) and GAPDH in the cytosol (Figure 22B).  
 
Figure 22. 14-3-3 or pCaMKII steady-state levels were unaltered in Pln+/∆R14 mouse heart 
membranes and cytosol.  
(A) Analysis of 14-3-3, pCaMKII, SERCA steady-state levels in WT (Pln+/+), PLN K.O. (Pln-/-), and 
PLN R14del heterozygous (Pln+/∆R14) mice membranes. (B) Analysis of 14-3-3 and pCaMKII steady-
state levels in WT (Pln+/+), PLN K.O. (Pln-/-), and PLN R14del heterozygous (Pln+/∆R14) mice cytosol. 
Equal loading of membrane and cytosol samples were confirmed with Western blotting for Na/K 
ATPase and GAPDH respectively. (A) and (B) were analysed by Western blotting with 
corresponding antibodies.  
 
Further, I aimed to test whether the PLN R14del mutation in a heterozygous mice model 
influences the ability of PLN to interact with 14-3-3. Therefore, a 14-3-3 binding assay with 
recombinant MBP-14-3-3 gamma was performed with ventricular membranes from the 
Pln+/∆R14 or Pln+/+ mouse. The eluates were analysed by Western blotting and showed that 
the PLN pentamer was enriched from both, membranes of the Pln+/∆R14 disease model or 
Pln+/+ control mouse (Figure 23A,B). MBP and MBP-14-3-3+R18 served as controls and 
did not show any non-specific PLN binding (Figure 23A,B). Surprisingly, the enriched PLN 
pentamer from the Pln+/∆R14 mouse was phosphorylated at S16 and T17 (Figure 23B). 
Given what is already known about the PLN R14del mutation, which disrupts the PKA 
target motif and therefore should be not able to be phosphorylated at S16 (Ceholski et al., 
2012; Haghighi et al., 2006), the detected amount of PLN pS16 was surprisingly high. In 
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the Pln+/∆R14 mouse model PLN proteins without the PLN R14del mutation are present, 
although I expected a reduction of PLN phosphorylated at S16 in pentamers enriched from 
the Pln+/∆R14 mouse. In line with the unexpected observation, also the steady-state-PLN 
analysis of Pln+/∆R14 membranes, performed before the 14-3-3 pull-down, did not revealed 
differences regarding the phosphorylation distribution of pS16 and pT17 (Figure 21). 
Altogether, the pull-down experiment from Pln+/∆R14 mouse model enriched PLN pentamers 
equally phosphorylated at S16 and T17 residues as compared to the WT control. Further 
analysis of the PLN R14del protein in the Pln+/∆R14 mouse model would be required to 
distinguish between the PLN R14del disease and WT PLN protein. 
 
Figure 23. PLN pentamers phosphorylated at pS16 and pT17 were enriched with 14-3-3 pull-
down experiments from Pln+/∆R14 mouse heart membranes.  
14-3-3 binding assay with membranes from the Pln+/+ control (A) and Pln+/∆R14 disease membranes 
mouse (B) were performed. Eluates were probed by Western blot for enriched PLN proteins and 
their phosphorylation status with corresponding antibodies.  
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From the performed pull-down experiment with Pln+/∆R14 disease model membranes I could 
not conclude if the PLN pentamers that were enriched with 14-3-3, were hetero-pentamers 
containing both WT and R14del PLN monomers or homo-pentamers of WT PLN. To 
answer this question, I enriched PLN pentamers with 14-3-3 gamma from Pln+/+ mice and 
Pln+/∆R14 disease model membranes and separated the eluates on a Phos-tag-PAGE. The 
hypothesis was that PLN pentamer enriched from the PLN+/∆R14 disease mouse should 
show less phosphorylated bands on a Phos-tag-PAGE because the PLN R14del protein 
cannot be phosphorylated at S16 by PKA (Haghighi et al., 2006). The Phos-tag-PAGE was 
transferred to nitrocellulose and analysed with a PLN antibody for the number of 
phosphorylation bands (Figure 24A). The phosphorylation band pattern did not differ 
between PLN pentamers enriched from Pln+/+ animals or Pln+/∆R14 disease model 
membranes (Figure 24A). However, the intensity of the bands is clearly reduced for all 
three enriched pentamers from Pln+/∆R14 membranes in comparison with the control (Figure 
24A,C). The same effect was visible when the eluates were analysed on a standard SDS-
PAGE for total PLN levels (Figure 24A), while the amount of MBP-14-3-3 bait protein used 
for the affinity enrichment experiments was equal as shown by Western blotting with a 
MBP antibody (Figure 24A). Solubilized membranes from Pln+/∆R14 and Pln+/+ which served 
as input samples, were analysed by Western blot with an PLN antibody, showing equal 
amounts of PLN pentamer and monomers before they were added to the MBP-14-3-3 bait 
(Figure 24B). The strongly reduced enrichment of the PLN pentamer with the Pln+/∆R14 
disease model was significant over the controls (Figure 24C). This result suggested that 
exclusively PLN WT was presented in the enriched pentamer from the Pln+/∆R14 disease 
model. It further indicates the PLN R14del protein was not addressable which may 
confirms already reported mislocalization or aggregation (Haghighi et al., 2012; te Rijdt et 
al., 2016). 
Altogether, I could show that the PLN protein expression level and the distribution of 
phosphorylation at S16 or T17 do not differ in the Pln+/∆R14 heterozygous disease model. 
However, in the 14-3-3 affinity purification experiment PLN pentamer was enriched from 
the Pln+/∆R14, mice which did not differ regarding the number of phosphorylated residues. 
Both the phosphorylation distribution and the reduced amount of PLN pentamers from the 
Pln+/∆R14 mouse membranes indicated, that exclusively homo-pentamers containing PLN 
WT monomers were enriched. This allows the assumption that the PLN R14del protein did 
not form 14-3-3-binding competent pentamers in the Pln+/∆R14 disease model. 
 
Chapter III: Further analysis of the PLN/14-3-3 interaction 
 121 
 
Figure 24. Phosphorylation distribution did not change in R14del PLN pentamers enriched 
from Pln+/∆R14 disease mice membranes . 
(A) Elution of 14-3-3 enrichment purification experiments from PLN Pln+/∆R14 and Pln+/+ mice 
membranes were loaded on Phos-tag-PAGE and analysed with an PLN antibody (upper panel). 
Membranes from Pln-/- animals were loaded as well to exclude unspecific antibody bands. In parallel 
elutions were analysed on SDS-PAGE with a PLN and MBP antibody. (B) Solubilized membranes 
from Pln+/∆R14 and Pln+/+ mice were analysed by Western blot with a PLN antibody to confirm equal 
input samples which then served for the pull-down experiment shown in (A). Loading of the input 
samples was monitored with detection for Na/K ATPase. (C) Quantification of experiment shown in 
(A) using values of enriched PLN pentamer intensity normalized to the signal observed for used 
MBP-14-3-3 gamma bait protein. The experiment was performed with 3 biological replicates. Data 
are presented as mean ± standard error of the mean (SEM). An unpaired t-test showed significant 
differences in (C) (*p=0.0117).  
 
3.3.5 Different PLN mutations do not alter the ER localization of PLN in mammalian 
cells 
The analysis of the Pln∆R14 /∆R14 and Pln+/∆R14 mouse disease models indicated for both 
models reduced amounts of the PLN R14del protein in membrane fractions. I wondered 
whether the disease-causing mutations would provoke some trafficking defect for which I 
wanted to analyse the subcellular localization of these mutants. Different PLN constructs 
were designed for mammalian expression and used in HEK293T and HeLa cells. Besides 
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the PLN R14del mutation, also PLN R9C was included as well as different phospho-dead 
constructs (Table 8). The PLN variants were fused with an opsin-tag at the C-terminus. 
The opsin-tag is a short tag that contains an N-glycosylation site which can be glycosylated 
when exposed in the ER lumen (Bulbarelli et al., 2002). These tags have been used in the 
literature to monitor the ER insertion of the tagged-protein by analysis of the glycosylation 
state (Buentzel & Thoms, 2017). The different PLN mutations were analysed along with 
different known organelle-marker proteins in order to determine the subcellular localization 
of the construct.  
 
Table 8. Sequence of PLN-opsin tagged constructs for expression in mammalian cell.  
Full-length PLN was fused with an opsin-tag. The di-arginine ER-retention signal in the PLN 
sequence is marked in green and the 14-3-3 binding site is highlighted in orange. Inserted point 























The expression of the opsin-tagged PLN mutants in human cells was analysed by Western 
blotting with an anti-opsin antibody (Figure 25). The WT, S10A and S16A variants had 
similar steady-state levels whereas the expression of the R9C and R14del disease variants 
was reduced in both tested cell lines (Figure 25A, B). In both HEK and HeLa cells, only 
monomeric PLN was detected (Figure 25A,B). Altogether, the expressed PLN mutant 
proteins behaved similar in HEK293 and HeLa cells. After the expression of the PLN 
mutant proteins was confirmed I analysed their subcellular localization using indirect IF 
experiments.  
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Figure 25. PLN-opsin protein variants expressed in HEK293T or HeLa cells.  
Transfected HEK293T cells (A) or HeLa cells (B) were solubilized and PLN protein levels were 
analysed by Western blot with anti-opsin and anti-Na/K ATPase antibodies. EV indicates empty 
vector control. 
 
First, the localization of the opsin-tagged PLN mutants at the ER compartment was 
analysed by co-staining against the Sec61beta translocon in HEK293 cells. All PLN 
variants co-localized with Sec61beta indicating localization within the ER (Figure 26). 
Interestingly, also the two PLN disease-causing mutations, R9C and R14del co-localized 
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Figure 26. PLN-opsin mutants co-localized with Sec61beta in HEK293T cells.  
Co-staining for Sec61beta (red) and opsin (green). Cells were cultured for 48 h after transfection, 
fixed with PFA and imaged by confocal microscopy. EV indicates empty vector control. All 
micrographs were obtained at the same exposure settings of the camera. Scale bars 20 µm.  
 
Second, the localization of PLN-opsin mutants and the early endosomal marker protein 
EEA1 were analysed (Figure 27). The early endosome transports cargo between the 
plasma membrane and Golgi (Jovic et al., 2010). Cells expressing the PLN R14del or R9C 
disease mutant showed an increased number of EEA1 positive vesicles in contrast to cells 
expressing PLN WT or phospho-dead mutants (Figure 27). However, none of the analysed 
PLN mutants show co-localized with EEA1 positive vesicles in HeLa cells (Figure 27).  
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Figure 27. PLN-opsin protein variants showed no co-localization with the early endosomal 
marker protein EEA1 in HeLa cells.  
Co-staining for the early endosomal maker protein EEA1 (green) and opsin (red). Cells were 
cultured for 48 h after transfection, fixed with PFA and imaged by confocal microscopy. EV indicates 
empty vector control. All micrographs were obtained at the same exposure settings of the camera. 
Scale bars 20 µm. 
 
Finally, co-localization between the middle-late endosomal marker protein Rab7 and PLN 
mutants was investigated (Figure 28). Late endosomes fuse with lysosomes for 
degradation (Huotari & Helenius, 2011). The PLN mutants showed no co-localization with 
Rab7 as well. The PLN WT looked close to Rab7 vesicles in the merged view but the Rab7 
vesicles shown in green are still separated (Figure 28). 
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Figure 28. PLN-opsin protein variants showed no co-localization with the late endosomal 
marker protein Rab7 in HeLa cells.  
Co-staining with the middle to late endosomal marker protein Rab7 (green) and opsin (red). Cells 
were cultured for 48 h after transfection, fixed with PFA and imaged by confocal microscopy. EV 
indicates empty vector control. All micrographs were obtained at the same exposure settings of the 
camera. Scale bars 20 µm. 
 
Altogether, subcellular localization of opsin-tagged PLN variants, that cover different PLN 
disease mutations and phospho-dead mutants, were analysed in mammalian cells. All PLN 
mutants were found to localize in the ER compartment, as shown by co-staining with the 
ER marker protein Sec61beta. Interestingly, no different localization could be observed for 
the PLN disease mutations (R9C and R14del) in the ER in this experimental set up. In 
addition, localization with endosomal vesicles was analysed to further investigate if the 
PLN mutations are mistargeted to the plasma membrane as already reported (Haghighi et 
al., 2012). The PLN WT construct, as well as all mutants were found to be localized in the 
ER. Contrarily to already published results about mislocalization of the PLN R14del 
mutation to the plasma membrane (Haghighi et al., 2012), in this study no altered 
subcellular localization was observed for the mutations tested. Moreover, no co-
localization of the PLN mutant proteins with the early endosomal marker protein EEA1 or 
with the middle to late endosomal marker Rab7 could be determined, indicating that the 
different mutations in the PLN protein do not alter the protein localization in the cell.  
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3.3.6 14-3-3 interacts with PLN pentamers in human atria  
The interaction I observed between 14-3-3 and PLN was identified in rodent cardiac tissue. 
The PLN protein itself is highly conserved but there are physiological differences in 
humans and mice (Haghighi et al., 2003). To analyse whether the interaction between 
14-3-3 and PLN is possible in human hearts, enrichment purification experiments with 
recombinant 14-3-3 and human atrial heart membranes were performed. The experiment 
was analysed by Western blotting with a PLN and PLN phospho-specific antibodies. 
Although the PLN pentamer was reduced in comparison with the monomer in the input, 
pentameric PLN was enriched with 14-3-3 from the human heart membranes (Figure 29A). 
The MBP and 14-3-3+R18 control excluded any unspecific binding (Figure 29B). The 
enriched PLN pentamer from human heart membrane contained both phosphorylated 
pS16 and pT17 residues (Figure 29A). Altogether, the interaction between 14-3-3 and the 
PLN pentamer could be also verified with human atrial membrane samples. 
  




Figure 29. PLN pentamers interact with 14-3-3 in human atrium. 
(A) 14-3-3 pull-down experiments with recombinant MBP-14-3-3 and membranes from human 
atriums were analysed by Western blot with antibodies detecting PLN and PLN pS16 or pT17 
protein levels. (B) Quantification of the experiment shown in (A) using values of enriched PLN 
pentamer intensity normalized to the MBP-14-3-3+R18 control. The experiment was performed with 
four biological replicates. Data are presented as mean ± SEM. A one-way ANOVA analysis showed 
significant difference between the groups presented in (B) (p=0.0026), followed by a Tukey test 
indicating differences in between 14-3-3+R18 versus 14-3-3 (**p= 0.0089). 
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3.4 Discussion  
A novel interaction between the cardiac regulator protein PLN and a phospho-adaptor 
protein 14-3-3 was identified in this study. The binding sites and the function of the novel 
interaction is shown and discussed in chapter 2. This chapter further characterizes the 
PLN/14-3-3 interaction and investigates two different R14del PLN disease animal models.  
 
3.4.1 14-3-3 binds adjacent phosphorylated PLNs rather than the two proximal 
phospho-sites 
In chapter 2, I could already show, that 14-3-3 binds to phosphorylated PLN. However the 
cytosolic region of PLN includes two physiologically relevant phosphorylation sites. The 
S16 residue, which is a target site of PKA, and the T17 residue, which is phosphorylated 
by CaMKII kinase (Mattiazzi & Kranias, 2014). Recombinant PKA phosphorylated PLN 
WT, S10A and T17A mutant proteins very efficiently, but not the PLN S16A protein 
(Figure 15A). This result confirmed that PKA phosphorylates the S16 residue in PLN. 
Single phosphorylation bands for the PLN WT and S10A proteins indicated that all 
constructs were singly phosphorylated and no cross phosphorylation of other potential 
phosphorylation residues occurred. CaMKII phosphorylated the PLN WT, S10A, S16A 
protein variants, but not the PLN T17A protein (Figure 15B). This verifies that the T17 
residue in PLN is specifically phosphorylated by CaMKII kinase. However, the 
phosphorylation efficiency was higher with PKA as indicated by the abundance of 
phosphorylated protein on a Phos-tag-PAGE. I was particularly interested in investigating 
whether double phosphorylation, which leads to two very proximal phospho-groups, would 
abolish 14-3-3 binding as observed in the context of another 14-3-3-binding motif with two 
closely spaced phospho-residues (Kilisch et al., 2015). Double phosphorylation of the PLN 
WT protein was possible as indicated by two shifts on a Phos-tag-PAGE subsequently 
14-3-3 binding indeed revealed that 14-3-3 binding was abolished (Figure 17). It was 
already shown that PKA has a higher affinity towards beta-adrenergic stimulation as 
CaMKII and can be phosphorylated individually (Coyler, 1998; Mundiña-Weilenmann et 
al., 1996) . But under full beta-adrenergic stimulation both kinases are activated leading to 
a double phosphorylation of PLN monomers (Coyler, 1998). How does 14-3-3 bind to PLN 
in such a situation? Based on pull-down experiments with recombinant 14-3-3 and cardiac 
lysate I showed that 14-3-3 binds preferably the PLN pentamer (chapter 2, figure 1,3). This 
result together, with the findings from the binding assay with double phosphorylated PLN 
(Figure 17) allow me to hypothesize that 14-3-3 binds to adjacent phosphorylated PLNs 
rather than the two proximal phospho-sites within the same PLN.  
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3.4.2 PLN R14del mutation may form aggregates in homozygous and 
heterozygous disease models 
Two PLN disease causing mutations in humans, the R14del and R9C mutation were 
further investigated regarding the 14-3-3/PLN interaction. 
The R14del PLN mutation is of great interest because the PKA binding motif is disrupted 
and prevents S16 phosphorylation (Haghighi et al., 2006). As a consequence, 
phosphorylation of T17 via CaMKII kinase is the only opportunity to phosphorylate PLN 
and partially relieve SERCA inhibition in the R14del disease mutation. I was already able 
to show that phosphorylated T17 is the high 14-3-3 binding affinity site in PLN (chapter 2, 
figure 3,4). Furthermore, I showed that 14-3-3 still physically interact with R14del PLN in a 
recombinant binding assay (chapter 2, figure 4). How the R14del PLN mutation influences 
the 14-3-3/PLN interaction was analysed in PLN R14del mouse models. In purified heart 
membranes from the homozygous R14del transgenic mice barely any PLN protein was 
identified, indicating that the PLN protein expression level was strongly reduced (Figure 
18). 14-3-3 and activated CaMKII kinase protein steady-state levels were not affected by 
the R14del mutation. Interestingly, also SERCA protein levels were reduced in the disease 
model. Overall, the R14del PLN mutation in a homozygous mouse model negatively 
influences proteins which are involved in cardiac Ca2+ handling. Although the PLN steady-
state levels were strongly reduced in the homozygous disease model, small amounts of 
R14del PLN were enriched with recombinant 14-3-3. The amount of enriched R14del PLN 
pentamer was too small to detect for phosphorylation with phospho-specific antibodies. 
Due to the disrupted PKA site in the R14del PLN protein the interaction could be only 
mediated via T17 phosphorylation. This result confirms findings from recombinant binding 
assays (chapter 2, figure 4) and showed that R14del PLN is still able to physically interact 
with 14-3-3. However, the enriched R14del PLN protein was very low and additional 
approaches to further investigate a possible 14-3-3/PLN R14del interaction are required, 
like an APEX proximity assay with R14del induced pluripotent stem cells or complexome 
profiling with cardiac lysate from homozygous or heterozygous mouse models and 
subsequently MS analysis. 
In addition, the 14-3-3/PLN interaction was also investigated in a R14del PLN 
heterozygous mouse model, which corresponds to the zygosity in patients. In the 
heterozygous R14del mouse model, the PLN steady-state level were found to be similar 
to healthy control mice. Furthermore, the PLN phosphorylation distribution of S16 or T17 
was not altered either (Figure 21). This was surprising as a different phosphorylation 
distribution for R14del PLN was expected due to the disrupted PKA interaction site. The 
heterozygous disease model expresses both PLN WT and R14del proteins, but a reduction 
of S16 phosphorylation in comparison with WT animals was expected. However, the 
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steady-state levels of all analysed PLN interaction partners such as SERCA, 14-3-3 or 
pCaMKII were found to be not altered due to the R14del mutation (Figure 22). To further 
characterize the Pln+/∆R14 mouse model, PLN pentamers were enriched from the Pln+/∆R14 
mouse and analysed for the phosphorylated S16 and T17 distribution. Again, the S16 
phosphorylation was not found to be reduced in PLN pentamers enriched from the Pln+/∆R14 
mouse with recombinant 14-3-3 (Figure 23). This result indicated that either hetero-
pentamers, including both R14del PLN and WT PLN monomers, or PLN WT homo-
pentamers were enriched. Clearly, no R14del PLN homo-pentamer was enriched in the 
pull-down experiment. If in a heterozygous R14del PLN background homo- or hetero-
pentamers are formed is not known so far. To further analyse the composition of the PLN 
pentamers in the R14del mice, pentamers enriched by 14-3-3 were analysed on a Phos-
tag-PAGE to separate the various present phosphorylation sites. Pentamers containing 
several R14del PLN monomers should show less phosphorylation bands on a Phos-tag-
PAGE than healthy PLN pentamers, due to the absent S16 phosphorylation. The enriched 
PLN R14del pentamers showed exactly the same phosphorylation band pattern on a Phos-
tag-PAGE as PLN WT pentamers (Figure 24). Only the amounts of enriched pentamers 
from the R14del disease mice were significantly reduced in comparison to the control mice. 
This result strongly suggests that only homomeric WT PLN pentamers were enriched by 
14-3-3 from the R14del heterozygous mouse model. Overall, in the experiments I 
performed to investigate the Pln+/∆R14 mouse model, I never obtained any altered 
phosphorylation distribution of the PLN. These results gave me the impression that the 
R14del PLN protein was not amenable to the types of extraction or fractionation protocols 
tested by my experiments. Taken together, barely any R14del PLN protein was identified 
either in the homozygous or in the heterozygous mouse model. A mis-localization of the 
R14del PLN was previously described in a heterozygous context (Haghighi et al., 2012). 
In addition, evidence that PLN forms large protein aggregates in ventricles of R14del 
patients was identified with immunohistochemistry and electron microscopy experiments 
(te Rijdt et al., 2016). In this study, 20 hearts from patients suffering under the R14del 
mutation were analysed and PLN aggregates were identified in all of them (te Rijdt et al., 
2016). Aggregation of the PLN R14del protein would explain why I could barely identify 
R14del PLN protein in either homozygote or heterozygote animal models. I assume that 
during the membrane separation of the samples the aggregates end up in the insoluble 
fraction and therefore were not amenable to further biochemical analysis. To test whether 
the R14del PLN protein aggregated in both R14del disease models immunohistochemical 
examination of PLN should be performed.  
Not much is known about the composition of PLN pentamers in the PLN R14del 
heterozygous background. The data I obtained, suggest that no hetero-multimeric PLN 
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pentamers are formed. However, I cannot exclude that possibly a single R14del PLN 
monomer was integrated in a pentamer with four WT PLN monomers. This would result in 
a change of a single phosphorylation site within the PLN pentamer which is maybe not 
visible on a Phos-tag gel. The PLN pentamer formation in a heterozygous disease 
background of PLN mutations is very interesting. To further investigate the R14del PLN 
pentamer distribution, an antibody detecting exclusively the R14del mutation in PLN would 
be helpful. As long as such an antibody is not available another experimental approach 
could be the analysis of enriched PLN pentamers from different PLN R14del disease 
models for the number of different S16 or T17 phosphorylation residues by MS analysis.  
 
3.4.3 PLN disease mutations are localized in the ER in mammalian cells 
In parallel to the investigation of the PLN R14del mice disease models, expression and 
localization of PLN mutant proteins in mammalian cell lines were investigated. Protein 
expression was analysed by Western blotting in HEK293T and HeLa cells. The expression 
levels of the two human disease mutants were found to be reduced by Western blotting in 
both cell lines. The PLN-opsin mutant proteins did not form SDS-resistant pentamers in 
HEK or HeLa cells (Figure 25). Pentamer formation is achieved by the transmembrane 
domain of PLN (Kimura et al., 1997), which is present in these constructs. Perhaps the 
opsin-tag prevented pentamer formation. Overall, there was no difference visible in 
HEK293T or HeLa cells regarding the expression of the PLN constructs (Figure 25). 
Localization analysis of the PLN mutant variants in mammalian cells demonstrated the 
correct localization of all PLN mutants to the ER compartment by co-staining with the ER 
marker Sec61beta (Figure 26). Interestingly, also the PLN R14del mutation was identified 
in the ER by co-staining with SEC61beta. In the literature the PLN R14del mutation has 
been reported to be localized at the plasma membrane after expression in HEK cells 
(Haghighi et al., 2012). I have not been able to confirm this result in my experimental set 
up.  
In addition to ER localization, different cellular compartments were investigated such as 
early and late endosomes. If the PLN disease mutants would be misrouted to the plasma 
membrane, they should be also visible at some point in the endosome, since endosomal 
pathways receive all incoming material from the plasma membrane and serve as an initial 
sorting route for either recycling or degradation (Scott et al., 2014). I performed IF 
experiments with early and late endosomal marker proteins and the opsin-tag fused to PLN 
mutants were performed. No localization of any PLN mutant could be observed in either 
early nor late endosomal vesicles. The PLN R14del mutation was also not localized in 
endosomal vesicles (Figure 227,28). Altogether, I could not confirm mislocalization of the 
R14del PLN mutation expressed in mammalian cells. Taken together with the results from 
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homozygous and heterozygous PLN R14del mouse models, where barely any R14del PLN 
protein could be identified, my data support the already suggested hypothesis of PLN 
R14del aggregate formation (te Rijdt et al., 2016) rather than mislocalization. To further 
proof this hypothesis, cardiac myocytes should be isolated from the homozygous and 
heterozygous PLN R14del mouse model and the staining experiments should be repeated.  
In addition, my IF analysis supports published work from Butler et al who also did not 
observe any PLN localization in early endosomes (Butler et al., 2007). Interestingly, Butler 
et al identified PLN in the ERGIC and suggested a model where PLN is maintained in the 
ER by retrieval trafficking between ERGIC and ER (Butler et al., 2007). To further confirm 
the PLN localization in the ERGIC a corresponding IF experiment should be performed. In 
addition, it seems worthy to also repeat the experiment with an alternative tag, such as a 
myc-tag to exclude that the opsin-tag is influencing the ability of PLN to form pentamers 
and thereby alter the localization. In addition, it would be interesting if phosphorylation of 
PLN in mammalian cells influences the localization. Therefore, cells could be stimulated 
with isoprenaline to activate beta-adrenergic stimulation.  
 
3.4.4 14-3-3 binds PLN pentamers in human atria  
Most of the analysis of the 14-3-3/PLN interaction was performed with in-vitro approaches 
or in mouse models. Although PLN is very conserved in human and mouse (McTiernan et 
al., 1999) differences between both species were observed. PLN deletion in mice shows 
increased cardiac contractile function without the development of HF (Haghighi et al., 
2003). In humans all PLN mutations that lead to protein truncation are lethal due to dilated 
cardiomyopathy and subsequent HF (Haghighi et al., 2003). 
As a consequence, it is important to understand the differences in cardiac physiology and 
Ca2+ handling in mice and humans. The heart rate in mice is 10 times faster than in 
humans. Moreover, 92% of Ca2+ removal is achieved by SERCA in mice, meanwhile just 
70% of Ca2+ is transported by SERCA in humans. In addition the basic ventricular motor 
proteins responsible for cardiac contraction differ in mice and human (Haghighi et al., 
2003). With a 14-3-3 pull-down experiment and cardiac membranes separated from 
human atrial biopsy samples I enriched PLN pentamers (Figure 29). This verifies a physical 
14-3-3/PLN interaction in human atrium. Atria and ventricle show different characteristics 
such as myocardial mass or wall thickness (Filgueiras-Rama & Jalife, 2016). In addition, 
they show functional differences in intracavitary pressures, ion channel composition, and 
electrophysical characteristics (Filgueiras-Rama & Jalife, 2016). As a consequence, it is 
important to also investigate the 14-3-3/PLN interaction in human ventricular samples. 
Alternatively, induced pluripotent stem cells derived from atrial ventricular cardiomyocytes 
(Cyganek et al., 2018) could be used.  
Chapter III: Further analysis of the PLN/14-3-3 interaction 
 134 
  
Chapter IV: Identification of novel interaction partners for TASK channels in the heart 
 135 
4 Chapter IV: Identification of novel interaction partners for TASK channels 
in the heart 
4.1 Introduction 
The family of K2P channels is one out of three K+ ion channel families involved in cardiac 
action potential generation and electrical signal transduction. K2P channels are 
background leak channels for potassium currents which are important regulators of the 
resting membrane potential (Hughes et al., 2017). The K2P channel family is defined by a 
structure of four transmembrane domains and two-pore forming domains per monomer 
(Goldstein et al., 2005). K2P channels are strongly expressed in the brain and central 
nervous system (Lesage, 2003). However, several members of K2P channels also were 
identified to be expressed in the heart like TASK channels (Gurney & Manoury, 2009). 
TASK channels are one group within the K2P channel family, defined by their high 
sensitivity to extracellular acidic stress (Duprat et al., 1997; Talley et al., 2000). Three 
different channels belong to the group of TASK channels: TASK-1, TASK-3 and the silent 
TASK-5 channel. TASK-1 is expressed on mRNA and protein levels in the heart and mostly 
in the atrium. Whereas for TASK-3, only mRNA transcripts could be found in the heart and 
in the aorta but was absent based on protein levels (Gurney & Manoury 2009).  
Homo- and heterodimeric TASK channels have been identified within the same channel 
family but also within different K2P channel families. For the TASK-1/TASK-3 heterodimeric 
channel different electrophysical and pharmacological properties were identified in 
comparison with the corresponding homodimers (Czirják & Enyedi, 2002). In 2007, Putzke 
et al detected first TASK-1 like currents in rat ventricular myocytes. They reported that the 
TASK-1 current contributes substantially to the total outward current during the plateau 
phase of the action potential (Putzke et al., 2007) indicating the physiological importance. 
In line, TASK homo- and heterodimers have been shown to be physiologically relevant in 
various tissues (Gurney & Manoury 2009). Interestingly, Rinné et al suggested the 
presence of a functional heteromeric TASK-1/TASK-3 channel in hearts (Rinné et al., 
2015). Altogether, TASK channels have been reported as an important regulator of the 
action potential duration and for resetting the resting membrane potential in the 
mammalian cardiovascular system.  
Functional TASK channels need to be exposed at the cell surface. Hence, trafficking of 
TASK channels is tightly regulated. The TASK-1 and TASK-3 proteins are highly 
conserved except for the cytosolic C-terminal domain which shows only 34% homology 
(O'Kelley et al., 2015, Rajan et al., 2002). The last 15 AA of the C-terminus of TASK-1 as 
well as TASK-3 channels contain a so called “trafficking control region” with several 
overlapping binding motifs, which regulate trafficking of these channels to the cell surface 
Chapter IV: Identification of novel interaction partners for TASK channels in the heart 
 136 
(Figure 30) (Kilisch et al., 2015). The trafficking control region of TASK-1 and TASK-3 
include an ER retrieval sequence (KRR), as well as an overlapping 14-3-3 binding motif 
containing one phosphorylatable serine residue (Zuzarte et al., 2009). Several binding 
partners are already known to interact with the TASK C-terminus, like the COPI vesicular 
coat as well as the phospho-adaptor protein 14-3-3. Binding of COPI or 14-3-3 to the TASK 
channel is regulated by PKA-dependent phosphorylation of the C-terminal trafficking 
control region (Mant et al., 2011). The phosphorylated serine residue S393 in TASK-1 and 
S373 in TASK-3 bind 14-3-3 with high affinities. 14-3-3 binding sterically hinders COPI 
interaction, promoting forward trafficking of the channels to the cell surface (Kilisch et al., 
2016). After 14-3-3 binding the TASK channels leave the early secretory pathway on their 
way to the cell surface, where they get glycosylated. Glycosylation is an important step for 
correct surface expression of many ion channels as shown for KATP or Kv1.4 (Steele et al., 
2007). COPI binding initiates retrograde trafficking of the channels to the ER and cis-Golgi 
(together also called “early secretory pathway”) thus allowing for correct assembly prior to 
cell surface expression of the channel (Mathie, 2007).  
Interestingly, the TASK-1 channel has a second serine residue in the trafficking control 
region adjacent to the 14-3-3 binding S393 (Figure 30), which is absent in the TASK-3 
channel. It was shown that the second serine residue (S392) in TASK-1 can also be 
targeted by PKA in vitro and in vivo (Kilisch et al., 2016). The S392 residue was found to 
be an inhibitory residue for 14-3-3 binding upon phosphorylation (Kilisch et al., 2016). 
Presence of the phosphorylated S392 residue in the TASK-1 C-terminus significantly 
reduced the affinity for 14-3-3. Consequently, the surface expression of TASK-1 was also 
strongly reduced upon S392 phosphorylation (Kilisch et al., 2016). Although TASK-1 and 
TASK-3 channels are very conserved a couple of protein interaction partners were 
exclusively identified for TASK-1. The cytosolic adaptor protein p11 binds TASK-1 via a 20 
aa long stretch in the C-terminus, which is also called p11 binding site and is located 
upstream over the trafficking control region (Figure 30). The TASK-1 p11 interaction leads 
to the retrieval of the channel to intracellular compartments of the early secretory pathway 
(Renigunta et al., 2006). Moreover, it was shown that TASK-1 interacts with the endosomal 
SNARE protein syntaxin-8. Interestingly, the interaction which syntaxin-8 and TASK- 1 was 
found to be involved in endocytosis processes (Renigunta et al., 2014). 
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Figure 30. Schematic representation of TASK-1 and TASK-3. 
Both channels show high sequence homology except for the C-terminus. The trafficking control 
region is represented in yellow (14-3-3 binding motif) and blue (ER retention/retrieval motif). The 
i20 domain is shown in green and a potential internalization motif is displayed in red (aa 294-314). 
Compared to TASK-1 (two adjacent serine residues, S392, S393), TASK-3 possesses a lysine 
residue adjacent to the serine residue, which is part of the 14-3-3 binding motif. The 14-3-3 
phospho-binding residue in the TASK-1 (S393) and TASK-3 (S373) trafficking control domain is 
depicted in red. Figure adapted from (Kilisch et al., 2015).  
 
Endocytosis can mediate retrieval from the cell surface, recycling, and degradation of 
membrane proteins. Therefore, endocytosis is also important to regulate cell surface 
expression of TASK channels (Mant et al., 2013). Clathrin-dependent endocytosis is one 
of the best investigated endocytosis pathways and involves adaptor proteins like AP-2, 
which direct the cargo protein into the vesicle (Lafer, 2002). It was already shown that 
TASK-1 and TASK-3 co-localize with clathrin. The co-localization was strongly decreased 
after disruption of the clathrin-mediated pathway (Gabriel et al., 2012; Mant et al., 2013). 
However, for TASK-3 it was shown that endocytosis is happening more rapidly than for 
TASK-1 (Mant et al., 2013). Although TASK-1 and TASK-3 both were found to co-localize 
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with proteins involved in the clathrin-dependent endocytosis, the syntaxin-8 interaction was 
only identified with TASK-1. This interaction was found to initiate co-endocytosis of both 
proteins together in a cooperative manner (Renigunta et al., 2014). It was suggested that 
the C-terminus of TASK-1 and the N-terminus of syntaxin-8 bind AP-2, which initiates 
clathrin-dependent co-endocytosis. A potential benefit resulting from the co-endocytosis 
could be that syntaxin-8 may influence the final destination of the vesicle by the interaction 
with SNARE proteins localized in different compartments (Renigunta et al., 2014). In 
addition it has been reported that PKC is involved in TASK-1 regulated endocytosis and 
that another endocytosis motif (SRERKLQYSIP) very close to the p11 binding motif in the 
TASK-1 C-terminus is involved in this process (Gabriel et al., 2012). The authors showed 
reduced TASK-1 currents after PKC stimulation in mammalian cells and an increased 
TASK-1 internalization and intracellular puncta formation by microscopy analysis. 
Interestingly, Gabriel et al suggested that PKC phosphorylation of the second serine 
(S324) in the identified endocytosis motif (SRERKLQYSIP) of TASK-1 may allow 14-3-3 
binding and subsequent endocytosis.  
 
The function and regulation of TASK channels in the heart is still in its infancy and not 
much is known about cardiac mediators, which may be involved in this regulation. The fact, 
that more interaction partners were identified for TASK-1 and the stronger expression in 
heart, indicate that TASK-1 channels are regulated in a more complex way. In line with this 
notion, the TASK-1 channel has a second PKA phosphorylatable serine residue (S392) in 
the trafficking control region which function is not fully understood so far. The goal of this 
chapter was the analysis of the cardiac interactome for the extreme C-terminus of TASK-1 
and TASK-3, including the trafficking control domain. Phosphorylation is an important 
regulator of TASK channels thereby the analysis was performed differentiated between 
the phosphorylated or unphosphorylated status of the C-terminus of the channels.  
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4.2 Material and Methods  
4.2.1 Chemicals 
Chemicals used in this study were purchased from Sigma Aldrich, Carl Roth, Roche, GE 
HealthCare, AppliChem, Merck, and Serva. Restriction enzymes were purchased from 
Thermo Fisher Scientific. DNA oligonucleotides and phosphorylated oligonucleotides were 
synthesized by Sigma-Aldrich. Phusion DNA polymerase was homemade. PKA catalytic 
subunit was provided by Dr. Daniela Bertinetti (Kilisch et al., 2016) or purchased from New 
England Biolab. Phos-tag™ acrylamide was purchased from NARD institute.  
 
4.2.2  Methods 
4.2.2.1 Molecular Cloning and Polymerase Chain Reaction (PCR) 
Plasmids for recombinant expression of proteins in bacteria and mammalian cells were 
generated as previously described (chapter 3, section 3.2.4.1). Plasmids for the 
recombinant expression of proteins and oligonucleotides used in this chapter can be found 
in table 10 - 12. For the exponential amplification of DNA fragments, encoding the proteins 
of interest, PCR reactions were employed as already described (chapter 3, section 3.2.4.2) 
with the following modifications: For the generation of TASK-1 and TASK-3 recombinant 
expression vectors phosphorylated oligonucleotides and corresponding cloning 
techniques were used.  
 
4.2.2.2 Cloning with phosphorylated oligonucleotides 
The ligation of DNA depends on interactions between the phosphorylated 5’ end of DNA 
with an unphosphorylated 3’end of the same or another DNA strand. This property was 
used to ligate short, synthetic and phosphorylated oligonucleotides into dephosphorylated 
recipient vectors. This allowed for a significant reduction of unspecific ligated plasmids 
during cloning. In general, every reaction was prepared in a total volume of 20 µl and 
pipetted on ice. For oligonucleotide hybridization 8 µl of the phosphorylated forward 
oligonucleotide was mixed with 8 µl of the phosphorylated reverse oligonucleotide in 1x 
annealing buffer (50 mM Tris HCl, 20 mM MgCl2, 50 mM NaCl, pH 7.5) and incubated for 
5 minutes at 90 °C to anneal the oligonucleotides. The samples were allowed to cool down 
to 37°C at RT and subsequently transferred to ice. The annealed oligonucleotide mixture 
was diluted 1:100, 1:1000 and 1:10.000 with sterile dH2O and ligated into the recipient 
vector. 
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4.2.2.3 Restriction enzyme digest, ligation and transformation in bacterial 
cells 
PCR products and recipient plasmid DNA vectors were digested with one or multiple 
restriction enzymes as already described (chapter 3, section 3.2.4.3). Followed by ligation 
reactions which were performed with 100 ng linearized vector and 5-fold molar excess of 
purified insert, which was either a PCR product or an annealed phosphorylated 
oligonucleotide. The ligation reaction was performed as already described (chapter 3, 
section 3.2.4.4). Finally, the DNA was transformed into bacteria via electroporation as 
already mentioned (chapter 3, section 3.2.4.5). 
 
4.2.2.4 Expression and affinity-purification of GST- or MBP-tagged proteins 
GST- or MBP- tagged proteins were recombinantly expressed and affinity-purified from 
E.coli (strain BL21 Rosetta) as already described (chapter 3, section 3.2.4.8, 3.2.4.9). 
 
4.2.2.5 SDS PAGE and Phos-tag-PAGE electrophoresis 
SDS PAGE gel electrophoresis was performed as already described (chapter 3, section 
3.2.4.10). Phos-tag-PAGE was used to visualize phosphorylated residues in proteins. 
Phos-tag-PAGE and electrophoresis were performed as indicated (chapter 3, section 
3.2.3.11). 
 
4.2.2.6 Coomassie staining of SDS-PAGE or Western blot transfer 
SDS PAGE or Phos-tag-PAGE gels were stained after the electrophoresis with Coomassie 
brilliant blue G-250 to visualize protein bands or transferred onto a nitrocellulose 
membrane in a wet blot electro transfer technique as already described in detail (chapter 
3, section 3.2.4.12 and 3.2.4.14). Western blot detection was performed with fluorescent 
labeled secondary antibody (LiCOR) and an Odyssey CLx LiCOR imaging system as 
indicated (chapter 3, section 3.2.15). 
 
4.2.2.7 TCA precipitation of proteins  
Prepared solubilized heart membranes or cytosol or complete lysate were precipitated by 
adding 12.5% final concentration of TCA as already described in detail (chapter 3, section 
3.2.4.19). 
 
4.2.2.8 In-vitro phosphorylation of recombinant proteins by PKA 
Recombinant affinity-purified TASK-1 and TASK-3 C-terminal fusion proteins were 
phosphorylated with recombinant catalytic subunit PKA (provided from Dr. Daniela 
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Bernetti), in vitro. In general, 200 µg recombinant GST-fusion protein was immobilized onto 
50 µl glutathione sepharose resin (GE Healthcare) in GST buffer pH 7.4 (20 mM HEPES 
pH 7.4, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1 mM DTT) in a total volume of 1 ml 
for 90 min at 4°C gently rotating. Beads were subsequently washed 3 times in GST Buffer 
pH 7.4 and resuspended in a total volume of 300 µl phosphorylation buffer (150 mM NaCl, 
50 mM Tris-HCl, 10 mM MgCl2, pH 7.5) supplemented with energy mix (EM, an ATP 
regeneration system (10 mM phosphocreatine, 0.5 mM ATP, 0.5 mM GTP, 50 µg/ml 
creatine phosphokinase)), as shown in table 9. The phosphorylation reaction was 
performed overnight at 4°C gently rotating. 
 
Table 9. Scheme for in-vitro phosphorylation of recombinant TASK mutant proteins. 
PKA phosphorylation of recombinant protein Unphosphorylated control 
200 µg recombinant protein 200 µg recombinant protein 
284 µl phosphorylation buffer 299 µl phosphorylation buffer 
15 µl 20x Energy mix  - 
1 µl PKA 1 µl PKA 
 
4.2.2.9 Preparation of total rat heart lysate  
Whole rat hearts were thawed on ice, fatty tissue was removed and the remaining heart 
was cut into small pieces. The tissue was mechanically disrupted with a MiccraD-1 
homogenizer for 30 sec in tissue homogenization buffer (20 mM HEPES pH 7.4, 220 mM 
Mannitol, 70 mM Sucrose, 1 mM EDTA, 1x protease inhibitor, 1x phosphatase inhibitor). 
Crudely lysed tissue was subjected to dounce homogenization for 30 strokes on ice. 
Mitochondria were removed by centrifugation at 10.000 g for 10 min at 4°C. Afterwards, 
the supernatant was centrifuged at 100.000 g for 30 min at 4°C to separate membrane and 
cytosol. The supernatant was the cytosolic fraction which was transferred into a Falcon 
tube and kept on ice until further processing. The pellet contains separated membranes 
which were washed once in tissue homogenization buffer. After washing, 1 mg of crude 
membrane was solubilized in 1 ml ComplexioLyte48 (Logopharm) solubilization buffer on 
ice for 30 min, followed by centrifugation at 55.000 g for 30 min at 4°C to separate 
solubilized proteins from insolubilized protein. The supernatant contains solubilized heart 
membrane proteins. 
For the preparation of total heart lysate the cytosolic fraction and the solubilized 
membranes were pooled 1:1. The detergent was removed from the sample by dialysis 
overnight in GST buffer pH 7.4 (20 mM HEPES pH 7.4, 150 mM KOAc, 5 mM Mg(OAc)2, 
1 mM EDTA, 1 mM DTT, 1 mM PMSF). 
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4.2.2.10 Preparation of 14-3-3 and COPI-depleted rat heart lysate  
Rat heart lysate was centrifuged at 100.000 g for 15 min after dialysis to remove 
precipitated proteins. The lysate was treated with 2 mM R18 peptide inhibitor to block 
native 14-3-3 from binding to in vitro phosphorylated GST-bait proteins (e.g. GST-MST27-
T1WT-CT) and 1 µM H-89 to inhibit PKA, for 1h at 4°C. After inhibitor treatment the lysate 
was diluted 1:2 in GST buffer pH 7.4 (20 mM HEPES pH 7.4m 150 mM KOAc, 5 mM 
Mg(OAc)2, 1 mM EDTA, 1 mM DTT, 1x protease inhibitor, 1 x phosphatase inhibitor). 
Native COPI protein was removed from the cardiac lysate by incubation with recombinant 
GST-MST27-KKXX protein. 1 mg GST-MST27-KKXX was immobilized onto glutathione 
sepharose beads (GE Healthcare), washed and subsequently incubated with total rat heart 
lysate for 45 min at 4°C gently rotating. After incubation the resin-bound GST-MST27-
KKXX protein was removed by separation through filter tip columns. The process was 
repeated twice. 
 
4.2.2.11 TASK-3 pull-down with rat heart lysate for mass spectrometry analysis 
Recombinant purified GST-MST27-TASK-3 protein variants were immobilized to 
glutathione sepharose affinity resin and recombinant phosphorylated with PKA as 
described in section 4.2.2.8. Briefly, 200 µg TASK-3 protein variants were immobilized to 
50 µl glutathione sepharose affinity resin (GE Healthcare), followed by phosphorylation 
overnight with the catalytic subunit of PKA and EM. For the unphosphorylated control the 
TASK-3 protein variant was treated in the same way but without EM in the phosphorylation 
set up. After overnight phosphorylation, the TASK-3 proteins were washed 3 times in GST 
buffer pH 7.4 (20 mM HEPES pH 7.4, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1 mM 
DTT 1x protease inhibitor, 1 x phosphatase inhibitor) and incubated with prepared total rat 
heart lysate (section 4.2.2.9) for 2h at 4°C under gentle rotation. After incubation, the resin-
bound recombinant TASK-3 proteins were collected, washed 4 times in GST buffer pH 7.4. 
Finally, proteins were eluted with incubation in L-Gluthathione elution buffer (20 mM 
HEPES pH 7.4, 150 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 20mM L-Gluthathione, 1x 
protease inhibitor, 1 x phosphatase inhibitor), followed by TCA precipitation (section 
4.2.2.7). The precipitated pellet was solved in 1x NuPAGE LDS sample buffer (Thermo 
Fisher Scientific) for 10 min at 30°C. Eluted proteins were analysed by LC-MS/MS 
(performed in collaboration with Dr. Christoph Lenz (UMG Göttingen)), followed by 
MaxQuant analysis. The experiment was conducted in three technical replicates. 
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4.2.2.12 TASK-1 pull-down with separated rat heart membrane or cytosol for 
mass spectrometry analysis 
The pull-down experiment of TASK-1 with separated heart membranes and cytosol was 
done as already described for TASK-3 in section 4.2.2.11. In contrast to the TASK-3 affinity 
purification experiment, the TASK-1 affinity experiment was performed with separated rat 
heart membranes and cytosol and eluted with 1M NaCl.  
Rat heart lysate was prepared as described in 4.2.2.9 but separated cytosol and solubilized 
membranes were used separately for the TASK-1 pull-down. Solubilized membranes were 
dialysed overnight, as described in section 4.2.2.9. Prepared cytosol was shock frozen and 
stored at -80°C overnight. After the dialysis of the membranes, the cytosol was thawed on 
ice and both were centrifuged at 100.000 g for 10 min at 4°C to remove precipitated 
proteins. Cytosol and membrane fractions were treated with protease-, phosphatase-, 
14-3-3- and PKA-inhibitors and native COPI was removed with GST-MST27-KKXX affinity 
peptides as described in section 4.2.2.9. The elution of the bait proteins was done with 600 
µl 1M NaCl solved in GST Buffer pH 8.5. The elution was incubated for 15 min at RT and 
collected by centrifugation. The eluted samples were TCA precipitated as described in 
section 4.2.2.7 and finally solved in 1x NuPAGE LDS sample buffer (Thermo Fisher 
Scientific) for 10 min at 30°C. The TASK-1 pull-down samples were analysed by LC-
MS/MS (performed in collaboration with Dr. Christoph Lenz (UMG Göttingen)), followed by 
MaxQuant analysis. The experiment was conducted in two biological and each three 
technical replicates. 
 
4.2.2.13 Langendorff perfusion of rat hearts  
The Langendorff perfusion protocol was developed based on a combination of the biotin 
labelling method used by Sierra et al (Sierra et al., 2013) in rat hearts, and the ouabain-
induced Na/K internalisation described by Cherniavsky-Lev et al (Cherniavsky-Lev et al., 
2014). In general, hearts were perfused with Krebs-Henseleit buffer (118.5 mml/l NaCl, 
1.4 mmol/l CaCl2, 11 mmol/l glucose, 1.19 mmol/l MgSO4, 25 mmol/l NaHCO3, 1.18 mmol/l 
NaH2PO4, 4.75 mmol/l KCL) bubbled with 95% O2, 5% CO2 at 37°C and pH 7.4. Perfusion 
with different ouabain concentrations was done at constant pressure of 80 mghh. 
Perfusions with PBS and biotin as well as perfusions with PBS and glycine were done at 
4°C and constant flow. The last flow during ouabain perfusion was used (10-15 ml/min). 
During the whole perfusion process the heart viability was monitored with an OICG 
electrode pierced in the ventricle. Only hearts with a heart rate above 200 beats/min were 
used for this study. For every perfusion all reservoirs were either warmed up to 37°C or 
chilled until 4°C and filled with buffers, all air bubbles were carefully removed from the 
perfusion system and the perfusion pressure as well as the flow were checked. The heart 
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was removed from a euthanatized rat and directly dropped in cold Krebs buffer, fat tissue 
was removed and the first and second entry of the aorta were opened with a cut for easier 
cannulisation. After cannulisation the heart was tightened on the canula with a string and 
perfusion with 38°C warm Krebs buffer at constant pressure of 80 mmgh were started. 
After 5 min set up time, the heart was perfused for another 20 min with 38°C warm Krebs 
buffer at constant pressure. Followed by 1h perfusion with 38°C warm Krebs buffer with 
different concentrations of ouabain (100 nM or 50 µM) at constant pressure. After ouabain 
perfusion the heart was perfused with 4°C cold PBS with glucose (10 mM) and Sulfo-NHS-
LC-biotin (1 mg/ml, Thermo Fisher Scientific) for biotin labelling for 25 min at constant flow. 
Finally, the heart was perfused with 4°C cold PBS and glycine (15 mM) for 5 min at 
constant flow to quench the biotinylation. The heart was removed from the canula, snap 
frozen and stored at -80°C. 
 
4 groups of n=4/group were perfused:  
Group 1: Control (no biotin, no ouabain perfusion) 
Group 2: Biotin control (biotin but no ouabain perfusion) 
Group 3: Low ouabain (biotin and 10 nm ouabain perfusion) 
Group 4: High ouabain (biotin and 50 µM ouabain perfusion) 
 
4.2.2.14 Neutravidin affinity purification with rat heart tissue  
Neutravidin affinity purifications protocols were done with ouabain stimulated rat hearts. 
First, membranes and cytosol were separated from the ouabain stimulated hearts as 
described in section 4.2.2.9. Briefly, the hearts were mechanically disrupted, cytosol and 
membranes were separated due to different high speed centrifugation steps. Protein 
concentrations were measured with Bradford and 100 µg aliquots from cytosol and 
membranes were prepared in tissue homogenization buffer (320 mM Sucrose, 50 mM 
NaCl, 2 mM EDTA, 20 mM HEPES pH 7.4) with protease and phosphatase inhibitors and 
stored at -80°C. For a neutravidin affinity enrichment experiment one aliquot of separated 
membranes or cytosol from each animal was defrosted and centrifuged at 100.000 g for 
15 min to collect the membranes. After centrifugation the membranes were solubilized in 
ComplexioLyte48 solubilization buffer as already described in section 4.2.2.9. Solubilized 
heart membranes were diluted 1:5 with ComplexioLyte48 dilution buffer. The cytosol 
samples were diluted 1:4 with ComplexioLyte48 dilution buffer and 1 volume 
ComplexioLyte48 solubilization buffer, that both fractions contain the same amount of 
detergent. 10% input samples from membrane and cytosol samples were removed, TCA 
precipitated (section 4.2.2.7) and stored at -20°C. For 100 µg cytosol or membrane sample 
50 µl neutravidin bead slurry (Thermo Fisher Scientific) was washed twice in 
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ComplexioLyte 48 dilution buffer with one volume ComplexioLyte 48 solubilization buffer. 
The washed neutravidin beads were added to the prepared membrane or cytosol heart 
samples and incubated overnight at 4°C under rotation. The beads were collected and 
washed three times in ComplexioLyte48 dilution buffer. Finally, the samples were eluted 
with SDS samples buffer (2% SDS, 0.1% Bromophenol blue, 10% glycerol, 50 mM Tris-
HCl pH 6.8) supplemented with 100 mM DTT and 10 mM biotin. The sample buffer was 
headed up to 70°C, added to the washed beads, incubated for 5 min at RT and the elution 
was collected by centrifugation.  
 
4.2.2.15 Wheat germ agglutinin affinity purification with rat heart tissue  
Wheat germ agglutinin (WGA) affinity purification experiments were done with separated 
membranes and cytosol from ouabain treated rat hearts. The membrane and cytosol inputs 
were prepared as described (section 4.2.2.9). The solubilization of membranes was done 
as described in section 4.2.2.9, the only difference was the solubilization buffer. For WGA 
affinity purification experiments the detergent TritonX-100 was used (10 mM NaCl, 1.5% 
TritonX-100, 50 mM Tris-HCl, pH 7.35). After cytosol and membrane preparation 10% of 
each input was removed, TCA precipitated (section 4.2.2.7) and stored at -20°C. For 
100 µg cytosol or membrane sample 12.5 µl WGA bead slurry (Tagarose conjugated with 
Triticum vulgaris lectin, Sigma Aldrich) was incubated for 5 min in wash buffer I (150 mM 
NaCl, 2 mM EDTA, 20 mM HEPES pH 6.8) followed by washing 4 times in equilibration 
buffer (10 mM NaCl, 5 mM MnCl2, 5 mM CaCl2, 20 mM Tris HCl, pH 7.35) and a final 
washing step in solubilization buffer. Solubilized membranes or cytosol were added to the 
prepared wheat germ agglutinin resin and incubated for 5h at 4°C under rotation. 
Afterwards, the resin was collected and washed 6 times in wash buffer II (150 mM NaCl, 
2.5 mM MnCl2, 2.5 mM MgCl2, 2.5 mM CaCl2, 50 mM Tris HCl, pH 7.35). The bound 
proteins were eluted from the resin with SDS sample buffer supplemented with 100 nM 
DTT. For elution, samples were incubated for 5 min at RT and finally collected by 
centrifugation.  
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4.2.2.16 Binding assay with recombinant purified TASK constructs 
15 µg of the recombinant purified GST-MST27-TASK-1 mutants were immobilized and 
phosphorylated as described in section 4.2.2.8. The phosphorylated and immobilized bait 
proteins were washed and resuspended in GST buffer pH 7.4 (20 mM HEPES pH 7.4m 
150 mM KOAc, 5 mM Mg(OAc)2, 1 mM EDTA, 1mM DTT 1 x phosphatase inhibitor, 0.1% 
TritonX-100). Equimolar amounts of the potential binding partners (PDZ domain containing 
proteins) were added to the GST buffer pH 7.4 and incubated for 1h at 4°C under gentle 
rotation. After binding, the samples were washed 4 times and eluted in elution buffer 
supplemented with 1mM DTT. Binding assays were analysed by Western blotting and 
Coomassie stained Phos-tag and SDS-PAGE gels.  
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Table 10. Plasmids generated and used in chapter IV. 
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Insert at ClaI-XhoI J. Menzel 
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Table 11. Oligonucleotides used for PCR’s. 
Name Description Sequence (5’-3’) 
Dlg-1-FP 
Used to generate Dlg1 
from rat cDNA template, 
forward primer 
CCG CCG GAA TTC ATG CCG GTC 
CGG AAG CAA GAT ACC CAG 
Dlg-1- V5-Rev 
Used to generate Dlg1 
from rat cDNA template, 
reverse primer 
ACG CAC GCG TCG ACT TAC GTA 
GAA TCG AGA CCG AGG AGA 
GGG TTA GGG ATA GGC TTA CCG 
CTG CCG CCG CCT AAT TTT TCT 
TTT GCT GGG ACC CAG ATG TAA 
GGA CCA GAC TGC 
TEV-Dlg-1 FP 
(short) 
Used to generate tev-
cleavable Dlg1 protein, 
forward primer 
GGG AAA ACC TGT ATT TTC AGG 
GCA TTT CAG AAA TGC CGG TCC 
GGA AGC AAG ATA CC 
TEV-Dlg-1 FP 
long 
Used to generate tev-
cleavable Dlg1 protein, 
forward primer 
GCT CGA ACA ACA ACA ACA ATA 
ACA ATA ACA ACA ACC TCG GGG 
AAA ACC TGT ATT TTC AGG GCA 
TTT CAG AAA TGC CGG TCC GGA 
AGC AAG ATA CCC AGA GAG C 
Dlg-1-V5-Rev 
shorter 
Used to generate tev-
cleavable Dlg1 protein, 
reverse primer 
CCA GTG CCA AGC TTG CCT GCA 
GGT CGA CTT ACG TAG AAT CGA 
GAC CGA GGA GAG GG 
Dlg1 For (new 
ECORI) 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
CAA CAA CAA CAA TAA CAA TAA 
CAA CAA CCT CGG GGA AAA CCT 
GTA TTT TCA GGG CGA ATT CAT 
GCC GGT CCG GAA GCA AGA 
TAC C 
Dlg-1 V5 longer 
Rev 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
CGA CGT TGT AAA ACG ACG GCC 
AGT GCC AAG CTT GCC TGC AGG 
TCG ACT TAC GTA GAA TCG AGA 
CCG AGG AGA GGG 
PDZ1 For 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
TAC TGA TGC AGA TTA TGA ATA 
TGA GAG GCG GAA GCC AGC C 
PDZ1 Rev 
Used to generate Dlg-1 
truncations in the PDZ 
domains, reverse primer 
TTT TTT CTG AGG CTG GCT TCC 
GCC TCT CAT ATT CAT AAT CTG 
CAT CAG TAC CAT TAA CAT AAG 
T 
PDZ2 For 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
GAA GCC AGC CTC AGA AAA AAT 
CAT GAC AAG TAT GTA TAT AAA 
TGA TGG CTA TGC ACC 
Chapter IV: Identification of novel interaction partners for TASK channels in the heart 
 150 
PDZ2 Rev 
Used to generate Dlg-1 
truncations in the PDZ 
domains, reverse primer 
AGC CAT CAT TTA TAT ACA TAC 
TTG TCA TGA TTT TTT CTG AGG 
CTG GCT TCC 
PDZ3 For 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
TGA TGA GAT CAC TAG GGA ACC 
TAG ACC TGA AGA GTA CAG TCG 
TTT TGA AGC 
PDZ3 Rev 
Used to generate Dlg-1 
truncations in the PDZ 
domains, reverse primer 
CTT CAA AAC GAC TGT ACT CTT 
CAG GTC TAG GTT CCC TAG TGA 
TCT CAT CAT CTC CA 
PDZ 1,2 For 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
TAC TGA TGC AGA TTA TGA ATA 
TGA GAC AAG TAT GTA TAT AAA 
TGA TGG CTA TGC ACC 
PDZ 1,2 Rev 
Used to generate Dlg-1 
truncations in the PDZ 
domains, reverse primer 
AGC CAT CAT TTA TAT ACA TAC 
TTG TCT CAT ATT CAT AAT CTG 
CAT CAG TAC CAT TAA CAT AAG 
T 
PDZ23 For 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
GAA GCC AGC CTC AGA AAA AAT 
CAT GAC AAG TAT GTA TAT AAA 
TGA TGG CTA TGC ACC 
PDZ 2,3 Rev 
Used to generate Dlg-1 
truncations in the PDZ 
domains, reverse primer 
AGC CAT CAT TTA TAT ACA TAC 
TTG TCA TGA TTT TTT CTG AGG 
CTG GCT TCC 
PDZ 2,3 For 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
TGA TGA GAT CAC TAG GGA ACC 
TAG ACC TGA AGA GTA CAG TCG 
TTT TGA AGC 
PDZ2,3 Rev 
Used to generate Dlg-1 
truncations in the PDZ 
domains, reverse primer 
CTT CAA AAC GAC TGT ACT CTT 
CAG GTC TAG GTT CCC TAG TGA 
TCT CAT CAT CTC CA 
PDZ 1,3 For 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
TAC TGA TGC AGA TTA TGA ATA 
TGA GAG GCG GAA GCC AGC C 
PDZ1,3 Rev 
Used to generate Dlg-1 
truncations in the PDZ 
domains, reverse primer 
TTT TTT CTG AGG CTG GCT TCC 
GCC TCT CAT ATT CAT AAT CTG 
CAT CAG TAC CAT TAA CAT AAG 
T 
PDZ-1 For 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
TGA TGA GAT CAC TAG GGA ACC 
TAG ACC TGA AGA GTA CAG TCG 
TTT TGA AGC 
PDZ13 Rev 
Used to generate Dlg-1 
truncations in the PDZ 
domains, reverse primer 
CTT CAA AAC GAC TGT ACT CTT 
CAG GTC TAG GTT CCC TAG TGA 
TCT CAT CAT CTC CA 
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PDZ1,2,3 For 
Used to generate Dlg-1 
truncations in the PDZ 
domains, forward primer 
TAC TGA TGC AGA TTA TGA ATA 
TGA GCC TGA AGA GTA CAG TCG 
TTT TGA A 
PDZ1,2,3 Rev 
Used to generate Dlg-1 
truncations in the PDZ 
domains, reverse primer 
CTT CAA AAC GAC TGT ACT CTT 
CAG GCT CAT ATT CAT AAT CTG 
CAT CAG TAC CAT TAA CAT AAG 
T 
Dlg-4 For 
Used to generate Dlg4 
from rat cDNA template, 
forward primer 
CCG CCG GAA TTC ATG GAC TGT 
CTC TGT ATA GTG ACA ACC 
 
Dlg-4 V5 Rev 
Used to generate Dlg4 
from rat cDNA template, 
reverse primer 
CCC CCC AAG CTT TTA CGT AGA 
ATC GAG ACC GAG GAG AGG 
GTT AGG GAT AGG CTT ACC GCT 
GCC GCC GCC GAG TCT CTC 
TCG GGC TGG GAC CC 
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Table 12. Phosphorylated oligonucleotides. 





Last 15 AA of 
TASK-1 C-
terminus 
CGAT GGC GGC GGC GGC TCG GGC GGC 
GGC GGC TCT CAC AGT TTA TCG ACA TTT 
CGA GGT CTC ATG AAG CGA AGA AGC TCA 





Last 15 AA of 
TASK-1 C-
terminus 
TCGAG TTA CAC TGA GCT TCT TCG CTT 
CAT GAG ACC TCG AAA TGT CGA TAA ACT 
GTG AGA GCC GCC GCC GCC CGA GCC 









CGAT GGC GGC GGC GGC TCG GGC GGC 
GGC GGC TCT CAC AGT TTA TCG ACA TTT 
CGA GGT CTC ATG AAG CGA AGA GCC TCA 








TCGAG TTA CAC TGA GGC TCT TCG CTT 
CAT GAG ACC TCG AAA TGT CGA TAA ACT 
GTG AGA GCC GCC GCC GCC CGA GCC 








CGAT GGC GGC GGC GGC TCG GGC GGC 
GGC GGC TCT CAC AGT TTA TCG ACA TTT 
CGA GGT CTC ATG AAG CGA AGA AGC GCA 








TCGAG TTA CAC TGC GCT TCT TCG CTT 
CAT GAG ACC TCG AAA TGT CGA TAA ACT 
GTG AGA GCC GCC GCC GCC CGA GCC 










CGAT GGC GGC GGC GGC TCG GGC GGC 
GGC GGC TCT CAC AGT TTA TCG ACA TTT 
CGA GGT CTC ATG AAG CGA AGA GCC GCA 










TCGAG TTA CAC TGC GGC TCT TCG CTT 
CAT GAG ACC TCG AAA TGT CGA TAA ACT 
GTG AGA GCC GCC GCC GCC CGA GCC 
GCC GCC GCC AT 





Last 15 AA of 
TASK-1 C-
terminus, include 
deletion of V394 
CGAT GGC GGC GGC GGC TCG GGC GGC 
GGC GGC TCT CAC AGT TTA TCG ACA TTT 





Last 15 AA of 
TASK-1 C-
terminus, include 
deletion of V394 
TCGAG TTA TGA GCT TCT TCG CTT CAT 
GAG ACC TCG AAA TGT CGA TAA ACT GTG 





Last 15 AA of 
TASK-3 C-
terminus 
CGA TGG CGG CGG CGG CTC GGG CGG 
CGG CGG CTC TAG CTT TAC CGA CCA CCA 





Last 15 AA of 
TASK-3 C-
terminus 
TCG AGT TAA ACG GAC TTC CGG CGT TTC 
ATC AGC CTC TGG TGG TCG GTA AAG CTA 
GAG CCG CCG CCG CCC GAG CCG CCG 








CGAT GGC GGC GGC GGC TCG GGC GGC 
GGC GGC TCT AGC TTT ACC GAC CAC CAG 









TCGAG TTA AAC GGC CTT CCG GCG TTT 
CAT CAG CCT CTG GTG GTC GGT AAA GCT 
AGA GCC GCC GCC GCC CGA GCC GCC 




Last 15 AA of 
TASK-3 C-
terminus, include 
deletion of V374 
CGAT GGC GGC GGC GGC TCG GGC GGC 
GGC GGC TCT AGC TTT ACC GAC CAC CAG 





Last 15 AA of 
TASK-3 C-
terminus, include 
deletion of V374 
TCGAG TTA GGA CTT CCG GCG TTT CAT 
CAG CCT CTG GTG GTC GGT AAA GCT AGA 
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Table 13. Antibodies used in chapter IV. 
Name Supplier Cat. No. Dilution Technique Clonality 




1:5000 WB polyclonal 
MAGUK pan NeuroMab 75-029 1:100 WB monoclonal 
Na/K ATPase 
alpha 
Santa Cruz Sc-21712 1:1000 WB monoclonal 
Dlg1 (SAP97) Abcam Ab3437 1:1000 WB polyclonal 
Dlg2 (PSD93) Abcam Ab2930 1:1000 WB polyclonal 






N100 1:5000 WB - 
TASK-1 - - 1:500 WB polyclonal 
pTASK-1 - - 1:500 WB polyclonal 
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4.3 Results  
4.3.1 Identification of novel cardiac interaction partners of the TASK-3 C-terminus 
The K2P channel TASK-3 exhibits a background leak current of K+ ions in neurons and 
other electrically excitable tissues as cardiomyocytes. Surface expression of TASK 
channels is tightly regulated by 14-3-3 and COPI interaction (Zuzarte et al., 2009). 
Phosphorylation of the S373 residue in the extreme C-terminus of TASK-3 allows high 
affinity binding of 14-3-3 proteins, which promotes forward trafficking of the channel to the 
cell surface. However, COPI binds to the unphosphorylated C-terminus of TASK-3 which 
leads to the retrieval of the channel to early compartments of the secretory pathway (Kilisch 
et al., 2016). For the TASK-1 channel additional interaction partners and regulators were 
identified which are not interacting with TASK-3 (e.g. p11, syntaxin 8) (Kilisch et al., 2015). 
This indicates differences in TASK-1 and TASK-3 channel regulation. 
I set out to further investigate the role of TASK-3 in the heart by analyzing the cardiac 
phosphorylation-dependent interactome of the TASK-3 trafficking control region, located 
in the extreme C-terminus.  
 
4.3.1.1 Recombinant expression of TASK-3 fusion proteins  
In order to identify novel interaction partners for TASK-3, pull-down experiments with the 
phosphorylated or unphosphorylated distal C-terminus of TASK-3 were performed with 
total rat heart lysate and analysed by mass spectrometry (MS). Therefore, TASK-3 fusion 
proteins were designed using the last 15 aa from the C-terminus fused to a GST-tag (Table 
14). In order to avoid steric impediment, a long linker separating GST and the TASK-3 
peptide was added. This linker is based on the MST27 protein, which has a high affinity to 
COPI (Sandmann et al., 2003), and will help to identify novel cardiac interaction partners 
beside 14-3-3 and COPI. To study the effect of phosphorylation of the TASK-3 C-terminus 
on potential novel interaction partners a phospho-dead mutant (S373A) was created as 
well (Table 14).  
 
Table 14. Sequence of recombinant TASK-3 fusion proteins used to identify novel interaction 
partners.  
The last 15 AA of TASK-3 were fused with a GST-tag and a MST27 linker. The ER-retrieval 
sequence (COPI binding site) is highlighted in blue. The phosphorylatable serine residue (part of 
mode II 14-3-3 binding motif) is shown in red and a serine to alanine mutation is depicted in green.  
Peptide name Detailed C-terminal sequence 
TASK-3 WT GST-MST27-CSFTDHQRLMKRRKSV-COOH 
TASK-3 S373A GST-MST27-CSFTDHQRLMKRRKAV-COOH 
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Recombinant GST-MST27-TASK-3 protein variants were expressed and affinity purified 
from E. coli and analysed by Coomassie stained SDS-PAGE gels. The purified TASK-3 
proteins migrated at the expected size of approximated 38 kDa. Lower molecular weight 
(MW) bands were attributed to degradation products of the GST-MST27-fusion protein 
(Figure 31A). After purification, the TASK-3 C-terminal protein variants were recombinantly 
phosphorylated with the catalytic subunit of PKA and analysed on Coomassie stained 
Phos-tag-PAGE. A shift was visible for the PKA phosphorylated TASK-3 WT protein after 
treatment with PKA and energy mix (EM) indicating phosphorylation (Figure 31B). The 
Phos-tag-acrylamide compound and MnCl2 incorporated into the gel mixture during 
casting, caused the retardation of phosphorylated protein on the gel by forming a complex 
with phosphate groups. Thus, I was able to distinguish between phosphorylated and 
unphosphorylated proteins. The migration of the TASK-3 S373A mutant was not altered 
upon incubation with the kinase, indicating that this protein was not phosphorylated by 
PKA (Figure 31B). Furthermore, the MST27-linker introduced into the TASK-3 fusion 
construct did not alter the ability to be phosphorylated. 
This experiment confirmed, that the S373 residue in TASK-3 can be recombinantly 
phosphorylated by PKA (Kilisch et al., 2016) and allowed further experimentation. The 
C-terminal TASK-3 constructs were employed in pull-down experiments with cardiac 
tissue.  
 
Figure 31. Recombinant purification and in-vitro phosphorylation of TASK-3 proteins.  
(A) Different GST-MST27-TASK-3 mutant proteins were purified to address the different possible 
phosphorylation states of the TASK-3 C-termini. The proteins migrated at the expected size of 
38 kDa, lower molecular weight species were attributed to degradation products of the GST-MST27-
fusion protein. (B) Recombinant phosphorylation of TASK-3 protein variants with PKA. 
Phosphorylation was analysed on Phos-tag-PAGE and indicated by a shift. For each TASK-3 
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4.3.1.2 Phosphorylation dependent enrichment of novel interaction partners 
of the TASK-3 C-terminus 
The purified and phosphorylated TASK-3 protein variants were incubated with total rat 
heart lysate to identify novel cardiac interaction partners. In order to avoid masking of the 
TASK-3 C-terminus endogenous 14-3-3 and COPI proteins were blocked or removed from 
the heart lysate prior the start of the experiment. Endogenous 14-3-3 proteins were blocked 
with the R18 peptide, a high affinity inhibitor of all 14-3-3 protein isoforms which binds very 
efficiently the 14-3-3 binding groove (Petosa et al., 1998). Endogenous COPI protein was 
removed by passing the rat heart lysate over beads containing GST-MST27-KKXX. The 
MST27 linker in combination with the KKXX motif represents a high-affinity COPI binding 
motif. This experimental set up allowed to enrich other interactors binding the TASK-3 C-
terminus, even those with lower affinity than 14-3-3 and the COPI vesicular coat. After the 
pull-down experiment the TASK-3 bait proteins were eluted and analysed on Coomassie 
stained Phos-tag-PAGE (Figure 32A) to monitor the phosphorylation state of the 
recombinant proteins since it could have been altered by kinases or phosphatases present 
in the lysate. The elutions were further analysed on SDS-PAGE (Figure 32B), to confirm 
that similar amounts of bait proteins were used for each experiment. Gels were stained 
with Coomassie solution and weaker appearing protein bands migrating above 55 kDa 
were considered as potential interaction partners, which could be enriched from total rat 
heart lysate (Figure 32B). To increase the resolution of the weak bands identified in 
Figure 32, the elution samples were resolved on a big SDS-PAGE gel followed by silver 
staining (Figure 32C). Silver staining has a 100 fold higher sensitivity then Coomassie 
staining (Chevallet et al., 2006). The silver-stained gel showed differential protein patterns 
depending on the phosphorylation state of TASK-3 (Figure 32C, marked with asterisks). 
The different enriched cardiac proteins identified with the TASK-3 mutant proteins were 
analysed using LC-MS/MS in collaboration with Dr. Christoph Lenz from the MS core 
facility (UMG Göttingen).  
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Figure 32. Novel cardiac TASK-3 interaction partners were enriched dependent on its 
phosphorylation state. 
(A) The phosphorylation state of eluted TASK-3 C-terminal bait proteins were analysed on 
Coomassie stained Phos-tag-PAGE. (B) Eluted samples of the TASK-3 pull-down with rat heart 
lysate were analysed on Coomassie stained SDS-PAGE. (C) Elution of affinity purification of 
TASK-3 constructs after incubation with heart lysate were analysed on silver-stained SDS-PAGE. 
Protein bands, which seemed to change upon in-vitro phosphorylation of the bait proteins are 
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The LC-MS/MS analysis identified new cardiac interaction partners which were enriched 
with the C-terminus of TASK-3 in a phosphorylation dependent manner. The obtained MS 
analysis was quantified by calculating and plotting the log2-fold changes of ratios of TASK 
WT +/- phosphorylation and the TASK-3 S373A mutant +/- phosphorylation. Proteins 
which were enriched over the cut-off of each measurement (defined as 2, where  is the 
standard abbreviation over all values) were assumed to be significantly enriched and 
highlighted in orange (Figure 33). I was especially interested in proteins which were 
specifically enriched to the TASK-3 C-terminus dependent on its phosphorylation status, 
because these proteins will be most likely involved in trafficking and regulation of TASK-3. 
Already known TASK-3 interaction partners like different 14-3-3 proteins were identified 
with phosphorylated TASK-3 WT C-terminus (Figure 33A; highlighted in pink). Among the 
main hits the Na/K ATPase alpha 1 subunit, several isoforms of the adaptor protein AP-2 
and dynamin were identified (Figure 33A, highlighted in blue). All mentioned proteins were 
specifically enriched with the phosphorylated TASK-3 C-terminus and absent in the 
analysis of the TASK-3 phospho-dead mutant S373A (Figure 33B). The enrichment of 
known TASK-3 interaction partners serves as a positive control for the experiment. It 
should be mentioned that different 14-3-3 isoforms were identified in the MS analysis 
although endogenous 14-3-3 was blocked with the R18 peptide. This is likely the result of 
pre-existent interactions that I was unable to block by the use of the inhibitor peptide R18. 
This fact most may indicate that 14-3-3 was involved in protein-protein interactions with 
the enriched novel cardiac protein interactors of TASK-3.  
 
 
Figure 33. Na/K ATPase and endocytic regulatory proteins were identified as novel TASK-3 
interaction partners in cardiac lysate. 
Dot plots analysing the MS results of affinity purification experiments with rat heart lysate and 
TASK-3 protein variants. The log2-fold changes of ratios of (A) TASK-3 WT +/- phosphorylation 
(phos) and (B) TASK-3 S373A +/- phosphorylation were calculated. Proteins which were enriched 
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over the cut-off of each measurement, defined as 2, where  is the standard abbreviation over all 
values, were assumed to be significantly enriched and highlighted in orange. Identified 14-3-3 
proteins are highlighted in pink. The enriched Na/K ATPase and endocytic regulatory proteins are 
highlighted in blue.  
 
4.3.1.3 Analysis of a co-endocytosis of Na/K ATPase with TASK-3 via biotin 
labelling of surface proteins in rat hearts using Langendorff perfusion 
The Na/K ATPase was identified for the phosphorylated TASK-3 C-terminus from cardiac 
tissue by MS analysis. In addition, proteins which are involved in endocytosis processes 
were identified for the phosphorylated TASK-3 C-terminus as well as different 14-3-3 
isoforms (Figure 33). Efendiev et al., published that 14-3-3 is important to recruit 
phosphoinositide 3-kinase to the Na/K ATPase during clathrin-dependent endocytosis 
(Efendiev et al., 2005). This prompted the idea, that 14-3-3 dimers may bring 
phosphorylated TASK-3 and the Na/K ATPase in close proximity for a potential co-
endocytosis mediated by AP-1 and dynamin. To further investigate this hypothesis, I 
performed an affinity purification experiment from rat heart lysate in a similar fashion to the 
one for subjected to MS. The affinity purification experiment was performed without 14-3-3 
inhibition followed by incubation of phosphorylated TASK-3 protein variants and Western 
blotting analysis with 14-3-3 and Na/K ATPase antibodies (Figure 34). 14-3-3 was strongly 
enriched with the phosphorylated TASK-3 WT protein but not with the unphosphorylated 
controls (Figure 34). However, no Na/K ATPase was detected with any of the TASK-3 
mutant proteins (Figure 34). Altogether, I was unable to confirm an interaction between the 
phosphorylated TASK-3 C-terminus and Na/K ATPase by Western blot. This indicates that 
the binding affinity between TASK-3 and Na/K ATPase is below the affinity of Western blot 
quantification and shows that MS analysis has a much higher sensitivity than Western 
blotting (Bass et al., 2017). 
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Figure 34. Western blot detection of the Na/K ATPase in samples obtained by TASK-3 pull-
down experiments with heart lysate. 
Analysis of affinity purification of TASK-3 protein variants with rat heart lysate and no R18 inhibitor 
treatment. The interaction between TASK-3 and 14-3-3 as well as with the Na/K ATPase were 
analysed (lower panel) by Western blot. 
 
Verification of a potential Na/K ATPase interaction with TASK-3 was not possible with pull-
down experiment followed by Western blot analysis. To further investigate the hypothesis 
of a potential co-endocytosis between TASK-3 and the Na/K-ATPase, the endocytosis rate 
of the Na/K ATPase was stimulated in rats. Therefore, whole rat hearts were stimulated 
with the putative endocytosis enhancing drug ouabain. Ouabain is a cardiac glycoside, 
which inhibits the Na/K-ATPase pump and was proposed to induce endocytosis in the 
heart (Liu, 2005). Internalization of endocytosed surface proteins was monitored by 
subsequent surface biotinylation of the hearts. The described treatment was performed in 
the context of Langendorff perfusion experiments. Rat hearts were perfused with different 
concentrations of ouabain followed by biotinylation with non-cell-permeable biotin to label 
proteins which are exposed at the cell surface (Figure 35A). Biotin-perfusion was 
performed at 4°C to stop intracellular trafficking during the labelling. Rat hearts were used 
since the TASK-3 Na/K ATPase interaction was identified in rat. However, the Na/K 
ATPase has a reduced sensitivity towards ouabain in rats (Cherniavsky-Lev et al., 2014). 
To ensure, that ouabain induces endocytosis in rat hearts a low dose of 100 nM and a high 
dose of 50 µM were used. To control the experiment and monitor background biotinylation 
the hearts were perfused in 4 different groups: (1) No ouabain and no biotin treatment 
during perfusion, (2) no ouabain but biotin treatment, (3) 100 nM ouabain and biotin 
treatment and (4) 50 µM ouabain and biotin treatment.  
After the heart treatment using Langendorff perfusion, membranes and cytosol were 
fractionated and analysed for the amount of biotinylated proteins by Western blotting with 
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ouabain and biotin, no enrichment of biotinylated proteins was visible for membranes or 
cytosol (Figure 35B). Biotinylated proteins were detected in membranes from heart 
samples which were perfused with biotin, but no differences were visible due to ouabain 
treatment (Figure 35B).  
Surprisingly, biotinylated proteins were also enriched from the cytosol fraction, even 
though the amount of enriched proteins was reduced in comparison with the membrane 
fractions analysed (Figure 35B).  
 
Figure 35. Enrichment of biotinylated proteins from rat hearts treated with ouabain.  
(A) Rat hearts were treated in a Langendorff perfusion with ouabain (100 nM or 50 µM) followed by 
surface biotinylation with non-membrane permeable Sulfo-NHS-LC-biotin at 4°C. (B) Membranes 
or cytosol separated from the Langendorff perfused hearts were analysed for the enrichment of 











(100 nM or 50 µM)
Biotin (4°C)






--- +50 µM ouabain








































Chapter IV: Identification of novel interaction partners for TASK channels in the heart 
 163 
Biotinylated proteins were enriched from the cytosolic fraction of hearts which were treated 
with biotin and ouabain (Figure 36). To exclude cross-contamination of the sample during 
the subcellular fractionation, cytosolic and membrane protein markers were analysed by 
Western blot using GAPDH and Na/K ATPase antibodies respectively. The cytosolic 
protein GAPDH was only detected in cytosol samples whereas Na/K ATPase was only 
detected in the membrane fraction samples (Figure 36). This indicates that the separated 
fractions of membrane or cytosol were clean, but it does not exclude that small amounts 
of biotin were introduced into the cytosol during sample preparation. 
 
Figure 36. Probing for different marker proteins in ouabain treated heart membrane and 
cytosol.  
The purity of the separated membrane or cytosolic fraction was confirmed by Western blotting and 
the detection of the cytosolic marker protein GAPDH (upper panel) or the membrane protein Na/K 
ATPase (lower panel). 
 
4.3.1.4 Enrichment of Na/K ATPase and 14-3-3 in biotinylated heart 
membranes 
I was able to show that membrane proteins expressed at the cell surface can be visualized 
with biotin surface labeling. Next, I wanted to analyse the behavior of biotinylated Na/K 
ATPase with or without ouabain induced endocytosis. Therefore, enriched biotinylated 
proteins from the membrane fraction were probed for the amount of Na/K ATPase under 
different ouabain concentrations. Ouabain has been shown to initiate Na/K ATPase 
endocytosis (Cherniavsky-Lev et al., 2014) and therefore ouabain-treated heart 
membranes should show less biotinylated Na/K ATPase after enrichment with neutravidin 
pull-downs. In the elution of the neutravidin pull-down, no biotinylated proteins were 
detected in the control sample which was not treated with biotin or ouabain. Biotinylated 
Na/K ATPase was enriched in all samples perfused with biotin, but no systematic 
difference was detectable compared to the control sample and the samples that were 
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visible among the different ouabain concentrations (Figure 37A,B). Altogether, the 
enrichment of proteins which are expressed at the cell surface from complete rat hearts 
was possible with the help of neutravidin enrichment, but no significant difference was 
visible for the amounts of Na/K ATPase present at the cell surface after ouabain treatment. 
 
 
Figure 37. Biotinylated Na/K ATPase protein was enriched in biotinylated heart membranes.  
(A) Na/K ATPase protein levels in perfused heart samples treated with different concentrations of 
ouabain and biotin were analysed. Biotinylated proteins were purified with neutravidin resin and 
analysed by Western blot with a Na/K-ATPase antibody. (B) Quantification of experiment shown in 
(A) using values of the Na/K ATPase intensity normalized to the sample perfused with biotin but 
without ouabain. The data of three independent experiments are presented as mean ± SEM. An 
unpaired t-test showed significant differences between control versus biotin (***p=0.0003), but not 
between biotin versus ouabain treated samples. 
 
Ouabain treatment did not influence the surface expression of Na/K ATPase in 
membranes. A potential co-endocytosis of the Na/K- ATPase with TASK-3 may require 
14-3-3 which clamps the proteins in close proximity. To further investigate the role of 
14-3-3, enriched biotinylated membrane proteins from neutravidin affinity experiments of 
the ouabain treated hearts were analysed regarding the presence of 14-3-3 proteins by 
Western blot. In the input samples used for the neutravidin enrichment experiment no 
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were detected (Figure 38). These 14-3-3 proteins were bound to biotinylated membrane 
proteins. In line, no 14-3-3 was detected in the control sample which was not treated with 
biotin (Figure 38). The amount of 14-3-3 proteins detected from biotinylated membranes 
did not vary between hearts treated with different doses of ouabain (Figure 38). 
 
Figure 38. 14-3-3 was enriched in biotinylated heart membranes.  
(A) Analysis of 14-3-3 protein levels in heart membranes treated with different concentrations of 
ouabain. Biotinylated proteins from perfused rat hearts were purified with neutravidin and analysed 
with Western blot and a 14-3-3 antibody. (B) Quantification of experiment shown in (A) using values 
of the 14-3-3 intensity normalized to the sample just perfused with biotin but without ouabain. The 
data of three independent experiments are presented as mean ± SEM. An unpaired t-test showed 
significant differences between control versus biotin (*p=0.0122), but not between biotin and 
ouabain treated samples. 
 
4.3.1.5 Enrichment of glycosylated Na/K ATPase in rat heart membranes 
Glycosylation is one of various post-translational modifications to ensure correct trafficking 
of proteins within the cell. Glycosylated proteins are transported to the plasma membrane 
(Bas et al., 2011). For presenting the membrane proteins to the extracellular matrix 
glycosylation is required as well (Hart, 1992). In addition, it was reported that glycosylation 
protects proteins from degradation resulting in a reduced rate of endocytosis (Altschuler et 
al., 2000; Russell et al., 2009). Ouabain treatment showed no influence on the amount of 
Na/K ATPase present in the plasma membrane or the amounts of 14-3-3 interacting with 
cell surface proteins. Another method to test whether ouabain influences the amount of 
cell-surface expressed membrane proteins is the analysis of glycosylated proteins. In order 
to test the effect of ouabain on Na/K ATPase endocytosis I analysed the glycosylation 
status of the Na/K ATPase with wheat germ agglutinin (WGA) enrichment experiments. 
WGA resin efficiently binds glycosylated proteins (Goldstein et al., 1997). Therefore, WGA 
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analysed with Coomassie stained SDS-PAGE (Figure 39). For heart membranes the 
amount of glycosylated proteins in the elution is reduced in comparison with the input or 
flow-through fraction. Moreover, slightly less glycosylated proteins were eluted after WGA 
affinity enrichment from the ouabain treated membrane samples. But no difference 
between low and high ouabain concentrations were observed.  
 
Figure 39. Glycosylated proteins were enriched from rat heart membranes.  
Affinity enrichment of glycosylated proteins from ouabain treated cardiac membranes with WGA 
resin. Enrichment of glycosylated proteins was analysed on Coomassie stained SDS-PAGE. Inputs, 
flow throughs and elutions of the purification were analysed. 
 
The analysis of the amount of glycosylated proteins in ouabain treated heart samples 
showed slightly less glycosylated proteins enriched from heart membranes after ouabain 
treatment. This result indicates that less membrane proteins are exposed to the 
extracellular matrix after ouabain treatment and may allow the conclusion that the 
endocytosis rate was increased in these samples. However, this effect should be also 
visible for the Na/K ATPase. Therefore, the samples were probed for specific amounts of 
glycosylated Na/K ATPase by Western blot with a Na/K ATPase antibody (Figure 40A). 
Input samples from solubilized membranes for the different ouabain and biotin treatments 
were compared with flow throughs and elutions after WGA affinity purification (Figure 40A). 
Glycosylated Na/K ATPase was massively enriched with the WGA affinity purification 
(Figure 40A). No statistical differences for Na/K ATPase protein levels were detected for 
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Altogether, the Na/K ATPase pump was strongly enriched in membranes after WGA 
enrichment purification, indicating that – as expected – Na/K ATPase is a major cardiac 
membrane glycoprotein, but no differences were detected for the ouabain treatment. 
 
Figure 40. The Na/K ATPase was glycosylated in ouabain treated and control heart 
membranes. 
(A) Glycosylated proteins were affinity purified with WGA, the elution was analysed by Western 
blotting with a Na/K ATPase antibody. Different levels of ouabain and different time points of the 
affinity purification were compared. (B) Quantification of experiment shown in (A) using values of 
the Na/K ATPase intensity normalized to the control sample which was not perfused with biotin or 
ouabain. The data of three independent experiments are presented as mean ± SEM. An unpaired 
t-test showed no significant differences between the samples. 
 
4.3.1.6 Na/K ATPase and many other membrane proteins were biotinylated 
and glycosylated at the same time in rat hearts 
To test the hypothesis of a 14-3-3 mediated co-endocytosis of the Na/K ATPase and 
TASK-3, I treated hearts with biotin, or biotin and ouabain to stimulate endocytosis. 
Consequently, the effect of ouabain treatment on exposed membrane proteins in the heart 
was analysed. Therefore, the amount of biotinylated and glycosylated Na/K ATPase was 
analysed with different affinity enrichment purifications. Neither the amount of biotinylated 
nor of glycosylated Na/K ATPase was altered due to ouabain treatment. Both methods 
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However, to further understand trafficking of the Na/K ATPase after ouabain treatment, I 
compared how many glycosylated proteins are also biotinylated at the same time. Elutions 
of the two different affinity purifications were analysed for the amount of biotinylated 
proteins with fluorophore-conjugated streptavidin by Western blotting (Figure 41). Indeed, 
many glycosylated proteins were identified in the elution of the WGA affinity enrichment, 
indicating that a lot of glycosylated proteins were also biotinylated at the same time (Figure 
41). 
 
Figure 41. Glycosylated membrane proteins were also biotinylated in ouabain treated and 
control heart membranes.  
Glycosylated proteins were affinity purified from ouabain treated heart membranes with WGA pull-
downs (PD), biotinylated proteins were affinity enriched from the glycosylated protein fraction with 
neutravidin. The amount of enriched biotinylated proteins from both affinity enrichment experiments 
was analyzed by Western blotting with Alexa Fluor 680 conjugated streptavidin.  
 
Subsequently, I analysed the amount of glycosylated and biotinylated Na/K ATPase or 
14-3-3 proteins dependent on ouabain treatment. Therefore, biotinylated or glycosylated 
proteins enriched from heart membranes after ouabain treatment were analysed by 
Western blot. I probed for the Na/K ATPase and also assessed the 14-3-3 protein levels 
using a 14-3-3 antibody (Figure 42A). This experiment demonstrated that much more Na/K 
ATPase was glycosylated than biotinylated (Figure 42A,B). The reduced amount of 
biotinylated Na/K ATPase indicate that in general a large pool of Na/K ATPase was not 
exposed to the extracellular matrix during perfusion experiments performed with rat hearts. 
Overall, ouabain treatment did not have a significant effect on surface expressed and 
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14-3-3 proteins were present in the elutions from biotinylated enriched samples and 
reduced from glycosylated samples (Figure 42A). This result shows that 14-3 3 proteins 
were interacting with membrane proteins exposed at the cell surface, but reduced 
interaction with glycosylated membrane proteins was detected (Figure 42C). Indeed, there 
is a membrane bound fraction of 14-3-3 present, explaining why 14-3-3 was enriched in 
the MS analysis of the pull-down experiment performed with rat heart membranes.  
 
Figure 42. Comparison of biotinylated and glycosylated Na/K ATPase and 14-3-3 proteins 
enriched from ouabain treated hearts.  
(A) Biotinylated proteins were affinity purified from ouabain treated cardiac membranes with 
neutravidin pull-downs (PD) meanwhile glycosylated proteins were enriched with WGA resin. 
Samples were analyzed by Western blot and detected for Na/K ATPase and 14-3-3 pan antibodies. 
(B) Na/K ATPase protein levels enriched with neutravidin or WGA pull-down experiments were 
normalized to the biotin control sample from neutravidin PD. The data of three independent 
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between biotin control from the neutravidin PD and the samples enriched from WGA PD (*p=0.0109 
or 0.0372, **p=0.0019 or 0.0060). (C) 14-3-3 protein levels enriched with neutravidin or WGA pull-
down experiments were normalized to the biotin control sample from neutravidin PD. The data of 
three independent experiments are presented as mean ± SEM. An unpaired t-test showed no 
significant differences between biotin control sample from neutravidin PD and the samples enriched 
from WGA PD. 
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4.3.2 Identification of novel cardiac interaction partners of the TASK-1 C-terminus 
After I analysed the interactome of heart proteins which interact with the extreme C-
terminus of TASK-3, I was also interested in potential novel cardiac interaction partners for 
the TASK-1 C-terminus. In comparison with TASK-3, the TASK-1 C-terminus has two PKA 
phosphorylatable serine residues (S392 and S393) in the trafficking control region. It is 
already known that 14-3-3 binds the phosphorylated S393 with high binding affinities in the 
micromolar range (Kilisch et al., 2016). The two different serine residues in the trafficking 
control of TASK1, which are absent in TASK-3, indicate that trafficking of TASK-1 is 
regulated in a more complex manner (Kilisch et al., 2016). To further understand the 
function of both serine residues in TASK-1 and identify novel interaction partners which 
are involved in TASK-1 trafficking and regulation pull-down experiments with rat heart 
tissue were performed and analysed by MS. 
 
4.3.2.1 Recombinant expression of TASK-1 fusion proteins  
To analyse the potential cardiac interactome depend on the phosphorylation status of 
TASK-1, recombinant proteins were designed and cloned in a similar manner as already 
described for TASK-3. The last 15 aa of the TASK-1 C-termini were fused to a GST-tag 
and a MST27-linker. In order to investigate the role of TASK-1 C-terminus phosphorylation 
state regulating the binding of interaction partners, I used serine phospho-dead mutants 
for the single serine residues and the combination of both (Table 15). 
 
Table 15. Sequence of recombinant purified TASK-1 proteins used to identify new cardiac 
interaction partners. 
The last 15 AA of TASK-1 were fused with a GST-tag and a MST27 linker. The ER-retrieval 
sequence is highlighted in blue. The phosphorylatable serine residues are shown in red and the 
serine to alanine mutations are depicted in green.  
 
The first step for the analysis of novel cardiac interaction partners for TASK-1 was the 
recombinant overexpression and purification of TASK-1 mutants, which addresses 
different possible phosphorylation states of TASK-1 from E. coli. The recombinant purified 
TASK-1 proteins were analysed on Coomassie stained SDS-PAGE (Figure 43A). The 
Peptide name Amino acid sequence 
TASK- 1 WT GST-MST27-CSLSTFRGLMKRRSSV-COOH 
TASK- 1 S392A GST-MST27-CSLSTFRGLMKRRASV-COOH 
TASK- 1 S393A GST-MST27-CSLSTFRGLMKRRSAV-COOH 
TASK- 1 S392A/S393A GST-MST27-CSLSTFRGLMKRRAAV-COOH 
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GST-MST27-TASK-1 mutants have a size of approximated 38 kDa, which was confirmed 
on a SDS-PAGE (Figure 43A). The bands below likely reflect degradation products of the 
MST27 linker or the GST-tag. For the identification of novel cardiac interaction partners 
the different phosphorylation states of the TASK-1 C-terminus were considered to be 
important. Therefore, the purified TASK-1 mutant proteins were recombinant 
phosphorylated with PKA in presence of an ATP regeneration system. Phosphorylation 
was confirmed on Coomassie stained Phos-tag-PAGE. All purified TASK-1 constructs 
were compared in its unphosphorylated or phosphorylated state. The TASK-1 WT protein 
has two potential PKA phosphorylation sites (S392 and S393). After phosphorylation, two 
slower-migrating bands were visible on a Phos-tag-PAGE, which indicates that both 
residues were phosphorylated (Figure 43B). TASK-1 S392A and S393A mutants just 
showed one slower-migrating band on the gel (Figure 43B), indicating single 
phosphorylation. As expected, no phosphorylation was detected in the case of double 
phospho-dead mutant TASK-1 S392A/S393A (Figure 43B). Altogether, this experiment 
confirms that the TASK-1 WT can be in-vitro phosphorylated by PKA on both serine 
residues S392 and S393 simultaneously but also individually. 
This experiment confirmed, that both serine residues in TASK-1 can be recombinantly 
phosphorylated by PKA (Kilisch et al., 2016) and allowed further experimentation.  
 
Figure 43. TASK-1 protein is phosphorylatable by PKA at S392 and S393 residues at the 
same time and individually in-vitro. 
(A) Different GST-MST27-TASK-1 mutant proteins were purified to address the different possible 
phosphorylation states of the TASK-1 C-terminus. All proteins were purified from E.coli and 
confirmed on Coomassie stained SDS-PAGE. (B). Recombinant TASK-1 constructs were 
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4.3.2.2 Phosphorylation dependent enrichment of novel cardiac interaction 
partners of the TASK-1 C-terminus 
With affinity purification experiments from cardiac tissue novel interaction partners for 
TASK-1 were identified. During the analysis of the affinity purification experiments with the 
TASK-3 C-terminus (section 4.3.1), I realized that separation of rat heart membranes and 
cytosol will be an additional control to exclude unspecific interaction. Moreover, I expected 
to gain more information about trafficking processes in cardiac membranes or cytosol. 
First, I separated membranes and cytosol and analyzed them by Western blot, detecting 
for GAPDH and Na/K ATPase antibodies (Figure 44A). Na/K ATPase protein levels were 
detected in the membrane fraction but absent in the cytosol (Figure 44A) and GAPDH 
protein levels were detected in the cytosol but just very low levels in the membrane fraction 
(Figure 44A).  
The already performed affinity purification experiments with TASK-3 showed that the 
TASK-3 bait proteins masks proteins with a molecular mass between 26-40 kDa size in a 
SDS-PAGE analysis. High-salt elution (NaCl) elution is another possibility to elute the bait 
proteins after a pull-down experiment. NaCl just elutes enriched proteins bound to the 
GST-bait protein without eluting the bait protein itself from the affinity resin. First, L-
Gluthathione elution was compared with 1 M NaCl elution (Figure 44B) on silver-stained 
SDS-PAGE. Recombinant purified TASK-1 WT C-terminal proteins were used as bait 
protein and incubated with rat heart membranes or cytosol which were again pre-cleared 
from native 14-3-3 and COPI. GST and a GST-MST27 control proteins were included to 
distinguish unspecific interactions (Figure 44B). The NaCl elution was cleaner, allowed the 
analysis of novel interaction partners which have similar sizes than the bait protein already 
on a SDS-PAGE (Figure 44B). Moreover, different bands were identified on the silver gel 
dependent on the phosphorylation state of the TASK-1 bait protein (Figure 44B, marked 
with asterisks), indicating novel cardiac interaction partners enriched with the 
phosphorylated TASK-1 C-terminus. Based on this optimization, I decided to use NaCl 
elution for the TASK-1 pull-down experiment with rat heart membranes and cytosol. 
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Figure 44. Compared L-glutathione and high salt elution of TASK-1 pull-downs with 
separated heart membranes and cytosol. 
(A)The purity of the separated membrane or cytosolic fraction was confirmed by Western blotting 
and the detection of the cytosolic marker protein GAPDH or the membrane marker Na/K ATPase. 
(B) Comparison of L-Gluthathione and NaCl elution after a pull-down experiment with GST-MST27-
TASK-1 WT unphosphorylated or phosphorylated and rat heart cytosol or membranes. GST or 
GST-MST27 (MST27) constructs were used as negative controls. Elutions were analysed on a 
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The purified and phosphorylated TASK-1 C-terminal fusion proteins (GST-MST27-TASK-1 
WT,- S392A,- S393A,- S392/S393A) were used for the TASK-1 pull-down experiment with 
cardiac tissue optimized as indicated. In order to avoid masking of the TASK-1 C-terminus 
endogenous 14-3-3 and COPI were removed from the separated heart cytosol and 
membranes. The elution of the TASK-1 pull-down experiments was analysed on Phos-tag 
SDS-PAGE to confirm the phosphorylation states of the TASK-1 bait proteins after the pull-
down from membranes (Figure 45A) and cytosol (Figure 45B). Therefore, the bait proteins 
were eluted with L-Glutathione after NaCl elution and analysed on SDS-PAGE. In both 
affinity purification experiments the TASK-1 WT protein was phosphorylated at both serine 
residues, meanwhile the single serine to alanine mutant proteins were single 
phosphorylated and the double serine to alanine mutant was not phosphorylated at all 
(Figure 45 A,B). Phosphorylation states were also confirmed with Western blotting with a 
TASK-1 antibody (Figure 45 A,B ) and phospho-specific TASK-1 antibody (Figure 45 A,B).  
 
Figure 45. Analysis of phosphorylation state GST-MST27-TASK-1 protein variants after the 
affinity purification experiment with membranes or cytosol.  
The phosphorylation state of eluted TASK-1 C-terminal bait proteins were analysed after a pull-
down experiment from membranes (A) or cytosol (B) on Coomassie stained Phos-tag-PAGE. 
Phosphorylation is indicated as a shift on the Phos-tag-PAGE (highest panel) and was confirmed 
by Western blot and detection with an antibody which binds TASK-1 (middle panel) or the 
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After confirmation of the phosphorylation status of the TASK-1 bait proteins the elutions 
obtained from the TASK-1 pull-down experiment were analysed on a silver-stained SDS-
PAGE (Figure 46). I focused on those bands that were differentially present depending on 
the phosphorylation state of TASK-1 C-terminus (Figure 46, marked with asterisks). These 
differential bands indicate enrichment of cardiac proteins due to the phosphorylation state 
of the TASK-1 C-terminus. The eluted samples were subjected to LC-MS/MS analysis 
which was performed in collaboration with Dr. Christoph Lenz (UMG Göttingen).  
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Figure 46. Affinity purification with recombinant phosphorylated GST-MST27-TASK-1 
proteins and solubilized rat heart membranes or cytosol. 
Elutions of TASK-1 pull-down samples were analyzed on big SDS-PAGE prior to be sent for MS 
analysis. GST and GST-MST27 proteins were used as controls to monitor background binding. 
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The LC-MS/MS analysis revealed new cardiac interaction partners which bind to the C-
terminal trafficking control region of TASK-1 depending on its phosphorylation state. The 
MS analysis was quantified by calculation and plotting the log2 fold changes of ratios of 
TASK-1 WT-/+ phosphorylation, TASK-1 S392A-/+ phosphorylation, TASK-1 S393A-/+ 
phosphorylation and TASK-1 S392A/S393A-/+ phosphorylation. Proteins which were 
enriched over the cut-off of each measurement (defined as 2, where  is the standard 
abbreviation over all values) were assumed to be significantly enriched and highlighted in 
orange (Figure 47 A-D). The protein with the highest log2-fold change identified in the MS 
analysis was disk large homolog 1 (Dg1, Figure 47A). Dlg1 belongs to the PDZ domain 
containing protein family. Beside Dlg1, more PDZ domain containing proteins were 
identified such as disk large homolog 4 (Dlg4) or membrane-associated guanylate kinase, 
WW and PDZ domain-containing protein 3 (Magi-3). All PDZ domain containing proteins 
are depicted in red (Figure 47A-D). Interestingly, the PDZ domain proteins were exclusively 
enriched with the unphosphorylated TASK-1 WT protein (Figure 47A) from cardiac 
membranes. However, none of the PDZ domain containing proteins were identified with 
the TASK-1 phospho-dead mutants regardless of their phosphorylation state (Figure 47A-
D). Furthermore, no PDZ domain containing protein was enriched with different TASK-1 
mutants from rat heart cytosol (Figure 48). 
Moreover, already known interaction partners like different 14-3-3 isoforms were enriched 
exclusively with phosphorylated TASK-1 C-terminus in both affinity purification 
experiments as well and highlighted in pink (Figure 47, 48), although the cardiac 
membrane and cytosol were treated with an inhibitor beforehand. Kilisch et al reported that 
phosphorylation of both serine residues in parallel abolish 14-3-3 interaction. In line with 
this notion, none of the 14-3-3 isoforms were enriched in the PKA phosphorylated TASK-1 
S392A/S393A mutant (Figure 47D).  
Interestingly, several different PDZ domain containing proteins were exclusively enriched 
in the affinity purification experiment with rat heart membranes with the unphosphorylated 
TASK-1 C-terminus. Among them just Dlg1 and Magi-3 were enriched over the cut-off.  
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Figure 47. PDZ domain containing proteins were identified as novel TASK-1 interaction 
partners in cardiac membranes.  
Dot plots analysing the MS results of affinity purification experiments with rat heart membranes and 
TASK-1 C-terminal protein variants. The log2-fold changes of ratios of (A) TASK-1 WT +/- 
phosphorylation (phos), (B) TASK-1 S392A +/- phosphorylation, (C) TASK-1 S393A +/-
phosphorylation, (D) TASK-1 S392A/S393A +/- phosphorylation were calculated. The cut-off of 
each measurement was calculated corresponding to 2, where  is the standard abbreviation over 
all values. Proteins which were enriched over the cut-off are highlighted in orange. Identified PDZ 
domain containing proteins are labelled in red and 14-3-3 isoforms in pink.  
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Figure 48. PDZ domain containing proteins were absent as TASK-1 interaction partners in 
cardiac cytosol.  
Dot plots analysing the MS results of affinity purification experiments with rat heart cytosol and 
TASK-1 C-terminal protein variants. The log2-fold changes of ratios of (A) TASK-1 WT +/- 
phosphorylation (phos), (B) TASK-1 S392A +/- phosphorylation, (C) TASK-1 S393A +/-
phosphorylation, (D) TASK-1 S392A/S393A +/- phosphorylation were calculated and plotted. The 
cut-off of each measurement was calculated corresponding to 2, where  is the standard 
abbreviation over all values. Proteins which were enriched over the cut-off are highlighted in orange. 
Identified 14-3-3 isoforms are labelled in pink, COPI is depicted in purple.  
 
4.3.2.3 PDZ domain containing proteins were identified as novel TASK-1 
interaction partners in the heart by MS analysis 
The analysis of the cardiac interactome of TASK-1 revealed PDZ domain containing 
proteins as the most prominent novel interaction partners. Interestingly, the last four amino 
acids of TASK-1 C-terminus contain a conserved PDZ-binding motif (X-S/T-X-V/I), which 
is absent in TASK-3 (Rajan, et al., 2002). This implicates that the unphosphorylated S392 
A
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is required for the PDZ protein interaction. In line, Dlg1 binding was abolished with the 
TASK-1 S392A protein in the MS approach (Figure 47B). However, also no PDZ domain 
protein was identified with the TASK-1 S393A protein (Figure 47C), although the PDZ 
binding site is intact in this TASK-1 mutant. To confirm the interaction of PDZ domain 
containing proteins in the predicted PDZ-binding motif of TASK-1 and to clarify the issue 
with the TASK-1 S393A protein the MS approach was repeated. Therefore, TASK-1 mutant 
proteins addressing the predicted PDZ binding motif were used. This includes the V394 
residue in TASK-1, which is also predicted to be required for PDZ protein interaction 
according to the PDZ-binding motif in TASK-1 (Rajan et al., 2002). Consequently, the C-
terminal TASK-1 dV394 protein was included as another control and a GST-MST27-
TASK-1 dV394 protein was recombinantly purified (Figure 49A) and phosphorylated with 
PKA (Figure 49B) as already shown for the other TASK proteins used in this study. 
 
Figure 49. Purification of TASK-1 dV394 protein variant. 
(A) The recombinant C-terminal GST-MST27-TASK-1 dV394 protein was used as an additional 
control. The purified GST-MST27-TASK-1 dV394 protein has an expected size of 38 kDa on a SDS-
PAGE. (B) Phosphorylation with PKA was confirmed on a Coomassie stained Phos-tag-PAGE.  
 
For the repetition of the MS approach C-terminal TASK-1 WT, single phospho-dead 
TASK-1 S393A, double phospho-dead TASK-1 S392A/S393A and TASK-1 dV394 were 
incubated in rat heart membranes. The membranes were again pre-cleared from native 
14-3-3 and COPI coat. Elutions were analysed on Coomassie stained Phos-tag-PAGE to 
confirm the right phosphorylation status of the different TASK-1 mutant proteins after the 
affinity purification experiment (Figure 50A). Besides, the eluted samples were analysed 
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samples were sent for LC-MS/MS analysis which was performed in collaboration with Dr. 
Christoph Lenz (UMG Göttingen).  
 
Figure 50. Analysis of affinity purification with TASK-1 proteins and rat heart membranes.  
(A) Phosphorylation status of TASK-1 bait mutant proteins after the affinity purification experiment 
was confirmed on Coomassie stained Phos-tag-PAGE. (B) Analysis of potential interaction partners 
after a TASK-1 affinity purification experiment with heart membranes. A specified set of C-terminal 
mutants was used to confirm interactions with PDZ domain containing proteins. 
 
The biological replicate of the affinity purification experiment of different C-terminal TASK-1 
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the MS analysis (Figure 51A-D). Especially, Dlg1 and Dlg4 were again significantly 
enriched. All PDZ domain proteins were enriched with the unphosphorylated TASK-1 WT 
protein and the S393A mutant variant (Figure 51A,B). As expected, the serine 392A/393A 
TASK-1 and as well as the TASK-1 dV394 mutant proteins disrupted the putative PDZ-
binding motif in the TASK-1 C-terminus and no PDZ protein was identified with one of 
these two mutant variants in the MS analysis (Figure 51A-D).  
Altogether, PDZ domain proteins were identified as the most promising novel TASK-1 
interaction partners in two independent MS analysis. The set of TASK-1 mutant proteins 
confirmed the suggested putative PDZ-binding motif X-S/T-X-V/I in the extreme C-
terminus of TASK-1 and showed that the S392 is relevant for the interaction. 
 
Figure 51. PDZ domain containing proteins were identified as TASK-1 interaction partners in 
cardiac membranes. 
Dot plot analysis of MS results after affinity purification of rat heart membranes with GST-MST27-
TASK-1 constructs. The log2-fold changes of ratios of (A) TASK-1 WT +/- phosphorylation (phos), 
(B) TASK-1 S393A +/- phosphorylation, (C) TASK-1 S392A/S393A +/- phosphorylation, (D) TASK-1 
dV394 +/- phosphorylation were calculated. The cut-off of each measurement was calculated 
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enriched over the cut-off are highlighted in orange. Identified 14-3-3 isoforms are highlighted in pink 
and PDZ domain containing proteins are depicted in red. 
 
Several different MS analyses of the extreme C-terminus of the TASK-1 or TASK-3 
channel were performed with either heart membranes, cytosol or total lysate and 
summarized in table 16. Already known binding partners like several 14-3-3 isoforms as 
well COPI were identified and serve as positive controls. Interestingly, the Na/K ATPase 
protein was identified in the TASK-1 and TASK-3 MS analysis, although the enrichment in 
the TASK-1 PD was reduced. The same was true for the endocytosis adaptor proteins like 
dynamin. However, PDZ domain proteins were specifically enriched in the TASK-1 affinity 
purification experiment with heart membranes. Unlike TASK-1, TASK-3 was unable to 
enrich PDZ domain proteins since it lacks a PDZ-binding motif. 
 
Table 16. Summary MS analysis performed with TASK-1 and TASK-3 C-termini constructs in 
affinity purification experiments carried out with cardiac tissue. 










14-3-3 epsilon ✓  ✓  (✓) 
14-3-3 eta ✓  ✓  ✓ 
14-3-3 zeta/delta ✓  ✓  ✓ 
14-3-3 beta/alpha ✓  ✓  ✓ 
14-3-3 theta ✓ ✓   
14-3-3 gamma ✓  ✓ (✓) 
COPI (✓) ✓  
 Na/K ATPase alpha (✓)   ✓ 
Involved in 
endocytosis 
AP-2 complex   ✓ 




Disk large homolog 1 ✓    
Disk large homolog 4 ✓   
Membrane associated guanylate 
kinase protein-3 







(at limit of significance) 
 not detected 
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4.3.2.4 PDZ domain containing proteins Dlg1 and Dlg4 are direct interaction 
partners of the unphosphorylated TASK-1 channel 
Intriguingly, I could identify several PDZ domain containing proteins as novel interaction 
partners of the TASK-1 C-terminus. This confirms a previously hypothesized but never 
demonstrated interaction of TASK-1 with PDZ domain containing proteins (Rajan et al., 
2002). To confirm the identified hits from the MS analysis binding assays using 
recombinant purified proteins were performed. From the several identified PDZ domain 
containing proteins, I focused on the top hits Dlg1 and Dlg4. The remaining PDZ domain 
containing proteins present in the list of hits were hardly expressed in hearts or the size 
was too big for an optimal recombinant expression in vitro (i.e. Magi-3). Full length MBP-
Dlg1 and MBP-Dlg4 were recombinant expressed, purified and confirmed on Coomassie 
stained SDS-PAGE (Figure 52). 
 
Figure 52. Recombinant purification of the PDZ domain containing proteins MBP-Dlg1 and 
MBP-Dlg4.  
Both proteins were expressed in E. coli and affinity purified. Results were analyzed on Coomassie 
stained SDS-PAGE. 
 
The binding assay allowed confirmation of the novel interaction between PDZ domain 
containing proteins and TASK-1 and allows simultaneously characterization of the binding 
site in TASK-1. Purified MBP-tagged PDZ proteins were used for binding experiments with 
recombinant purified GST-tagged TASK-1 C-terminus mutants either phosphorylated or 
unphosphorylated. TASK-1 WT and TASK-1 S393A proteins are both proteins containing 
an intact PDZ binding motif. Besides, TASK-1 S392A/S393A, TASK-1 dV394 and TASK-3 
proteins were used as negative controls because in these mutants the PDZ-binding motif 
in TASK-1 is disrupted. The C-terminal TASK bait proteins were recombinant 
phosphorylated, immobilized to an affinity resin and offered to equimolar amounts of MBP-
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stained SDS-PAGE gels. Along the same line as the MS results, both MBP-Dlg1 and MBP-
Dlg4 interact with unphosphorylated TASK-1 WT protein and unphosphorylated TASK-1 
S393A protein (Figure 53, 54). Phosphorylation disrupts the interaction in both cases 
(Figure 53, 54). The double mutation of both phosphorylatable serine residues in the 
TASK-1 C-terminus (S392A/S393A) disrupts the interaction with Dlg1 and Dlg4 (Figure 53, 
54), indicating that the unphosphorylated serine 392 in TASK-1 is important for the 
interaction. Besides, neither Dlg1 nor Dlg4 interact with TASK-1 dV394 or TASK-3 
independent of the phosphorylation status (Figure 53, 54). The binding was confirmed by 
Western blot and detection with anti-Dlg1 and anti-Dlg4 antibodies (Figure 53, 54). 
Phosphorylation of C-terminal GST-TASK-1 and GST-TASK-3 proteins was probed by 
Coomassie stained Phos-tag SDS-PAGE (Figure 53, 54).  
Altogether, Dlg1 and Dlg4 were confirmed as novel and direct interaction partners of the 
TASK-1 channel with MS analysis and reconstitution experiments using recombinant 
proteins. It was also shown that the interaction is phosphorylation independent and that 
the S392 and V394 in the TASK-1 C-terminus are required for the interaction. These 
findings confirm the predicted PDZ interacting motif in the extreme TASK-1 C-terminus as 
a functionally relevant motif and indicate a novel function for the S292 as the target site for 
regulating the interaction with the PDZ domain. 
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Figure 53. Dlg1 binds in-vitro to the unphosphorylated TASK-1 C-terminus. 
(A) Recombinant purified MBP-Dlg1 binds to the unphosphorylated TASK-1 WT and S393A protein 
variants. Phosphorylation disrupted the interaction (upper panel). Binding was confirmed by 
Western blotting with a Dlg1 antibody (middle panel). The phosphorylation state of the bait protein 
was analyzed on Phos-tag-PAGE (lower panel). (B) Quantification of Dlg1 binding to different 
unphosphorylated TASK-1 and TASK-3 protein variants. Dlg1 protein levels were normalized to the 
TASK-3 WT control sample. The data of three independent experiments is presented as mean ± 
SEM. A one-way ANOVA analysis showed significant differences between the groups presented in 
(B) (p=<0.0001), followed by a Tukey test revealing significant differences between T1 WT versus 
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Figure 54. Dlg4 binds in-vitro to the unphosphorylated TASK-1 C-terminus. 
(A) Recombinant purified MBP-Dlg4 binds to the unphosphorylated TASK-1 WT and S393A protein 
variants. Phosphorylation disrupted the interaction (upper panel). Binding was confirmed by 
Western blotting with a Dlg4 antibody (middle panel). The phosphorylation state of the bait protein 
was analyzed on Phos-tag-PAGE (lower panel). (B) Quantification of experiment shown in (A). Dlg4 
protein levels binding to the different TASK proteins were normalized to the TASK-3 WT control 
sample. The data of three independent experiments is presented as mean ± SEM. A one-way 
ANOVA analysis showed significant differences between the groups presented in (B) (p=<0.0001), 
followed by a Tukey test revealing significant differences between T1 WT versus T3 WT 
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I could demonstrate that Dlg1 and Dlg4, enriched in binding experiments, bind directly to 
PDZ binding motif in the TASK-1 C-terminus. Dlg1 and Dlg4 belong to membrane-
associated guanylate kinase homologs family (MAGUK) and contain three PDZ domains, 
a Src-homology 3 (SH3) domain and a guanylate kinase-like domain which is enzymatically 
inactive (McGee et al., 2001). Dlg1 is strongly expressed in the heart and involved in the 
regulation and trafficking of several cardiac ion channels (Gillet et al., 2015a). 
Consequently, I decided to characterize the binding of Dlg1 to the distal C-terminus of 
TASK-1 potassium channel in detail. It was already shown, that Dlg1 interacts via its PDZ 
domains with other potassium ion channels (El-Haou et al., 2009; Kim et al., 1995). Here, 
I analysed which of the three PDZ domains in Dlg1 are required for the Dlg-1/TASK-1 
interaction. In addition to a MBP-tagged full-length Dlg1 fusion protein construct, different 
truncation constructs covering all possible combinations of the three PDZ domain ablations 
were designed (Figure 55A), recombinantly expressed and affinity purified from E. coli 
(Figure 55B).  
 
Figure 55. Design and expression of recombinant Dlg1 PDZ truncation proteins to identify 
the TASK-1 interaction site in Dlg1. 
(A) MBP-Dlg1 full-length protein and several MBP-tagged Dlg1 PDZ truncation proteins were 
designed to cover all possible combinations of the three PDZ domain ablations. (B) The 
recombinant proteins were expressed in E. coli and affinity purified. Purified MBP-Dlg1 PDZ 
truncation proteins were analyzed on a Coomassie stained SDS-PAGE. 
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Purified truncated Dlg1 proteins employed in binding assays with the unphosphorylated 
TASK-1 C-terminus. The TASK-1 C-terminal protein was immobilized and equimolar 
amounts of the different truncated MBP-Dlg-1 proteins were offered. The experiment was 
analysed by Western blot and probed for Dlg1 and MBP with corresponding antibodies. 
The Dlg1 antibody does not bind to the PDZ domains in Dlg1 but to confirm that the Dlg-1 
antibody is still able to bind the truncated versions of Dlg1 with similar affinities, an anti-
MBP antibody was used in parallel (Figure 56A). Equal loading of the TASK-1 protein was 
confirmed by detection with a GST antibody (Figure 56A) and equal input of PDZ-1 
truncation proteins offered in the binding assay was shown Coomassie stained SDS-PAGE 
(56C). 
The TASK-3 C-terminus was used as a negative control. Full-length MBP-Dlg1 with all 
three PDZ domains was used as a positive control. Recombinant MBP was incubated with 
immobilized GST-MST27-TASK-1 to exclude unspecific interactions between the tag of 
the Dlg1 or Dlg4 constructs and the TASK-1 construct. The truncation of PDZ domain 2, 
either alone or in combination with other PDZ domains, was enough to abolish the 
interaction with TASK-1 C-terminus (Figure 56A,B). The binding of TASK-1 remained 
unaltered, compared to full-length Dlg1, when other Dlg1 PDZ truncations were present. 
This experiment indicated that the PDZ domain 2 is the preferred TASK-1 binding site in 
Dlg1.  
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Figure 56. PDZ-2 domain of Dlg1 is preferentially bound by the TASK-1 C-terminus. 
(A) Recombinant binding assays were performed with immobilized TASK-1 or TASK-3 protein and 
Dlg1 PDZ truncation proteins. Dlg1 was used as a positive control, immobilized TASK-3 with Dlg1 
was a negative control. Binding assays were analysed by Western blotting with a Dlg1 (upper panel) 
and MBP (middle panel) antibody. Equal loading was confirmed with a GST antibody (lower panel). 
(B) Binding of the Dlg1 PDZ truncations proteins to TASK-1 was normalized to full-length Dlg1 
bound to TASK-1. The data of six independent experiments are presented as mean ± SEM. A one-
way ANOVA analysis showed significant differences between the groups presented in (B) 
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length Dlg1 versus T1 2 (**** p=<0.0001), or versus T1 1,2 (**** p=<0.0001), or versus 2,3 (**** 
p=<0.0001), or versus 1,2,3 (**** p=<0.0001), or versus T3 full length Dlg1 (**** p=<0.0001). (C) 
Equal offered inputs were confirmed on Coomassie stained SDS-PAGE.  
  
Chapter IV: Identification of novel interaction partners for TASK channels in the heart 
 193 
4.4 Discussion  
K2P channels are so called open-leak channels, meaning once expressed at the cell 
surface they contribute substantially to the leak current of K+-ions measured in cells such 
as neurons, or cardiac myocytes (Renigunta et al., 2015). Therefore, trafficking and 
insertion of these channels into membranes require careful regulation. It is already well 
established, that trafficking of the TASK channels is regulated via phosphorylation 
dependent binding of 14-3-3 and COPI (Kilisch et al., 2016). To further understand the 
regulation and trafficking of TASK channels especially in the cardiovascular system, 
cardiac interaction partners for TASK-3 and TASK-1 were investigated in this chapter. 
 
4.4.1 TASK-3 and the Na/K ATPase are potentially co-endocytosed by clathrin-
mediated endocytosis 
Affinity purification experiments using recombinant TASK-3 proteins and heart lysate were 
performed and analysed by MS. The Na/K ATPase was identified as a potential interaction 
partner of TASK-3. Because phosphorylation is an important aspect of TASK trafficking 
the affinity purification experiments were performed with phosphorylated and 
unphosphorylated TASK-3 bait proteins. Interestingly, Na/K ATPase was exclusively 
enriched in samples obtained from PD experiments performed with phosphorylated GST-
MST27-TASK-3 fusion protein (Figure 33). This indicates specific interaction between the 
phosphorylated TASK-3 protein and Na/K ATPase but leaves open whether this is a direct 
or an indirect interaction. Besides Na/K ATPase, proteins involved in clathrin-mediated 
endocytosis (i.e. AP-2 or dynamin-1) were enriched with phosphorylated TASK-3 (Figure 
33). Interestingly, MS analysis revealed that also known TASK-3 binding partners, such as 
different 14-3-3 isoforms, were enriched, indicating either that inhibition of 14-3-3 did not 
completely prevent these proteins from binding or that the enriched proteins were already 
bound to later enriched TASK-3 interaction partners during the inhibitor treatment and 
therefore not addressable. The fact, that several 14-3-3 isoforms were significantly 
enriched in several independent pull-down experiments (Figure 33,47,51), suggests that 
the 14-3-3 proteins were tightly bound to interaction partners which were later purified in 
the pull-down experiments.  
Efendiev et al published in 2011, that Na/K ATPase is endocytosed together with 
phosphoinositide-3 kinase mediated by 14-3-3 after phosphorylation of Na/K ATPase. 
They could show that dopamine enhances the interaction between 14-3-3 and Na/K 
ATPase and that 14-3-3 recruits the phosphoinositide-3 kinase, followed by 
clathrin-mediated endocytosis of the complex (Efendiev et al., 2005). Taken together with 
the results from the MS analysis of TASK-3, I developed the hypothesis that 14-3-3 dimers 
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scaffold phosphorylated TASK-3 and phosphorylated Na/K ATPase which recruits the 
mediators of clathrin-based endocytosis like AP2 or dynamin (Figure 57). 
 
Figure 57. Model for a potential 14-3-3 mediated co-endocytosis of TASK-3 and Na/K ATPase.  
The phosphoadaptor-protein 14-3-3 binds the C-terminus of TASK-1 and the N-terminus of the Na/K 
ATPase and bring both proteins in close proximity for AP-1 and dynamin mediated co-endocytosis.  
 
Co-localization between TASK-3 and clathrin was identified, indicating that TASK-3 
endocytosis is regulated by clathrin-dependent endocytosis (Mant et al., 2013). In line with 
this notion, Mant et al showed with surface biotinylation assays in mammalian cells that 
TASK-3 is endocytosed via dynamin mediated endocytosis within 60 min (Mant et al., 
2013). Based on my MS results, I obtained further confirmation that clathrin-mediated 
endocytosis is responsible for TASK-3 endocytosis. AP-2 and dynamin were enriched with 
the phosphorylated TASK-3 C-terminus. For the TASK-1 channel it was already shown 
that phosphorylation plays a role during endocytosis. It was found that PKC 
phosphorylation of TASK-1 recruits 14-3-3 which initiates endocytosis (Gabriel et al., 
2012). Also Efendiev et al showed that endocytosis of the Na/K ATPase is initiated upon 
phosphorylation and 14-3-3 interaction (Efendiev et al., 2005). Therefore, it is plausible 
that a potential co-endocytosis of TASK-3 and Na/K ATPase is regulated by 
phosphorylation and 14-3-3.  
However, I was unable to confirm the presumably indirect interaction via 14-3-3 proteins 
between phosphorylated TASK-3 and Na/K ATPase by Western blot of the pull-down 
experiment (Figure 34). A possible explanation could be that MS analysis has a higher 
sensitivity then Western blot detection (Bass et al., 2017). It is possible that the interaction 
between TASK-3 and Na/K ATPase requires mediators or is regulated in the context of a 
bigger protein complex. Therefore, the potential co-endocytosis of TASK-3 and Na/K 
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ATPase was analysed in rat hearts that were treated with ouabain (Figure 35). Ouabain 
induces Na/K ATPase endocytosis which was monitored by surface glycosylation in 
hearts. Affinity enrichment assays for biotinylated proteins showed that the Na/K ATPase 
was expressed at the plasma membrane, but the amount of present Na/K ATPase 
remained unaltered upon ouabain treatment (Figure 37). This raises the question whether 
ouabain initiates Na/K ATPase endocytosis in rat hearts and if the concentrations 
suggested by one publication were sufficient (Cherniavsky-Lev et al., 2014). The Na/K 
ATPase is a receptor for cardiac glycosides such as ouabain. Almost all mammalian 
species are very sensitive for ouabain beside rats (Cherniavsky-Lev et al., 2014; Hansen, 
2003). The Na/K ATPase consist of a hydrolytic alpha-peptide responsible for the transport 
of Na+ and K+ ions and a small alpha-glycoprotein. Four different isoforms have been 
identified for the alpha-peptide. In rats the alpha-1 form of the Na/K ATPase has a very 
reduced sensitivity to ouabain (Hansen, 2003). However, cardiac rat tissue express a 
mixture of different Na/K ATPase alpha-isoforms, but the ratio between the insensitive 
alpha-1 isoforms and the sensitive isoforms is not well known (Hansen, 2003). Overall, 
with surface biotinylation I could not confirm the effect of ouabain on the Na/K ATPase 
internalization. Glycosylation is a post-translational modification involved in intracellular 
forward trafficking to the plasma membrane (Bas et al., 2011). With a WGA pull-down 
experiment, I could analyse the total amount of mature, glycosylated Na/K ATPase in the 
rat membranes (Figure 40). Consequently, the ratio between glycosylated and biotinylated 
Na/K ATPase can be compared, which allows to differentiate between the total amount of 
Na/K ATPase and the exposed Na/K ATPase pool (Figure 42). The Na/K ATPase was 
found to be strongly glycosylated in all heart samples but the amount of glycosylated 
proteins was not influenced by ouabain treatment (Figure 40,42).  
Overall, neither the surface pool nor the intracellular amount of the Na/K ATPase was 
altered upon ouabain treatment implying that no endocytosis of the Na/K ATPase was 
induced by ouabain. This indicates that not the right ouabain concertation was used to 
induce endocytosis in rat or that ouabain does not trigger endocytosis as proposed. A 
possibility would the repetition of the experiment with mice heart. Mice do not have the 
ouabain insensitive Na/K ATPase alpha1 isoform and therefore show a high sensitivity 
(Hansen, 2003).  
In addition to the analysis of the Na/K ATPase also 14-3-3 proteins, enriched from 
biotinylated membranes, were analysed (38,42). 14-3-3 proteins are located in the cytosol 
(Fu et al., 2000). The used biotin was non-cell permeable, suggesting that the enriched 
14-3-3 proteins were co-purified together with biotinylated cell surface exposed membrane 
proteins such as Na/K ATPase. This also explains why 14-3-3 proteins were enriched in 
the TASK-3 MS analysis.  
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However, MS analysis with TASK-1 also identified the Na/K ATPase as a novel TASK-1 
interaction partner, although with less efficiency (Figure 47). Likewise, phosphorylation of 
TASK-1 channel was required in order to interact with Na/K ATPase. Even though in the 
absence of biochemical confirmation, two independent MS analysis identified the Na/K 
ATPase as a binding partner for TASK channels. The lack of a commercially-available 
TASK-3 antibody makes the analysis of TASK-3-Na/K ATPase interaction difficult. To 
further investigate this interaction, in vitro binding assays with recombinant proteins could 
be an option. Besides, a tagged TASK-3 construct could be overexpressed in mammalian 
cells in order to overcome the lacking TASK-3 antibody. Subsequent immunostaining 
experiments would further provide information about co-localization TASK-3 and Na/K 
ATPase. Immunostaining experiments could be also performed after stimulation of 
endocytosis in mammalian cells to further investigate this aspect.  
 
4.4.2 PDZ domain containing proteins Dlg1 and Dlg4 are novel TASK-1 interaction 
partners in heart 
Further analysis of the MS data obtained from TASK-1 affinity enrichment experiments 
identified several PDZ domain containing proteins exclusively enriched with the distal, 
unphosphorylated C-terminus (Figure 47). Especially, Dlg1 and Dlg4 were identified as 
main hits. These proteins are known as important scaffolds, involved in variety cellular 
functions such as trafficking, ion channel regulation and signaling processes. In many 
cases PDZ domains were identified to bind short C-terminal motifs in their ligands (Espejo 
et al., 2017). Rajan et al reported in 2002, that the last five amino acids of the extreme C-
terminus constitute a PDZ-binding motif (X-S/T-X-V/I) which overlaps the already known 
COPI and 14-3-3 binding motifs and is absent in TASK-3 (Figure 58). Interestingly, the 
PDZ binding domain in TASK-1 requires the first serine residue (S392) in the trafficking 
control region of TASK1 (Figure 58). There was no PDZ domain containing protein 
identified as TASK-1 interactor in literature (Rajan et al., 2002; Mathie et al., 2010). My MS 
analysis of TASK-1 with heart membranes identified several PDZ domain containing 
proteins and all interacting with the unphosphorylated TASK-1 channel exclusively in 
cardiac membranes (Figure 47, 51). With binding assays with recombinant purified 
proteins, I confirmed direct interaction with Dlg1 and Dlg4 (Figure 53,54). Phosphorylation 
of S392 in TASK-1 disrupted the interaction between TASK-1 and PDZ domain containing 
proteins Dlg1 and Dlg4, indicating that this serine residue is required for the interaction 
and confirms the suggested PDZ motif. 
The sequence of the C-terminal PDZ domain binding motifs is divided into three main 
classes depending on the aa in the third last position of the motif. In case of the identified 
TASK-1 PDZ domain binding motif a serine residue is located in this position defining this 
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motif as a class 1 motif (Gogl et al., 2020). Consequently, the S392 residue in the TASK-1 
C-terminus is a target side for PDZ domain containing proteins. The S392 residue is 
located within the 14-3-3-binding site of TASK-1 (Figure 58). No competition will occur 
between 14-3-3 and PDZ domain proteins (Figure 58) because 14-3-3 binding requires 
phosphorylation meanwhile PDZ domain containing proteins bind to the unphosphorylated 
TASK-1 C-terminus. Phosphorylation of PDZ domain binding motifs have been identified 
to be common resulting in an abolished interaction between the PDZ domain containing 
proteins and the corresponding motif (Gogl et al., 2020). An overlapping 14-3-3/PDZ 
domain binding motif regulated as a “switch” by phosphorylation was already identified in 
other ion channels such as Kir2.1 (Espejo et al., 2017). However, the PDZ-binding motif in 
TASK-1 is also neighboring the COPI-binding site (KKR) (Figure 58). Curiously, PDZ 
domain containing proteins and COPI bind to the unphosphorylated TASK-1 trafficking 
control domain. Therefore, it could be hypothesized that COPI and PDZ domain containing 
proteins compete for binding to the TASK-1 C-terminus. Consequently, the binding of one 
of these two proteins will mask the binding site for the other one. This can be tested, with 
competition binding experiments with recombinant proteins and alternating ratios of the 
two binding partners offered to unphosphorylated TASK-1 protein. 
 
Figure 58. Overlapping 14-3-3, COPI and PDZ motifs in the C-terminus of TASK-1.  
The last 5 aa of TASK-1 and TASK-3 contain an overlapping 14-3-3 motif (orange) with an ER 
retention motif (pink). 14-3-3 binds upon phosphorylation to the serine residues depicted in red 
(S393 in TASK1, S373 in TASK-3). TASK-1 has an additional PDZ domain motif (light blue) 
localized within the last 5 aa of the C-terminus. This motif is absent in TASK-3. PDZ domain 
containing proteins bind to the unphosphorylated serine depicted in purple (S392). 
 
Chapter IV: Identification of novel interaction partners for TASK channels in the heart 
 198 
4.4.3 Potential functional consequences of the Dlg1/TASK-1 interaction 
From all identified PDZ domain containing proteins, Dlg1 is the most abundant in heart 
tissue (Godreau et al., 2002). Dlg1 has been reported to regulate assembly, trafficking and 
localization of several ion channels like Kv (1.5, 4.2, 4.3) or Kir (2.1, 2.2, 2.3, 4.1) 
(Leonoudakis et al., 2004; Gillet et al., 2015). In many cases Dlg1 regulates membrane ion 
channels as a scaffold by forming multi-protein complexes, bringing required interaction 
partners together or by anchoring them in a specific cellular localization (Fourie et al., 
2014). It was already shown that Dlg1 is involved in trafficking of Kv1 and other potassium 
channels from the ER to the Golgi (Walch, 2013). As a consequence, down-regulation of 
Dlg1 in ventricular cardiomyocytes reduces the inward rectifier potassium current 
(Vaidyanathan et al., 2010). Moreover, Dlg1 and different ion channels showed that both 
co-localize at the plasma membrane and the intercalated disc (Eichel et al., 2016). TASK-1 
is expressed in these two subcellular localizations as well. This allow to speculate whether, 
a potential in vivo interaction between TASK-1 and Dlg1 could regulate trafficking and 
stabilization TASK-1 at the membrane in a similar fashion as reported for other ion 
channels. In line, the interaction between TASK-1 C-terminus and Dlg1 was exclusively 
identified in affinity purification experiments from heat membranes and absent in the 
experiment performed in cytosol (Figure 47,48). It is well investigated that upon 
phosphorylation of the TASK-1 C-terminus 14-3-3 binding initiates forward trafficking by 
masking the COPI motif (Kilisch et al., 2016), but it is not investigated so far whether 14-3-3 
dissociates upon TASK-1 insertion in the plasma membrane. Based on the reported 
function of Dlg1 on other ion channels and the specific enrichment in cardiac membranes, 
it seems plausible that 14-3-3 dissociates upon TASK-1 insertion in the plasma membrane. 
This allows dephosphorylation of the TASK-1 C-terminus by cellular phosphatases and 
Dlg1 binding which anchor TASK-1 at the plasma membrane.  
Moreover, it is well established that Dlg1 directly interacts with the beta-adrenergic 
receptor and recruits the PKA-anchoring protein-79 (AKAP 79) which in turn recruits PKA. 
It has also been reported that the Dlg1/AKAP-79 complex targets PKA to the AMPA 
receptor and calcium sensitive channels (Walch, 2013). Demonstrating the essential role 
of Dlg1 in many cellular processes. So far it is not known which AKAP’s recruit PKA to the 
TASK channels. Interestingly, AKAP79 is also expressed in the heart (Diviani et al., 2011). 
No AKAP protein was identified in the MS analysis for TASK-1, but the recombinant 
proteins used for the MS analysis were already phosphorylated before incubation in the 
heart lysate and membranes and cytosol were separated for this experiment. Another 
speculation about a potential function of the Dlg1 TASK-1 interaction could be the 
recruitment of the required AKAP’s and PKA to the C-terminus of TASK-1. However, 
TASK-3 is missing the PDZ binding domain in the extreme C-terminus but is also 
Chapter IV: Identification of novel interaction partners for TASK channels in the heart 
 199 
phosphorylated by PKA and regulated by 14-3-3 and COPI. TASK-1 protein levels are 
more abundant in the heart than TASK-3 protein levels (Gurney & Manoury, 2009). 
Furthermore, TASK-1 and TASK-3 show specific regulatory characteristics, such as 
different affinities for 14-3-3 (Kilisch et al., 2016) or different interaction partners. Additional 
regulatory sites in the trafficking control domain of TASK-1 further indicate that TASK-1 
require an enhanced regulation. Besides, the formation of a TASK-1/TASK-3 heterodimer 
channel was found in cardiac tissue (Rinné et al., 2015).  
Furthermore, Dlg1 was found in a complex with clathrin and a subunit of AP-1 in endothelia 
cells (Philippe et al., 2013). In this study the complex of Dlg1 with clathrin and AP-1 was 
shown in the formation of Weibel bodies, which is a specific form to store the von 
Willebrand factor protein. In addition, Dlg1 has been reported to be involved in the 
regulation of 3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor endocytosis 
by identifying a complex of AMPA receptors, AP-2, Dlg1 and myosin-VI in neurons. It was 
found that Dlg1 recruits myosin-VI to endocytotic vesicles containing AMPA receptors 
resulting in clathrin-mediated endocytosis (Osterweil et al., 2005). The mentioned 
examples are the only hint of a relationship between Dlg1 and clathrin-dependent protein 
transport. Further research is required to test whether Dlg1 could be the missing link 
between TASK channels and the Na/K ATPase identified in the MS analysis. Such a 
hypothesis raises again the question how a potential co-endocytosis of Na/K ATPase and 
TASK-3 is regulated. The circumstance that the Na/K ATPase was identified in several MS 
analysis for TASK-1 and TASK-3 well speaks for an additional adaptor protein which is 
involved in this interaction and brings TASK channels and Na/K ATPase together. In 
addition to the function of a Dlg1 TASK-1 interaction, it is of course an interesting question 
whether TASK-1 can also interact with Dlg1 in neurons. This should be analysed by affinity 
purification experiments from brain lysate. Moreover, the idea that TASK-1 may form a 
potential complex between TASK-1, Dlg1, AKAP79 and PKA should be further analysed, 
for example with APEX labeling or complexome profiling from total heart lysate.  
 
Altogether, several novel cardiac interaction partners were identified for the C-terminus of 
TASK-1 and TASK-3. MS analysis revealed an alteration of the interaction with the Na/K 
ATPase depending on the phosphorylation state of the bait proteins involved. Identification 
of components of the endocytosis machinery indicated that TASK-1 and TASK-3 may be 
co-endocytosed together with other membrane proteins such the Na/K ATPase. I was not 
able to confirm a direct interaction between the TASK channels and the Na/K ATPase. 
Since either the Na/K ATPase or TASK-1 and TASK-3 bind 14-3-3 I hypothesize that 
14-3-3 or other adaptor proteins might influence the spatial organization of these proteins 
during endocytosis.  
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In addition, my binding experiments yielded strong evidence that the distal C-terminus of 
TASK-1 indeed contains a PDZ binding motif. I could show that this PDZ binding motif 
preferentially bind to PDZ domain two of Dlg1. These findings expand the knowledge of 
the TASK-1 /TASK-3 interactome in hearts, although many of these interactions require 
confirmation in vivo and further characterization regarding their physiological functions.  
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Data File S2-S5. All detected proteins in the MS approach using GST-MST27-TASK-3 or 
GST-MST27-TASK-1 and different preparations of total heart lysate and separated 
membranes and cytosol can be found under this link: 
https://owncloud.gwdg.de/index.php/s/v18RVghJqu0uE5w 
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5 Chapter V: Discussion 
This work identified the phospho-adaptor protein 14-3-3 as a novel interaction partner of 
the cardiac protein PLN, an inhibitor of the Ca2+ pump SERCA (Tada et al., 1975). A 
regulatory mechanism of PLN was uncovered where different kinases create different 
14-3-3 binding sites allowing a fine-tuned regulation of PLN. 14-3-3 binding to 
phosphorylated PLN resulted in protection from phosphatases and prolonged SERCA 
activity under physiological conditions.  
In addition, the cardiac interactome of TASK channels was analysed. 14-3-3 is also an 
interactor of TASK channels and responsible for the stable expression of the channels at 
the plasma membrane (Kilisch et al., 2016; Rajan et al., 2002). Here, I identified a direct 
interaction between TASK-1 and the PDZ domain containing protein Dlg1. 
Both novel interactions uncover new regulatory mechanisms and functions of PLN and the 
K+ ion channel TASK-1. 
 
5.1 14-3-3 is a novel interactor of the cardiac protein PLN 
PLN is a small tail-anchored protein containing a cytosolic domain, a small loop and a 
transmembrane domain (Ablorh & Thomas, 2015) (Figure 59). Interaction between PLN 
and SERCA, as well as the oligomerization of PLN pentamers, are regulated by different 
functional motifs present in the transmembrane domain of PLN (Ablorh & Thomas, 2015). 
The regulatory cytosolic domain of PLN includes a di-arginine signal (R13, R14) followed 
by two phosphorylatable residues (S16, T17) (Figure 59).  
Di-arginine based signals (xRRx) bind the vesicle coat complex COPI and in many cases 
also the phospho-adaptor protein 14-3-3 (Michelsen et al., 2005; Nufer & Hauri, 2003). 
Closer observation of the PLN N-terminus revealed a putative 14-3-3 binding motif 
overlapping with the di-arginine xRRx signal and the two phospho-residues (Arakel et al., 
2014; Figure 59). Consequently, the overlapping dibasic COPI interaction site with a 14-3-3 
binding motif in PLN was analysed for the possibility of 14-3-3 interaction.  
 
Figure 59. Schematic representation of the N-terminal domain of PLN.  
The cytosolic domain Ia contains a di-arginine motif (XRRX, highlighted in orange) and two 
phosphorylatable residues (depicted in green). The putative 14-3-3 binding motif is marked in red.  
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The putative 14-3-3 interaction site in PLN was analysed by pull-down experiments with 
recombinant 14-3-3 proteins and solubilized mice heart membranes. A strong enrichment 
of a protein migrating at 28 kDa on a SDS-PAGE gel was observed and identified to be 
pentameric PLN (chapter 2, figure 1E). This result was the first indicator that 14-3-3 and 
PLN physically interact with each other. Based on these findings, I further investigated 
whether 14-3-3 and PLN interact in-vitro and in-vivo. The 14-3-3 binding motif present in 
PLN includes the two phospho-residues S16 and T17 which are either phosphorylated by 
PKA or CaMKII kinases. In many cases, 14-3-3 binds to the phosphorylated residue 
present in the 14-3-3-binding motifs but not always (Fu et al., 2000). Further dissection of 
the 14-3-3 binding site in PLN showed that 14-3-3 is able to bind either phospho-residue 
(S16 and T17) present in PLN (chapter 2, figure 3). This confirmed that PLN includes a 
14-3-3 binding motif in the N-terminus, which is very similar to a mode II type 14-3-3 binding 
motif (RXY/FX(pS/pT)XP) and overlaps with a dibasic COPI retention signal (Figure 59).  
 
The potential COPI interaction site in PLN had been investigated (Sharma et al., 2010). 
The authors found that COPI and PLN co-localized in the ER and verified direct binding 
with different co-immunoprecipitation experiments (Sharma et al., 2010). These findings 
suggest that PLN is retrieved from the Golgi to the ER by COPI via the di-arginine motif in 
the N-terminus of PLN. However, Sharma et al did not discuss why a protein located in the 
sarcoplasmic reticulum, such as PLN, should traffic to the Golgi. Another study performed 
by Stenoien et al found that Golgi-mediated trafficking of PLN to the plasma membrane is 
important for muscle cell maturation (Stenoien et al., 2007). In contrast, it was reported 
that PLN is confined to the SR by retrieval from the ERGIC without any further trafficking 
of PLN in the cellular periphery (Butler et al., 2007). In line with the findings of a direct 
PLN/COPI interaction (Sharma et al., 2010), Butler et al suggested that retrieval of PLN 
from the ERGIC to the ER is mediated by COPI vesicular retrograde trafficking (Butler et 
al., 2007).  
I also investigated the localization of PLN by co-localization experiments staining 
mammalian cells transfected with different PLN mutants for ER localization and various 
subcellular markers. I observed that PLN is localized in the ER, but no robust co-
localization was identified with the early endosomal marker EEA1 or the late endosomal 
marker Rab7 (Figure 26-28). These findings suggest, that PLN is confined to the ER in 
mammalian cells and does not escape to other secretory compartments or the cell 
periphery as previously reported (Butler et al., 2007). Overall, the possibility of intracellular 
PLN trafficking has been barely investigated so far. The few studies, which analysed PLN 
trafficking and localization used different cellular model systems ranging from different 
mammalian cells over muscle cells until cardiomyocytes.  
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Several K+ ion channels such as KATP channels or the K2P channels TASK-1 and TASK-3 
also present di-arginine (xRRx) signals, often with overlapping 14-3-3 motifs, very similar 
to the ones identified in PLN (Figure 60 A,B). For TASK channels it was shown that 
phosphorylation dependent binding of 14-3-3 sterically masks COPI binding allowing 
anterograde trafficking and cell surface expression (Kilisch et al., 2016). Consequently, the 
presence of trafficking signals of COPI or 14-3-3 in PLN raises the questions if PLN traffic 
within the cell or whether these motives are involved in maintaining PLN in the ER as 
already suggested (Butler et al., 2007) or fulfill other physiological functions. Further 
research is required to investigate the raised questions, as well as the functional 
consequence of the COPI interaction.  
 
Figure 60. Schematic representation of di-arginine ER retention signal and 14-3-3 motif 
present in (A) TASK-1 channel and (B) PLN.  
The di-arginine motif is highlighted in orange, the putative 14-3-3 binding domain is shown in red 
and phospho-residues are depicted in green.  
 
5.2 14-3-3 binds to different binding motifs in PLN and TASK-1 
Even though, the overlapping di-arginine ER retention and 14-3-3 motives are quite similar 
in PLN and TASK-1 (Figure 60A,B), there are differences in 14-3-3 binding. 
TASK-1 contains a mode III 14-3-3 binding motif which is characterized by the localization 
at the distal C-terminus and by the position of the phosphorylated residue as a penultimate 
residue (Coblitz the al. 2005). Analysis of the 14-3-3 motif in the C-terminus of TASK 
showed that 14-3-3 is able to recognize and bind the S393 residue upon phosphorylation 
(Kilisch et al., 2016). 14-3-3 binding requires an arginine residue in position -3 or -4 relative 
to the phospho-residue to stabilize the phospho-peptide in the 14-3-3 binding groove by 
hydrogen bonds and intramolecular salt bridges (Gouw et al., 2018, Rittinger et al., 1999). 
The two phospho-residues in TASK-1 are located adjacent to the arginine residues (Figure 
61A). Consequently, the arginine residues are required in position -3 or -2 relative to the 
phosphorylated S393 residue to form a canonical mode III 14-3-3 binding site. The S392 
residue in TASK-1 cannot fulfill the requirement for a 14-3-3 phospho-residue due to the 
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position of the phosphorylated residue at position -3 from the distal C-terminus and the 
direct positioning of arginine residues.  
 
Like TASK-1, PLN contains two adjacent phospho-serine residues in the 14-3-3 motif in 
adjacent to the di-arginine motif (Figure 61B). The two phospho-residues in PLN are 
separated by one alanine residue from the di-arginine motif (Figure 61B). Consequently, 
the 14-3-3 binding site is shifted in PLN by one residue which allows a different positioning 
of the di-arginine motif in the 14-3-3 binding pocket and consequently both phospho-
residues create a 14-3-3 binding site (Figure 61B). Further analysis of both 14-3-3 
interaction sites in PLN showed different 14-3-3 binding affinities. Recombinant binding 
assays identified the phosphorylated S16 residue as a low affinity binding site and the 
phosphorylated T17 residue as a high affinity binding site (chapter 2, figure 3C,G,S4). 
Molecular dynamic simulations showed that 14-3-3 is able to bind PLN in two different 
manners depending on their phosphorylation and this results in different placements of the 
two arginine residues in the 14-3-3 binding groove (chapter 2, figure 4A,B). Furthermore, 
the polar side chain of the T17 residue adjacent to the phosphorylated S16 residue 
provides an energetically less favored placement of the peptide in the 14-3-3 binding 
groove (Figure 61B). 
 
Figure 61. Schematic representation of TASK-1 or PLN placed in the 14-3-3 binding groove.  
For the TASK-1 channel (A), the solely phosphorylated S393 residue binds the 14-3-3 binding 
groove. In PLN (B) either phospho-residue, S16 and T17, can bind to the 14-3-3 binding groove but 
different orientations of the phospho-peptide inside the 14-3-3 binding groove explain different 
binding affinities. The 14-3-3 binding motif in (A) TASK-1 and (B) PLN is highlighted in red, the 
14-3-3 binding groove is shown in purple.  
 
Altogether, molecular dynamic simulations showed that 14-3-3 binds both PLN phospho-
residues in the canonical binding groove consistent with a mode II binding motif, but does 
so with different affinities. However, different 14-3-3 binding affinities are not exclusively 
explained by the placement of the phospho-residues in the canonical binding motif. 
Although the canonical binding groove is highly conserved among the different 14-3-3 
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isoforms present in humans, many targets bind different isoforms with different affinities 
(Fu et al., 2000). This was also shown for TASK-1, where binding affinities of the seven 
different 14-3-3 isoforms were measured with SPR experiments and ranged about 7 fold 
(Kilisch et al., 2016).  
 
5.3 14-3-3 interaction with PLN depends on kinase interplay in cardiomyocytes 
PLN can be present in a monomeric or pentameric form in cardiomyocytes (Kimura et al., 
1997). 14-3-3 proteins are dimeric and hence beside affinity also avidity influences the 
apparent binding affinity resulting in a higher 14-3-3 affinity towards PLN oligomers 
(chapter 2, figure 3A,E). Functionally, the 14-3-3/PLN interaction was found to protect 
phosphorylated PLN from cellular phosphatases in recombinant dephosphorylation assays 
(chapter 2, figure 5,S7). Consistently, 14-3-3 prolonged SERCA activity in living 
cardiomyocytes upon beta-adrenergic stimulation (chapter 2, figure 7).  
Under basal conditions, as well as in stress situations, the balance between kinases and 
phosphatases determines the precise features of PLN and 14-3-3 regulation and 
consequently will influence SERCA regulation (Cerra & Imbrogno, 2012). 
 
The S16 residue of PLN is phosphorylated by PKA upon beta-adrenergic stimulation as 
previously shown (Coyler, 1998). Phosphorylation of S16 in PLN was found to be sufficient 
for maximal cardiac output (Vincent 2008; Chu et al., 2000). Exclusive S16 phosphorylation 
in PLN occurs either at baseline phosphorylation of PLN in resting organisms or under high 
beta-adrenergic stimulation with low Ca2+ concentrations (Wittmann et al., 2015).  
With recombinant binding assays I determined phosphorylated S16 in PLN as the low 
14-3-3 affinity site (chapter 2, figure 3C). However, PLN pentamers containing 
phosphorylated S16 residues bound to 14-3-3 from heart tissue indicating that beside 
affinity also avidity influences the apparent 14-3-3 binding affinity (chapter 2, figure 1G, 
3A). Based on these results, I conclude that 14-3-3 does not bind monomeric PLN 
phosphorylated at S16, but PLN pentamers phosphorylated at S16.  
Time course experiments showed that PKA phosphorylation of S16 happens within 30 sec, 
meanwhile CaMKII phosphorylation of T17 takes 1-3 min (Grimm & Brown, 2010). 
Consequently, the S16 phosphorylation site in PLN is regulated faster than T17 
phosphorylation. The cardiac contraction cycle occurs within seconds and the 
PLN/SERCA interaction exchanges every few seconds (Robia et al., 2007). However, 
14-3-3 binds the phosphorylated S16 residue in PLN and stabilizes the phosphorylated 
form by sterically protection from phosphatases (chapter 2, figure S7). Consequently, a 
monomeric PLN pool phosphorylated at S16, which cannot bind to 14-3-3, maintains the 
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PLN/SERCA interaction within the rapid cycle of the cardiac contraction and contributes to 
cardiac relaxation.  
 
On the other hand, CaMKII kinase phosphorylates the T17 residue in PLN (Coyler, 1998). 
Higher Ca2+ levels are required for CaMKII activation, therefore initial findings suggested 
that prior phosphorylation of S16 and beta-adrenergic stimulation are required for T17 
phosphorylation in PLN (Mattiazzi & Kranias, 2014). Mundiña-Weilenmann et al 
demonstrated that PLN can be phosphorylated by CaMKII at T17 without prior S16 
phosphorylation under high Ca2+ concentrations and simultaneously suppression of the 
phosphatase PP1 (Mundiña-Weilenmann et al., 1996). Based on these observations, it 
was suggested that PKA and CaMKII can phosphorylate PLN individually and 
independently from each other. Intriguingly, the conditions under which the authors 
showed an independent T17 PLN phosphorylation did not occur physiologically because 
PP1 is not suppressed without beta-adrenergic stimulation or high cAMP levels (Mundiña-
Weilenmann et al., 1996). Physiologically, such conditions are happening during frequency 
stimulation resulting in exclusive phosphorylation of T17 by CaMKII (Hagemann et al., 
2000, Valverde et al., 2005). CaMKII was found to translate Ca2+ spikes in kinase activity 
(De Konick et al., 1998), resulting in phosphorylation of T17 in PLN in the absence of beta-
adrenergic stimulation and the use of phosphatase inhibitors (Mattiazzi & Kranias 2014). 
I determined binding affinities for PLN phosphorylated at S16 and T17 and observed that 
T17 results in the generation of a high affinity 14-3-3 binding site, able to interact with 
monomeric and pentameric PLN (chapter 2, figure 3,G). Furthermore, I performed 
dephosphorylation assays and in line with the different 14-3-3 affinity sites in PLN, 14-3-3 
protected the phosphorylated T17 residue much longer from phosphatases than 14-3-3 
bound to phosphorylated S16 (chapter 2, figure 5,S7). Grimm and Brown previously 
described that CaMKII kinase activation and phosphorylation occurs slower compared to 
activation and phosphorylation of PKA (Grimm & Brown, 2010). This indicates that 14-3-3 
binding to phosphorylated T17 of PLN traps this slowly phosphorylated protein population 
of PLN longer in its inactivated phosphorylated state, thus prolonging SERCA activity.  
My findings, of the CaMKII induced high affinity 14-3-3 binding site in PLN could contribute 
to the further understanding of PLN phosphorylation by CaMKII under frequency 
stimulation without inhibition of PP1. While many publications support the involvement of 
CaMKII in frequency stimulated cardiac relaxation, this mechanism is not widely accepted 
(Mattizzia & Kranias 2014). The involvement of 14-3-3 in this mechanism stays elusive and 
should be further investigated.  
In physiological conditions under full beta-adrenergic stimulation, both kinases PKA and 
CaMKII are active and have an additive effect resulting in double phosphorylation of PLN 
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(Mundiña-Weilenmann et al., 1996). In turn, active PKA additionally phosphorylates the 
protein phosphatase PP1 resulting in its inactivation (Mattiazzi et al., 2005). However, in 
my binding experiments with recombinant monomeric PLN, I observed that 14-3-3 binding 
to doubly phosphorylated PLN is abolished in vitro (Figure 17). A similar effect was 
previously observed for 14-3-3 binding to the C-terminus of the K+-ion channel TASK-1, 
which also has two adjacent phospho-residues within the 14-3-3 binding motif (Kilisch et 
al., 2016). With 14-3-3 pull-down experiments with separated PLN monomers and 
pentamers I showed an increased affinity of 14-3-3 for PLN pentamers (chapter 2, figure 
1). Subsequently, I conclude that 14-3-3 preferentially binds and stabilizes adjacent 
phosphorylated PLN proteins in the pentamer rather than the two closely phospho-sites in 
a monomer. These findings suggest that under full adrenergic stimulation 14-3-3 does not 
bind to double phosphorylated PLN monomers, allowing for a distinct pool of PLN able to 
regulate SERCA during fast contraction cycles. In addition, PLN pentamers 
phosphorylated at S16, or T17 are stabilized by 14-3-3 binding, allowing for a fine-tuned 
modulation of the ratio between PLN monomers and PLN oligomers during cardiac action.  
In conclusion, different 14-3-3 binding affinities towards PLN were identified based on the 
number and kind of phosphorylation present in PLN monomers or pentamers. This 
suggests a model where the abundance of pS16 or pT17 in PLN pentamers determine the 
14-3-3 occupancy (Figure 62).  
 
Figure 62. Schematic representation of 14-3-3 binding affinities to PLN dependent on 
phosphorylation and oligomerization. 
14-3-3 binding affinities dependent on the phosphorylation and oligomerization status of PLN. The 
T17 phospho-site in PLN is the high affinity 14-3-3 binding site. PLN pentamers containing a single 
T17 phosphorylated residue have an increased 14-3-3 affinity than pentamers exclusively 
phosphorylated at S16. 14-3-3 dimer is shown in green, S16 phosphorylation is depicted in purple 
and T17 phosphorylation is indicated in orange.  
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5.4 The physiological role of the PLN pentamer 
In cardiac tissue PLN can be found in its monomeric or oligomeric form, whereby the 
majority of PLN (70-80%) is present as a pentamer which is in a dynamic equilibrium with 
a small fraction of monomer (Glaves et al., 2019; Kimura et al., 1997; Reddy et al., 1999). 
Several publications suggest a shifted monomer/pentamer configuration based on the 
phosphorylation status of PLN, resulting in an increased pentameric population upon 
phosphorylation and a reduced amount of monomers (Cornea et al., 2000; Hou et al., 
2008; Robia et al., 2007). In contrast, unaltered PLN pentamer populations upon 
phosphorylation were observed on SDS-PAGEs in several other studies (Cornea et al., 
1997; Wittmann et al., 2015). Interestingly, a shift in the pentamer/monomer ratio of PLN 
upon phosphorylation would be further stabilized by the interaction with 14-3-3. SDS-
PAGE studies here clearly show an increased steady-state level of PLN pentamers 
phosphorylated at S16 upon isoprenaline stimulation in cardiomyocytes and suggests an 
increased PLN oligomerization upon phosphorylation (chapter 2, figure 6C). However, it 
was reported that the exchange of PLN pentamers was found to be slow and occurs on a 
minute time scale (Robia et al., 2007). A very slow pentamer formation or dissociation is 
in contrast to the fast cardiac cycle, which would require that the increased pentamer 
population of PLN dissociates rapidly (within seconds) in every cardiac cycle to provide a 
pool of inhibitory PLN monomers. In addition, the postulated subunit inhibitory model in 
which PLN inhibits SERCA by structural remolding without dissociation from SERCA 
contradicts an increased PLN pentamer population upon phosphorylation as well (Bidwell 
et al., 2011; Gustavsson et al., 2013; Mueller et al., 2004). It is still under discussion, 
whether phosphorylation of PLN influences the pentamer/monomer equilibrium (Wittmann 
et al., 2015) as well as the different models of PLN/SERCA inhibitory interaction.  
 
Initially, it was assumed that phosphorylated pentamers are a consequence of 
oligomerized phosphorylated monomers (Kimura et al., 1997, Kimura et al., 1998). In 
contrast, Wittmann et al found that PLN pentamers can also be phosphorylated directly by 
PKA (Wittmann et al., 2015). Furthermore, the authors reported that the PLN pentamer 
has a higher affinity towards PKA than the monomer (Wittmann et al., 2015). Based on 
these findings, Wittmann et al proposed a model where the SERCA/PLN interaction is 
prolonged after beta-adrenergic stimulation by first phosphorylating the pentamer 
(Wittmann et al., 2015). CaMKII phosphorylation of PLN pentamers was not analysed in 
this study, but it can be assumed that full beta-adrenergic stimulation also activates CaMKII 
which phosphorylates the PLN pentamer as well. In line, 14-3-3 has a higher affinity for 
pentameric PLN and further stabilizes the pentamer in the phosphorylated state upon beta-
adrenergic stimulation. Furthermore, I could show that 14-3-3 protects PLN after 
Chapter V: Discussion 
 211 
isoprenaline stimulation in cardiomyocytes with patch clamp measurements resulting in 
prolonged SERCA activity (chapter 2, figure 7). The 14-3-3/PLN interaction supports the 
idea of Wittmann et al that regulation of the PLN pentamer can influence the interaction 
between SERCA and PLN.  
Disassembly of the PLN pentamer plays an important role for the SERCA/PLN inhibition 
(Kimura et al., 1998) and is also interesting with respect to the 14-3-3 interaction. 
Surprisingly, not much is reported in the literature about PLN pentamer disassembly. The 
pentamer is stabilized by an isoleucine zipper in the transmembrane domain of PLN 
(Kimura et al., 1997). PLN is primarily present as an oligomer in membranes, but when 
labeled PLN was reconstituted with purified SERCA, the monomeric fraction of PLN was 
strongly increased by 30-40% in FRET experiments (Reddy et al., 1999). From this 
experiment, it was concluded that the PLN/SERCA ratio influences the PLN disassembly 
into monomers (Reddy et al., 1999). However, I found that 14-3-3 preferentially binds and 
stabilizes phosphorylated PLN pentamers. This finding elucidates a novel aspect into PLN 
pentamer disassembly because dissociation of 14-3-3 is an additional requirement for PLN 
de-oligomerization and subsequent SERCA inhibition. With recombinant 
dephosphorylation assays and with Ca2+ measurements in living cardiomyocytes I 
observed that 14-3-3 dissociates slower from T17 phosphorylated PLN than from S16 
phosphorylated PLN (chapter 2, figure 5,7,S7). Consequently, PLN oligomer dissociation 
may also depend on the number and kind of phosphorylation residues present in the 
pentamer and the resulting strength of 14-3-3 interaction. 
A recent study, compared the dissociation constants of several oligomeric SERCA 
interaction partners like PLN, DWORF or SLN with FRET experiments in human embryonic 
kidney cells (Singh et al., 2019). A surprisingly low dissociation constant for oligomeric 
PLN was measured in comparison with the other oligomeric proteins (Singh et al., 2019). 
Since 14-3-3 and beta-adrenergic receptors are expressed in human embryonic kidney 
cells one can speculate, that 14-3-3 was bound to phosphorylated PLN pentamers in the 
FRET analysis influencing the low dissociation constant. The impact of 14-3-3 binding on 
PLN oligomer association and dissociation should be further addressed. 
 
5.5 PKA and CaMKII kinase activity under pathophysiological conditions 
Pathophysiological conditions such as acidosis, myocardial stunning or HF influence the 
balance between kinases and phosphatases activity involved in PLN regulation (Cerra & 
Imbrogno, 2012). Especially, CaMKII activity was found to be significantly elevated under 
several pathophysiological or stress conditions (Grimm & Brown, 2010; Mattiazzi & 
Kranias, 2014). Acidosis occurs during ischemia, resulting in decreased cardiac 
contractions, due to a decreased Ca2+ sensitivity of myofilaments, impaired with a 
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depressant effect on SERCA function (Mattiazzi & Kranias, 2014). The initial decreased 
contractility and relaxation is followed by a spontaneous mechanical recovery in which 
CaMKII plays an important role (Vittone et al., 2008). Acidosis is associated with an 
increase of CaMKII activity and at the same time inhibition of PP1. This mode of action 
leads to the phosphorylation of T17 of PLN and was found to be responsible for 50% of 
early cardiac relaxation recovery (Mattiazzi et al., 2007). During acidosis, PLN 
phosphorylation at S16 is significantly reduced (Vittone et al., 1996), underlining the 
importance of CaMKII activity (Mattiazzi & Kranias 2014). The role of 14-3-3 binding to 
PLN under stress conditions stays elusive and would require further investigation. My 
findings may, however, suggest that phosphorylated T17 is the 14-3-3 high affinity binding 
site, that 14-3-3 is involved in the recovery of acidosis by stabilizing phosphorylated T17 
residues. It should be analysed whether 14-3-3 is recruited to phosphorylated PLN under 
such pathophysiological conditions in ischemic mice models where ischemia is induced by 
surgical processes (Traystman 2003).  
Interestingly, the K+ channel TASK-1 is inhibited by acidosis and has been described to 
contribute to the net outward current during the cardiac action potential plateau phase 
(Putzke et al., 2007). Functional TASK-1 expression at the cell surface is mediated by PKA 
phosphorylation followed by 14-3-3 binding (Kilisch et al., 2016). Thus, reduced PKA 
activation during acidosis could further contribute to reduced TASK-1 expression in 
addition to the inhibitory effect of acidosis. The general reduced contractility during acidosis 
suggest that more than a single population of K+-channels with different pH sensitivity are 
involved (Putzke et al., 2007), but the mentioned TASK-1 characteristics suggest a 
potential involvement of TASK-1 channels in cardiac acidosis, which should be further 
addressed.  
 
Beside the involvement in the recovery of acidosis, CaMKII activity was also found to be 
altered in HF (Mattiazzi et al., 2005). HF is associated with decreased intracellular Ca2+ 
transients and diminished SR Ca2+ load causing altered contractility (Mattiazzi et al., 
2005). Consistently, with diminished Ca2+ load also SERCA expression is decreased in 
HF. In many HF models beta-adrenergic stimulation was found to be down-regulated 
(Bristow et al., 1986; de Lucia et al., 2018), whereas PP1 activity was identified to be 
increased (Gupta et al., 2003). Consistently, phosphorylation of both residues S16 and 
T17 in PLN were determined to be decreased in HF (Schwinger et al., 1999; Munch et al., 
2002). This downregulation of PLN phosphorylation in HF models further inhibit SERCA 
and contributes to a reduced Ca2+ uptake (Vittone et al., 2008). Interestingly, the decrease 
in S16 and T17 phosphorylation in PLN was observed despite an increase in CaMKII 
activity, which is also an characteristic of HF (Anderson et al., 2011; Grimm & Brown, 
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2010). Excessive CaMKII activity in combination with PLN ablation was found to be 
disadvantageous on overall cardiac function due to accelerating Ca2+ uptake in the SR and 
increased SR Ca2+ load (Mattiazzi & Kranias, 2014; T. Zhang et al., 2010). Altering SERCA 
and PLN protein levels or activity are potential strategies to restore Ca2+ handling and treat 
HF (Vittone et al., 2008). Under such conditions, the 14-3-3/PLN interaction could also play 
a role as a stabilizer of phosphorylated PLN. Therefore, the function of PLN 
phosphorylation and 14-3-3 binding in HF should be further investigated. I was able to 
show that 14-3-3 binds T17 phosphorylated PLN pentamers and monomers with high 
affinities in pull-down experiments and recombinant binding assays (chapter 2, figure 
3E,G). Followed recombinant dephosphorylation assays showed that 14-3-3 binding 
stabilizes phosphorylated, monomeric PLN and protects from phosphatases (chapter 2, 
figure 5). Based on these results, 14-3-3 presumably protects PLN monomers and 
pentamers upon CaMKII phosphorylation from dephosphorylation by cellular 
phosphatases and potentially helps to balance the overall reduced PLN phosphorylation 
during reduced beta-adrenergic stimulation in HF. A starting point would be the analysis of 
14-3-3 steady-state levels in fractionated cardiac membranes from different HF disease 
mouse models. 
 
5.6 The 14-3-3/PLN interaction in PLN disease mutations 
Different mutations in the PLN gene occur naturally in humans, such as R9C, R14del and 
L39Stop mutations (Young et al., 2015). All of them are associated with DCM and HF 
(Young et al., 2015). The R9C and the R14del mutation are interesting with respect to their 
14-3-3 interaction, since in both mutations PKA phosphorylation is abolished (Haghighi et 
al., 2006; Schmitt et al., 2003). Both mutations were only identified in heterozygous 
patients so far (Haghighi et al., 2006; Young et al., 2015).  
Haghighi et al analysed the functional consequences of the R14del mutation by co-
expression of the R14del PLN mutant with or without WT PLN in mammalian cells 
mimicking homozygous and heterozygous disease backgrounds. In the absence of 
endogenous WT PLN, the PLN R14del mutant is mislocated to the plasma membrane after 
expression (Haghighi et al., 2012). Co-expression of the R14del PLN mutant and WT PLN 
resulted in an PLN protein which strongly inhibits SERCA. This inhibition was not reversible 
upon phosphorylation (Haghighi et al., 2014). Consequently, the authors assumed that the 
heterozygous R14del PLN mutation leads to persistent interaction with SERCA. The 
consequences of a non-interrupted PLN SERCA interaction will be reduced back-transport 
of Ca2+ ions in the SR after contraction and cardiac relaxation.  
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The R14del mutation disrupts the PKA target motif in PLN and abolishes PKA 
phosphorylation at S16 (Haghighi et al., 2006). As a consequence, CaMKII 
phosphorylation is the only remaining mechanism to phosphorylate the PLN R14del 
mutant, which makes the potential 14-3-3 interaction interesting. First, it was questioned 
whether 14-3-3 can bind this mutant, because the R14 residue was found to be a stabilizing 
residue in the 14-3-3 binding groove in molecular dynamic simulations. To address this 
question, I phosphorylated recombinant PLN R14del protein with recombinant PKA and 
CaMKII kinases and analysed the result on Phos-tag-PAGE gels (chapter 2, figure S6). 
This experiment confirmed that PKA phosphorylation is abolished, but also that CaMKII 
kinase phosphorylation is possible in vitro (Haghighi et al., 2006, te Rijdt et al., 2016). After 
phosphorylation, I performed a recombinant binding assay with 14-3-3 and CaMKII 
phosphorylated PLN R14del protein revealing that the 14-3-3 interaction is still possible 
(chapter 2, figure 4D). Molecular dynamic simulations showed that R14 is stabilized by the 
14-3-3 interaction directly to the phosphorylated T17 residue in PLN and in addition 
revealed that the R13 residue is not placed in the canonical binding groove of 14-3-3 
(chapter 2, figure 4B). This indicates that the missing R14 residue is replaced by the R13 
residue and therefore stabilize the 14-3-3 interaction. In-vitro binding assays showed that 
14-3-3 is able to physically interact with PLN carrying the R14del mutation upon CaMKII 
phosphorylation. Based on the functional analysis of the 14-3-3/PLN interaction it seems 
plausible that 14-3-3 stabilizes R14del PLN in its phosphorylated state and thus enhances 
SERCA activity. To further investigate the 14-3-3 interaction with the PLN R14del mutation 
I analysed homozygous and heterozygous PLN R14del mouse disease models.  
The steady-state levels of PLN R14del and 14-3-3 were analysed by Western blotting of 
separated membranes and cytosol from both R14del mouse models (Figure 18,19,21,22). 
In both R14del mouse models the PLN R14del mutant protein was decreased (Figure 
18,21,24). The reduced steady-state levels of R14del PLN complicate the intended 
analysis of investigating whether membrane-associated 14-3-3 protein levels vary with the 
presence of PLN R14del. This approach was based on the hypothesis that PLN recruits a 
substantial amount of 14-3-3 to cardiac membranes. 14-3-3 levels were not altered either 
in the homozygous nor in the heterozygous mice model (Figure 19,22), which is hard to 
interpret because of the decreased R14del PLN levels. The observation of reduced R14del 
PLN protein level is consistent with findings made in cardiomyocytes from R14del 
heterozygous patients where PLN aggregates were identified by immunohistochemistry 
(te Rijdt et al., 2016). My observations and te Rijdt et al suggest that the R14del mutation 
leads to the formation of cellular PLN aggregates. The potential formation of PLN R14del 
aggregates contradict the hypothesis that the R14del mutation represents a super-
inhibitory form of PLN (Haghighi et al., 2006; te Rijdt et al., 2016). This discrepancy also 
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questions the functional consequences of the R14del PLN mutation in heterozygous 
patients. The formation of PLN R14del aggregates in heterozygous patients suggests that 
exclusively the “healthy” PLN population is able to regulate SERCA in patients. My 
observations in R14del disease mouse models support the proposed aggregation model. 
To further clarify this issue, isolated cardiomyocytes from both disease models should be 
subjected to staining protocols that may reveal such aggregates and would allow to test 
the presence of 14-3-3 proteins in them.  
Further studies are required to understand the functional consequences of the R14del PLN 
mutation on cardiac action and during beta adrenergic stimulation. To this end, mice 
disease models or corresponding induced pluripotent stem cell-derived cardiomyocytes 
can be used. Using such a model, one could further analyse the physiological effects of 
the 14-3-3/PLN R14del interaction and clarify whether the regulation of this interaction 
could be a putative target to increase cardiac performance in these patients. 
 
The PLN R9C mutation was identified in 2003 by sequencing unrelated patients suffering 
DCM (Schmitt et al., 2003). Initially, the R9C mutation was identified as a loss-of-function 
mutation because it was found that PKA strongly bound to the PLN R9C mutation. 
Consequently, traps PKA blocked the S16 phosphorylation site in PLN and prevents 
SERCA inhibition (Schmitt et al., 2003). Later studies showed that the R9C mutants are 
clustered together in pentamers stabilized by disulfide bridges (Ha et al., 2011, Abrol et 
al., 2015). These stable pentamers were reported to be less accessible for the catalytic 
subunit of PKA (Ha et al., 2011). Furthermore, the PLN R9C pentamers are not able to 
interact with SERCA because of the disability to dissociate into monomers (Ha et al., 
2011). 
However, the cellular localization of this mutant was reported to be unaltered (Abrol et al., 
2015) and I confirmed this finding with IF experiments after expression of a recombinant 
PLN R9C construct in mammalian cells (Figure 26-28). 
The R9C mutation is not located in the identified 14-3-3 interaction site in PLN. 
Consequently, I predict that the R9C mutation in PLN will not affect 14-3-3 binding resulting 
in a low affinity 14-3-3 binding site upon S16 phosphorylation and a high 14-3-3 binding 
ability upon CaMKII phosphorylation. With recombinant phosphorylation assays I showed 
that the monomeric PLN R9C protein was phosphorylated by PKA, indicating that the 
reported reduced PKA accessibility (Ha et al., 2011) is caused due to the formation of very 
stable pentamers (chapter 2, figure S6). With recombinant phosphorylation assays, I also 
showed that CaMKII phosphorylation is not affected by the R9C mutation. Further, I tested 
14-3-3 binding with a recombinant binding assay indicating that 14-3-3 is able to bind the 
PLN R9C protein upon CaMKII phosphorylation (chapter 2, figure 4D). With recombinant 
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de-phosphorylation assays and Ca2+ measurements in cardiomyocytes, I investigated the 
function of 14-3-3 binding implying that 14-3-3 protects PLN from phosphatases and 
prolongs PLN phosphorylation and SERCA activity (chapter 2, figure 5,S7,7). Due to the 
avidity effect 14-3-3 clamps and stabilizes pentamers with high affinities. Consequently, 
one can assume that 14-3-3 further stabilizes the strong pentamer formation in the PLN 
R9C mutation. Notably, the R9C mutation was also found to enhance PLN WT 
oligomerization and increases the stability of these pentamers (Abrol et al., 2015). 
However, it is still in question whether CaMKII phosphorylation is also affected in the stable 
PLN R9C pentamers and whether homo- or heteropentamers are formed in heterozygous 
patients. The role of CaMKII phosphorylation and 14-3-3 interaction in this mutation should 
be further evaluated by using a corresponding disease mouse model. Such analysis would 
also help to clarify whether regulation of 14-3-3 could potentially help to weaken the stable 
pentamers of the PLN R9C mutants as a therapeutic strategy. 
 
Overall, CaMKII activity was found to be important for several pathophysiological 
conditions in the heart. Currently, CaMKII inhibitors are of general interest to increase 
cardiac performance and to treat heart diseases (Beauverger et al., 2019). CaMKII 
inhibition results in a reduction of T17 phosphorylation of PLN in disease mouse models 
(Beauverger et al., 2019). The CaMKII inhibitors, should be administered with caution 
regarding the various PLN mutations, since in the PLN R14del mutation PKA 
phosphorylation is abolished. Consequently, CaMKII kinase phosphorylation is important 
for PLN regulation in these patients and reduced phosphorylation of PLN could be 
detrimental. From recombinant binding assays, I have evidence that 14-3-3 binds PLN 
R14del and R9C mutants upon CaMKII phosphorylation (chapter 2, figure 4D) resulting in 
stabilization of pentamers and protection from phosphatases. Inhibition of CaMKII will lead 
to a reduced 14-3-3 binding to these proteins with unknown potential effects. In vivo this 
action would affect the regulation of SERCA by PLN through further decrease of PLN 
phosphorylation resulting in decreased SERCA function. In general, the administration of 
CaMKII inhibitors might cause dangerous side effects due to the number of potential client 
proteins phosphorylated by CaMKII. 
Overall, the newly discovered 14-3-3/PLN interaction requires additional characterization 
especially in the light of the various disease-causing mutations (in both PLN and 14-3-3) 
and pathophysiological conditions. The 14-3-3 interaction regulates PLN phosphorylation 
in a fine-tuned manner. Further understanding of PLN regulation may help to improve 
cardiac performance under disease or pathophysiological conditions.  
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5.7 Involvement of regulatory proteins like Dlg1 or 14-3-3 in cardiac function 
Regulatory proteins like Dlg1 or 14-3-3 are involved in several distinct cellular functions in 
various tissues (Balse & Eichel, 2017; Godreau et al., 2003; Walch, 2013). Dlg1 was 
reported to be altered in different forms of cardiomyopathy (Asimaki et al., 2014). 
Consequently, Dlg1 was analysed in the PLN R14del mutation, which is associated with 
DCM or ACM. In 88% of analysed heart samples from PLN R14del patients, Dlg1 was 
found to be mislocated to the sarcomere (te Rijdt et al., 2019).  
In healthy hearts, Dlg1 is located at the intercalated disc and lateral membranes, and is 
responsible for signal transduction and ion channel activity (Eichel et al., 2016). It is well 
established that altered potassium ion channel expression can cause arrhythmia and 
contribute to HF (Mustroph et al., 2014). In cardiomyocytes complexes of Kv4.2/Kv4.3 
channels with Dlg1 and CaMKII were identified (El-Haou et al., 2009). Interestingly, in 
different cardiomyopathies CaMKII was found to be upregulated, whereas Dlg1 was 
downregulated or mislocated changing the outward current of Kv4.2/Kv4.3 channels 
(Mustroph et al., 2014).  
The K2P channel TASK-1 was found to contribute to arrhythmogenic effects and HF 
(Schmidt et al., 2011, Schmidt at el., 2019). The exclusive atrial expression turns TASK-1 
into an interesting target to treat AF specifically (Limberg et al., 2011; Schmidt et al., 2014). 
Dlg1 was identified as a novel cardiac interaction partner of TASK-1 in this thesis (Figure 
47,51). Dlg1 was identified as a direct interaction partner of TASK-1 binding via its PDZ 
domain to the unphosphorylated TASK-1 channel (Figure 53,56). Based on the already 
known function of Dlg1 on other ion channels, it is conceivable that Dlg1 stabilizes the 
TASK-1 channel at the plasma membrane surface (Hong et al., 2015). The physiological 
function of the Dlg1/TASK-1 interaction needs to be further investigated and could help to 
clarify the involvement of TASK-1 channels in arrhythmias (Ma et al., 2013) or other cardiac 
pathophysiological conditions.  
Overall, the involvement of regulatory proteins like 14-3-3 and Dlg1 in main pathways of 
excitation-contraction coupling mechanism illustrates their importance in cardiac function. 
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5.8 14-3-3 proteins as a potential drug target – possible treatments in various 
diseases 
Pathophysiological cardiac conditions or PLN human disease mutations result in many 
cases in increased CaMKII activity or/and in abolished beta-adrenergic signaling (Grimm 
& Brown 2010; Anderson et al., 2011; Najafi et al., 2016). Although, the function of 14-3-3 
under this pathophysiological condition has not been well investigated so far, it is 
conceivable that 14-3-3 could be used to stabilize phosphorylated PLN under 
pathophysiological conditions modulating SERCA activity and recover cardiac function. 
14-3-3 proteins are involved in numerous protein-protein interactions and are prevalent in 
several human diseases, such as cancer, neurodegenerative or reproductive disorders, 
which points to a general interest as valuable drug targets (Aghazadeh & Papadopoulos, 
2016; Stevers et al., 2018). 14-3-3 proteins serve as adaptor proteins and have a broad 
spectrum of phosphorylated and non-phosphorylated ligands, a compound against 14-3-3 
alone could impact several 14-3-3 interactions and lead to unwanted pharmacologically 
side effects (Stevers et al., 2018). Consequently, the drug has to specifically target the 
complex formation between 14-3-3 and a specific ligand by either inhibition or stabilization 
(Thiel et al., 2012, Stevers et al., 2018). Therefore, a series of small molecules was already 
identified and is under further evaluation (Study et al., 2012, Stevers et al., 2019). With 
regard to the 14-3-3/PLN interaction, stabilization and inhibition could both be potential 
strategies for modulating the pool of phosphorylated PLN and the SERCA/PLN inhibitory 
interaction according to different pathophysiological conditions. The identification of protein 
stabilizers is more complex than the identification of specific inhibitors (Study et al., 2012). 
Such a stabilizer must be able to stabilize a ternary complex by simultaneously contacting 
two partner proteins (Study et al., 2012). An example for a 14-3-3 stabilizer is fusicoccin A, 
a diterpene glycoside from the fungus Phomopsis amygdali. Fusicoccin A was found to 
bind the rim of the interface of the 14-3-3 interaction with the plasma membrane H+-
ATPase and to increase the affinity of 14-3-3 for the H+-ATPase about 90-fold (Study et 
al., 2012). Remarkably, fusicoccin A binds exclusively to the complex and not the two 
individual interaction partners (Study et al., 2012). Several stabilizers and inhibitors have 
been identified so far for several 14-3-3 interactions (Study et al., 2012, Stevers et al., 
2018), but the presence of seven 14-3-3 isoforms in mammals further complicates the 
identification of specific compounds targeting such interactions. Regarding, the 14-3-3 
PLN interaction, I found with recombinant bindings assays that all 14-3-3 isoforms can bind 
phosphorylated PLN (chapter 2, figure S3). In addition, an APEX affinity proteomic 
approach identified six out of seven 14-3-3 isoforms in close proximity with PLN in 
cardiomyocytes (chapter 2, figure 2). The binding grooves of the different 14-3-3 isoforms 
are conserved and in many cases all 14-3-3 isoforms are able to bind the phosphoresidue-
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containing motif of a ligand (Yaffe et al., 1997) but the affinities may vary among them 
(Kilisch et al., 2016). Consequently, differences in the PLN binding affinities for the seven 
14-3-3 isoforms should be further evaluated, for example with surface plasmon resonance 
or isothermal titration experiments.  
 
14-3-3 as a drug target could also be interesting for the regulation of TASK channels. 
Especially, TASK-1 was found to be associated with AF (Schmidt et al., 2019). 14-3-3 was 
identified to regulate forward trafficking and thereby surface expression of TASK-1 and 
TASK-3 channels (Kilisch et al., 2006). A semi-synthetic fusicoccin THF analogue was 
already tested for stabilization of the TASK-3/14-3-3 interaction by binding the interface of 
the two interaction partners (Anders et al., 2013). Transfection of TASK-3 in Xenopus 
oocytes and treatment with 10 µM fusicoccin THF showed a 45% increased TASK-3 
expression at the plasma membrane (Anders et al., 2013). However, fusicoccin THF was 
identified to stabilize the complex between 14-3-3 and a protein presenting a 14-3-3 mode 
III motif (Stever at al., 2018). Consequently, fusicoccin THF was also found to modulate 
surface expression of TASK-1 with a comparable efficiency as identified for TASK-3 
(Anders et al., 2013). Fusicoccin THF was identified as a specific 14-3-3 mode III stabilizer. 
So far only six 14-3-3 ligands are known to present a 14-3-3 mode III binding motif (Anders 
et al., 2013). The bulky tetrahydrofuran substitution in fusicoccin THF is responsible for the 
specificity between 14-3-3 and a mode III motif (Anders et al., 2013). It can be assumed, 
that fusicoccin THF stabilizes all six known 14-3-3 target proteins with a mode III motif. 
Further studies are required to diminish unwanted pharmacological effects and strategies 
to enhance specificity for the 14-3-3/TASK channel interaction.  
 
In general, 14-3-3 might represent a drug target protein but due to the number of potential 
14-3-3 target proteins and the involvement in various cellular processes the risk of 
unwanted pharmacologically side-effects are high. Targeting 14-3-3 in a cellular context 
would prove to be challenging, if not impossible. Current studies attempt to target 14-3-3 
protein-protein interactions individually to identify specific compounds which stabilize or 
disrupt a specific 14-3-3-protein interaction. A first step to target the PLN/14-3-3 interaction 
would be the determination of a crystal structure between 14-3-3 and the two different 
phospho-target sites in PLN. This would allow a better understanding of the interaction and 
could contribute to a successful high throughput screen for potential small molecules which 
may either stabilize or interrupt the 14-3-3/PLN interaction. Therefore, the generation of 
such a structure should be a priority for further investigation of 14-3-3 as a drug target to 
overcome regulatory problems of PLN associated with PLN disease mutations or 
pathophysiological conditions.  
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